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Abstract 
Traumatic brain injury (TBI) is frequently associated with cognitive impairment, which can 
be either transient or lifelong.  Despite this, the ability to predict who will experience poorer 
cognitive outcomes remains challenging.  The APOE gene, which has three alleles; APOE ɛ2, 
ɛ3, and ɛ4, has recently attracted attention as a biomarker that may be of prognostic value, as 
the resultant protein is believed to facilitate post-injury repair. The protein derived from the 
APOE ε4 allele is less structurally sound than that of the ε2 or ε3 alleles and as such, it has 
been proposed that APOE ε4 carriers may have impaired recovery of cognitive function after 
injury.  Although there is growing literature exploring this hypothesis, the findings to date 
have been inconclusive.  This ambiguity may be due in part to methodological limitations, 
such as the small sample sizes typically associated with genetic studies in clinical 
populations, and also may be due to moderating factors being overlooked.  For example, it 
has been proposed that APOE ε4 may have an antagonistic pleiotropic effect whereby it 
confers beneficial effects during the reproductive phase of life, and becomes detrimental 
during the post-reproductive life phase.  Furthermore, there is evidence that female sex 
hormones enhance the expression of APOE, but that this may not occur for female APOE ε4 
carriers due to the structural nature of the protein.  However, the possible effects of age and 
sex are yet to be investigated in relation to post TBI cognitive function.   The aims of the 
current thesis are twofold; firstly, to provide a more integrative and in-depth investigation of 
the relationship between APOE ε4 and TBI by conducting a meta-analysis of the literature to 
date, and secondly, to investigate whether factors such as age and sex may interact with the 
expression of APOE ε4 in relation to post-TBI cognitive function.  This thesis comprises four 
studies: Firstly, a meta-analysis was conducted to provide a more comprehensive 
interpretation of the extant literature.  This revealed no significant differences between APOE 
ε4 carriers and non-carriers, either in terms of general cognitive function or within specific 
x 
cognitive domains known to be commonly impacted by TBI.  Limitations of the literature to 
date were identified and attempts were made to redress these in the following two studies, 
which both assessed the processing speed, working memory and executive function of 
participants who had sustained a TBI.  One study assessed these functions during the acute 
recovery period by exploring the contribution of all three APOE alleles separately (N = 142; 
APOE ε4 = 37, APOE ε3 = 92, APOE ε2 = 13), and also considering whether injury severity 
influenced the expression of APOE ɛ4.  This revealed that possession of APOE genotype was 
unlikely to contribute to differences, regardless of injury severity.   The following study 
employed a longitudinal design, and measured outcomes at 3, 6 and 12 months post injury (N 
= 119; APOE ε4 = 30, APOE ε3 = 77, APOE ε2 = 12).  In this study, as well as considering 
the general effect of APOE ɛ4, age and/or sex differences were evaluated to determine 
whether there was an interaction between these factors and APOE ɛ4.  There was tentative 
evidence that APOE ɛ4 was associated with impaired executive function, but this was 
inconsistent.  There was no evidence of an interaction between age and APOE ɛ4, and little 
evidence of an interaction between sex and APOE ε4.  In an adjunct methodological study, 
the effect of missing data was explored in the sample and a number of traditional and more 
recently developed techniques used to compensate for missingness were applied to determine 
the ability of each to provide the best estimate of the true sample parameters. This thesis has a 
number of strengths, including the separate categorising of all three alleles, and the 
consideration of potential interactions between age, sex and APOE ɛ4.  The key finding of 
this thesis is that APOE ɛ4 is unlikely to have a pervasive effect on cognitive recovery after 
TBI, but that further investigation of the interaction between APOE status and age and sex is 
needed.    
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Chapter 1:  Introduction and Thesis Overview 
2 
 
 
 
Traumatic brain injury (TBI) is a relatively common injury, affecting millions of 
children and adults worldwide (Hyder, Wunderlich, Puvanachandra, Gururaj, & Kobusingye, 
2007).  Severity can range from temporary impairment of consciousness, to death, and for 
those who survive the initial injury, the damage sustained can result in chronic disability.  
There is also growing evidence that TBI is associated with increased risk of developing a 
number of disorders, including depression, epilepsy, Alzheimer’s disease (AD), chronic 
traumatic encephalopathy, and Parkinson’s disease (Masel & DeWitt, 2010).  Therefore, TBI 
has the potential to exert serious direct and indirect life-long effects on an individual’s well-
being.  Further, with the prevalence of TBI being highest during childhood and early 
adulthood, any resultant impairment can last decades, having devastating consequences for 
the sufferer and their families (Myburgh et al., 2008; Verhaeghe, Defloor, & Grypdonck, 
2005).  Sustaining a TBI can result in impairment to cognitive, emotional and motor function, 
and as such there is the potential for a wide range of negative outcomes, including physical 
disability, reduced capacity to work, difficulty in making responsible financial decisions and 
performing normal activities of daily living, and inability to engage in and maintain 
relationships (Hoofien, Gilboa, Vakil, & Donovick, 2001; Konrad et al., 2011; Morton & 
Wehman, 1995; Shames, Treger, Ring, & Giaquinto, 2007). The financial and emotional toll 
on the sufferer and their family members can be enormous, with an ongoing and significant 
financial burden and demand placed on the public health system (Kolakowsky-Hayner, 
Miner, & Kreutzer, 2001; Leibson et al., 2012; Mar et al., 2011; Ponsford, Olver, Ponsford, & 
Nelms, 2003; Tuominen, Joelsson, & Tenovuo, 2012).   
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Definition of TBI 
Menon, Schwab, Wright, Maas, and Common (2010) describe TBI as “an alternation 
in brain function, or other evidence of brain pathology, caused by an external force” (2010, p 
1638).  According to this definition, for an alteration in brain function to be diagnosed, there 
needs to be at least one of the following; loss of, or reduced, consciousness, retrograde or 
posterior grade amnesia for the time of injury, neurological impairment, or change in mental 
state at time of injury.  Brain pathology can also be used to diagnose TBI, and may 
incorporate neuroimaging, visual assessment, and/or testing for bio-markers associated with 
TBI.  The external forces that inflict the injury can include collision of the head with an 
object, damage caused by acceleration/deceleration forces, penetration of the brain by a 
foreign object, or percussive injury, as inflicted by explosive forces.  TBI excludes those 
brain injuries arising from other cerebral accidents such as stroke, damage due to hypoxia, 
substance abuse, or congenital impairment.   
Estimating injury severity is often challenging.  While diagnosis typically occurs at 
the time of injury it is possible, especially in cases of mild TBI, for the injury to remain 
undiagnosed until a considerable time after the event due to the subtle and/or delayed nature 
of some symptoms (Bazarian et al., 2009; Menon et al., 2010).  This is particularly the case 
for psychological effects such as mood disorders, memory impairment, and executive 
dysfunction (Dean & Sterr, 2013; Vanderploeg, Curtiss & Belanger, 2005).  It can also be 
difficult to establish length of time that length of coma (LOC) and/or post traumatic amnesia 
(PTA) have occurred. For example, if medical interventions such as mechanical intubation 
and/or anaesthetic drugs are administered, or if there are delays in the individual presenting 
for treatment (for example blast injuries in the military setting, or in rural settings), self-report 
is necessary to estimate injury severity (Menon et al., 2010; Roozenbeek, Maas, & Menon, 
2013).  Furthermore, some diagnostic tools routinely used at time of injury, such as CT scans, 
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may not be sufficiently sensitive to detect mild TBI, despite later detection of damage when 
MRI is used (Yuh et al., 2013).  Additionally, there is evidence of inconsistency between 
scales used to measure injury severity, such as the Glasgow Coma Scale (GCS) which 
measures depth of coma, and length of coma and PTA estimates (Sherer, Struchen, Yablon, 
Wang, & Nick, 2008).  As such, there is considerable heterogeneity in the methodology used 
to estimate injury making comparisons both between individuals and between scales difficult. 
 
 
 
TBI Epidemiology – An Australian Perspective 
 
Establishing accurate incidence and prevalence rates of TBI is challenging.  There are 
a range of diagnostic criteria used, and it is likely that many individuals who sustain a mild 
TBI are not diagnosed or hospitalised, whilst others with severe injuries may die before being 
admitted to hospital.  It is also not uncommon for an individual to sustain multiple TBIs over 
the course of their life (Fortune & Wen, 1999; Roozenbeek et al., 2013).  With these 
limitations in mind, Fortune and Wen (1999) estimated that in Australia approximately 149 
per 100,000 individuals are hospitalised annually with a diagnosis of TBI, based on 
hospitalisation data obtained in the financial year of 1996-1997.   Approximately 70% of 
these cases were male, with injuries mostly occurring in paediatric cohorts (ages 0-4), young 
adults (15-19), and in the very old (85+), with the young adult group having the highest 
incident rate (284/100,000).  Given the high frequency of TBIs in the young adult population, 
Harrison, Berry and Jamieson (2012) reviewed the incidence rates for Australians aged 15 to 
24 years old.  They report that hospitalisation for TBI in this age cohort was 169.3 per 
100,000 of the population.  It was also noted that males were 3.2 times more likely than 
females to experience TBI. 
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Myburgh and colleagues (2008) investigated a number of epidemiological factors in 
an Australian and New Zealand adult cohort and also reported that males accounted for most 
TBIs (74%), and that approximately 45% of TBI patients were aged 20-39, however, given 
their age brackets were broader than Fortune and Wen, and did not include paediatric cohorts, 
no direct comparison can be made.  In Myburgh et al’s study severity of TBI was also 
assessed using the GCS, with more than half of the cohort (57.2%) classified as having 
sustained a severe TBI, with 18.1% and 24.7% categorised as moderate and mild, 
respectively.  It was noted that the most common cause of TBI was motor vehicle accidents 
(61.4%), falls (24.9%) and assault (7.2%).  However, this study recruited those admitted to 
intensive care units, or who died in the emergency department or during surgery, thus those 
with less severe TBIs may not be adequately accounted for. 
Butterworth, Anstey, Jorm, and Rodgers (2004) estimated that approximately 6% of 
adults in Australia had sustained a TBI.  Incorporating this finding into their meta-analysis, 
Frost, Farrer, Primosch, and Hedges (2013) analysed data from The United States of 
America, Canada, Australia and New Zealand and estimated that approximately 12% of the 
adult population in these countries had experienced a TBI, with males being 2.2 times more 
likely than females to sustain a TBI.  Although there is a clear difference between these 
estimations, it should be noted that Butterworth and colleagues required participants to have 
experienced at least 15 minutes of LOC, whereas Frost and colleagues do not appear to have 
a minimum length of time for LOC, and therefore the higher prevalence rate is reported in the 
larger study by Frost and colleagues is unsurprising.   
Due to demographic and diagnostic changes, there have been some recent changes in 
the incidence rates of TBI (Roozenbeek et al., 2013). For example, whilst the incidence rate 
of TBI in elderly populations has not changed dramatically, with an increasingly aging 
population as well as the demographic “baby-boomer” bubble there has been a commensurate 
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increase of TBIs, as reported in international and Australian studies (Myburgh et al., 2008; 
Roozenbeek et al., 2013).  Furthermore, with the development of more sophisticated 
neuropathological assessment and treatments, there has been some reduction of mortality 
associated with TBI, although some authors report little change as compared to a decade ago 
(Myburgh et al., 2008; Roozenbeek et al., 2013).  When considered together, these factors 
suggest that there is likely to be an increase in the number of individuals with TBI, with 
potentially a larger proportion for whom impairment is significant.   
 
 
Neuropathology in TBI 
From the moment of impact, a series of cerebral events occur which contribute to the 
short and long term outcomes of TBI.  There are two injury processes – primary and 
secondary.  Primary injury effects are a result of the mechanical and compressive forces 
inflicted by the impact (whether it was caused by a physical object, acceleration/deceleration 
or percussive force).  Secondary injury effects are the neurochemical and physiological 
changes to the brain triggered by the primary injury effects.  While the primary injury 
processes are immediate and can be catastrophic, the secondary injury processes typically are 
longer in duration, and have been argued to be more influential in determining long-term 
outcome (Greve & Zink, 2009).   
 
Primary injury response. 
Primary injury describes the immediate mechanical effects of the impact/force of 
initial injury.  Because of the viscoelastic nature of the brain, when there is a blow to the 
skull, or sudden changes in speed and/or direction of movement, mechanical forces can have 
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a dramatic effect on brain tissues, with strain and tearing of cells and blood vessels often 
causing widespread and severe damage (Mustafa & Alshboul, 2013).  Furthermore, the brain 
can rebound against the skull, causing serious trauma due to the skull’s inflexibility and bony 
prominences.  There are two forces which exert an effect on the brain structure during 
impact; linear acceleration and rotation (Greve & Zink, 2009).  Linear acceleration damage 
tends to occur in the cortical surface are area, whereas rotational forces occur within the 
deeper sub-cortical regions, although in higher velocity damage rotational forces can also 
cause damage to cortical regions (Greve & Zink, 2009; Post & Hoshizaki, 2012).  Although 
each of these forces is associated with different effects, they rarely, if ever, occur 
independently of each other in TBI.   
According to Post and Hoshizaki (2012), there are four key processes associated with 
primary injury.  Firstly, where there is a direct blow to the head, contusions can occur at the 
site of impact (referred to as a coup injury), and/or in the opposing brain region, if the brain 
reverberates from the initial impact and compresses against the opposite part of the skull 
(contrecoup injury), and damage from impact can also spread laterally.  The flexion of the 
skull bones may also cause damage to the underlying dura (or the vessels that transverse the 
dura) potentially leading to subdural or extradural haematomas, although the latter are not 
common, occurring in less than 1% of TBIs (Mustafa & Alshboul, 2013).  Tearing of blood 
vessels within the brain can also cause haematoma within the brain itself (Mustafa & 
Alshboul, 2013). Often associated with primary injury is secondary damage caused by 
changes in intracranial pressure (ICP), which can compress and stress brain tissue throughout 
the brain, or at focal sites.  ICP, which can be considered an aspect of both primary and 
secondary injury, can occur as a result of haematoma and oedema.  Furthermore, when the 
brain changes position relative to the skull, there can be a decrease in ICP in the regions of 
the brain distal to point of impact, thus a varying pressure gradient may occur and place strain 
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on the brain tissue throughout the brain (Greve & Zink, 2009; Post & Hoshizaki, 2012).  
Thirdly, when rotational forces occur, these can inflict damage throughout the brain, and 
indeed is thought to cause the greatest level of strain on brain tissues (Zhang, Yoganandan, 
Pintar, & Gennarelli, 2006).  Rotational forces are believed to be the primary cause of diffuse 
axonal injury (DAI), in which axons are torn and stretched, often leading to the cascade of 
neurological events associated with secondary injury (Mustafa & Alshboul, 2013; Smith, 
Meaney, & Shull, 2003).  Finally, it has been argued that the combination of linear and 
rotational forces work synergistically, each force exacerbating the effect of the other (Post & 
Hoshizaki, 2012).  
 
Secondary injury response.  
The damage inflicted during primary injury is instantaneous and potentially fatal. 
However primary injury also triggers a secondary injury response which involves a cascade 
of biochemical and neurological events, the effects of which can be insidious and long 
lasting.  Where the initial TBI is survived, secondary injury effects are generally considered 
to be more harmful than primary effects. While secondary injury effects are also more 
treatable, to date effective treatments have remained elusive (Greve & Zink, 2009; Park, Bell, 
& Baker, 2008).   Secondary injury responses can be broadly divided into two categories; 
excitotoxic and inflammatory, although it must be noted that these processes are interlinked. 
The excitotoxic response to injury typically involves widespread depolarisation across 
various cell types, and a surge in nitric oxide and excitatory amino acids, most notably 
glutamate and aspartate (Greve & Zink, 2009).  Increases in extracellular glutamate leads to 
increases in calcium within cells, which is associated with oxidative stress and mitochondrial 
dysfunction (Walker & Tesco, 2013).  There is also an increase in free radicals, and it is 
believed that these molecules, in conjunction with the increased calcium, trigger further 
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release of nitric oxide and excitatory amino acids, thus creating an excitotoxic cycle which 
may spread from injury site to adjacent brain regions, leading to widespread dysfunction and 
damage (Greve & Zink, 2009). 
Inflammatory responses also commence soon after injury, and persist for some time 
following injury, with some studies finding inflammatory effects lasting years (Johnson et al., 
2013; Smith et al., 2013).  Neuroinflammation involves increased activation of glial and 
macrophage cells, and a dramatic change in the expression of a large number of 
neurochemicals, including pro and anti-inflammatory cytokines and chemokines, (Finnie, 
2013; Walker & Tesco, 2013).  While some neuroinflammatory responses are beneficial, 
many processes have been found to be detrimental, and it remains unclear which factors exert 
positive or negative effects.  Indeed, it has been suggested that many factors have a dual role 
which is possibly mediated by timing of release and levels of production of a given 
neurochemical (Finnie, 2013; Schmidt, Infanger, Heyde, Ertel, & Stahel, 2004).  As for 
excitotoxic responses, inflammatory responses can also spread to adjacent regions, resulting 
in more far-reaching damage to tissue (Jaerve & Muller, 2012).   
The excitotoxic and inflammatory responses, along with the mechanical forces 
incurred during TBI, work synergistically leading to a series of harmful pathophysiological 
changes.  The integrity of the blood-brain barrier is often compromised, with increased 
permeability and reduced capacity to regulate cerebral blood flow (CBF) and other 
homeostatic mechanisms (Finnie, 2013; Mustafa & Alshboul, 2013; Werner & Engelhard, 
2007).  CBF is commonly reduced, and can result in focal or widespread ischemia, which is 
particularly troublesome given the evidence that damaged tissue can be more susceptible to 
ischemia than healthy brain tissue (Botteri, Bandera, Minelli, & Latronico, 2008).  
Hypotension may also occur, and there is typically reduced blood flow (hypoperfusion) either 
focally or globally.  Alternatively, individuals can also experience increased CBF, resulting 
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in hyperperfusion, which can occur in response to injury or due to medical intervention 
(Werner & Engelhard, 2007).  There can also be impaired cerebrovascular autoregulation, 
resulting in inability to maintain appropriate CBF, and cerebral vasospasm and metabolic 
dysfunction can also occur.  These factors all typically result in hypoxia which is a strong 
predictor for mortality and morbidity (Greve & Zink, 2009).  Oedema also occurs, which 
involves either an increase in intracellular fluid (cytoxic oedema) or increased extracellular 
fluid (vasogenic oedema).  Typically both types of oedema are present, and the length and 
timing of both vary depending on the nature of injury, although cytotoxic oedema may be 
more common than vasogenic oedema (Finnie, 2013; Werner & Engelhard, 2007).  Increased 
cranial pressure (ICP) frequently occurs, due to haemorrhage (caused either by initial injury 
or by secondary processes) and oedema, and this is argued to be the most harmful secondary 
process (Finnie, 2013; Greve & Zink, 2009).   As a result of these factors, cell death, both 
necrotic and apoptotic, occurs from time of injury and may lead to increased neuronal 
degeneration indefinitely (Bigler, 2013; Stoica & Faden, 2010; Walker & Tesco, 2013), and 
there is evidence that other detrimental events such as increased amyloid pathology occur 
after TBI (Chen et al., 2004; Marklund et al., 2014).   
As can be seen from the above description, the processes that occur as a result of TBI 
are both complex and long-lasting.  Furthermore, there is increasing evidence that there are a 
number of biological and physiological factors which may exacerbate or ameliorate the 
progression of injury and subsequent outcomes.  The factor of interest in the current work is 
the APOE gene, which synthesises the protein apolipoprotein E (apoE).  As will be 
demonstrated in the following sections, isoformic differences in apoE have been shown to 
influence a number of injury processes.   
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The Role of APOE in TBI 
The focus of the current thesis is on the impact of the APOE gene, which synthesises 
apolipoprotein E (apoE).  One of the primary functions of apoE is lipid transport; indeed it is 
considered the main lipid transporter within the CNS (Leoni, Solomon, & Kivipelto, 2010; 
Mahley & Huang, 1999).  In addition to a transportation function, apoE is implicated in lipid 
clearance and recycling (Ignatius et al., 1986; Leoni et al., 2010; Struble, Nathan, Cady, 
Cheng, & McAsey, 2007).  Lipids, particularly cholesterol, are essential for normal 
neurological function and pivotal in the CNS response to TBI (Proust-Lima, Dartigues, & 
Jacqmin-Gadda, 2011).   Being the primary lipid transporter, apoE plays a crucial role in 
maintenance of neurological integrity and facilitation of post injury repair. There is also 
evidence that apoE is involved in amyloid accumulation and processing, although the 
relationship between apoE and amyloid pathology is complex and not yet well understood 
(Kanekiyo, Xu, & Bu, 2014). 
There is strong evidence that apoE is a key factor in the brain’s response to injury.  
Levels of apoE increase dramatically following TBI, with increased levels being reported up 
to 90 days post injury in rodent studies (Boyles, Pitas, Wilson, Mahley, & Taylor, 1985; 
Horsburgh, McColl, White, & McCulloch, 2003; Iwata, Browne, Chen, Yuguchi, & Smith, 
2005; Proust-Lima et al., 2011; White et al., 2001).  This increase appears to occur in both 
intra and extracellular areas, and both proximal and distal to the injury site (Orihara & 
Nakasono, 2002).   Poirier, Hess, May and Finch (1991) observed that in rats, apoE levels 
peaked at six days post injury; a time when regeneration of synapses also occurs, suggesting 
that apoE may play a role in reactive synaptogenesis. Given these results, it has been 
proposed that apoE promotes sprouting and synaptogenesis in the injured brain, both acutely 
and in the long term (Orihara & Nakasono, 2002; Snipes, Mcguire, Norden, & Freeman, 
1986; White et al., 2001).   
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Evidence suggests that apoE also has antioxidant properties, and as such it may 
reduce damage caused by lipid peroxidation and oxidative stress in TBI (Lomnitski et al., 
1999; Lomnitski et al., 1997). Lynch, Morgan, Mance and Laskowitz (2001) report that apoE 
deficiency results in increased inflammatory responses in mixed glial cultures (Lynch et al., 
2001), and further research indicated animals deficient in apoE experienced increased 
oxidative stress, oedema, and more widespread damage following TBI, particularly in 
hippocampal regions (Han & Chung, 2000; Lynch et al., 2002).  Animal studies also indicate 
that apoE may be important in maintaining the integrity of the blood brain barrier following 
TBI (Methia et al., 2001), and may influence amyloid aggregation after injury (Hartman et 
al., 2002; Leclercq, Murray, Smith, Graham, Nicoll, & Gentleman, 2005). Given these 
functions, it is believed that apoE plays a key role in multiple processes implicated in 
recovery following TBI (Houlden & Greenwood, 2006; Nicoll & Graham, 1997).  Figure 1 
depicts the primary and secondary responses associated with TBI, and identifies the processes 
which have been found to be impacted by the apoE protein.   
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Figure 1.  Primary and secondary injury responses (responses reported to be influenced by 
APOE are asterisked). 
 
 
 
 
APOE genotype: Implications for TBI recovery. 
 
In humans, there are the three common APOE alleles; ɛ2, ɛ3, and ɛ4, with estimated 
population frequencies of 11%, 72%, and 17% respectively (Zannis, Just, & Breslow, 1981).  
Each of the three alleles has been found to differ at only two sites – residues 112 and 158.  
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APOE ɛ2 has the amino acid cysteine at both residues, APOE ɛ3 has cysteine at residue 112 
and the amino acid arginine at residue 158, and APOE ɛ4 has arginine at both residues (Rall, 
Weisgraber, & Mahley, 1982).  Despite this relatively small difference, there are noteworthy 
isoformic differences in the structure of the resultant protein, as well as significant variations 
in affinity to cellular lipoprotein receptors, and binding to lipids (for a review see Mahley & 
Rall, 2000).  The structure of apoE ɛ4 has been demonstrated to be the least stable of the 
three isoforms and has increased misfolding, with evidence that this lack of structural 
integrity has a negative effect on secondary injury processes (Mahley & Huang, 2006).  
Notably, APOE ɛ4 has been found to be associated with greater post-TBI inflammation 
(Lynch et al., 2003) and also is associated with higher levels of amyloid plaques following 
TBI (Hartman et al., 2002; Nicholl, Roberts, & Graham, 1995), even when injury is mild 
(Yang et al., 2015). APOE ɛ4 has also been found to increase levels of aspartate and 
histamine post injury (Kerr et al., 2003; Mace et al., 2007), and to also be associated with 
increased ischaemic damage (Smith, Graham, Murray, Stewart, & Nicoll, 2006).  In short, it 
appears that possession of the APOE ɛ4 allele is associated with a range of detrimental 
neuropathological responses following TBI. 
 
APOE ɛ4 and cognitive function following TBI. 
It has been recognised that impaired cognitive ability is the most common complaint 
following TBI, and that this impairment is strongly associated with functional outcomes, 
regardless of injury severity (Gronwall & Wrightson, 1974; Konrad et al., 2011; Levin & 
Robertson, 2013; Spitz, Ponsford, Rudzki, & Maller, 2012).  Despite the relatively high 
incidence of TBI, injury severity estimates such as GCS and PTA have been found to offer 
limited prognostic value in terms of cognitive impairment, both in short and long term 
recovery (Azouvi, 2000; Balestreri et al., 2004; Lingsma, Roozenbeek, Steyerberg, Murray, 
15 
 
 
 
& Maas, 2010; de Oliveira Thais et al., 2014; Lovell, Iverson, Collins, McKeag, & Maroon, 
1999). 
 In response, there has been growing interest in identifying biological markers that 
might improve the ability to predict cognitive outcome after TBI, including APOE.  Interest 
in the APOE gene was initially prompted by the reported link between possession of the 
APOE ɛ4 allele and increased risk of Alzheimer’s disease (Corder et al., 1993; Saunders et 
al., 1993) and other neurological disorders in which cognitive dysfunction is a defining 
feature (Alfieri et al., 2008; Borroni et al., 2006; Chang et al., 2011). Despite the evidence 
that APOE ɛ4 may have detrimental properties in relation to post-injury neuropathology, how 
this translates to cognitive function following TBI remains unclear.  A number of studies 
report that APOE ɛ4 is associated with poorer outcomes post-TBI, but an equal number of 
studies have reported no effect.  Furthermore, there is tentative evidence that APOE ɛ4 can be 
ameliorative in some cohorts.  The following section reviews the literature to date in which 
the effect of APOE ɛ4 on post-TBI cognitive impairment has been investigated, in animal, 
paediatric, and adult TBI, with a focus on the extant adult TBI literature. 
 
Evidence from animal TBI models. 
Although animal models of TBI have demonstrated that a general apoE deficiency 
reduces cognitive function after injury (Chen, Lomnitski, Michaelson, & Shohami, 1997; 
Lomnitski, Chen, Shohami, Kohen, & Michaelson, 1997), the evidence regarding the specific 
effect of APOE ɛ4 on cognition post TBI is scant, with only two published findings to date.  
Mannix and colleagues (2011) found that compared to adult wild-type mice, adult APOE ɛ4 
mice displayed impaired cognitive performance following TBI, an effect that remained at up 
to 12 months post injury, however there was no difference in cognitive function between 
juvenile APOE ɛ4 and juvenile wild-type mice.  A later study by the same group (Mannix et 
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al., 2013) found that when repeated mild brain injury occurred APOE ɛ4 was not predictive 
of short or long term cognitive impairment, suggesting that any detrimental effects of APOE 
ɛ4 may only be present where pathology is moderate to severe.  Thus, both reports indicate 
that although APOE ɛ4 may have some impact on cognitive function post injury, age and 
injury severity may moderate outcomes.   
 
Evidence from paediatric TBI cohorts. 
Evidence from paediatric cohorts is also limited, with only two studies investigating 
paediatric TBI using neuropsychological measures.  Blackman, Worley and Strittmatter 
(2005) compared function in 71 children (mean age of 13.16 years) using the Functional 
Improvement Measure for Children, which provides a discrete measure of cognitive function, 
at time of injury and again at discharge.  They reported that the APOE ɛ4 carriers (n = 4) 
displayed better levels of function at time of discharge, suggesting greater recovery than non-
carriers.  Similarly, Moran and colleagues (2009) used a range of tasks to assess cognitive 
outcomes at 3 and 12 months following mild TBI in 99 children aged 8 to 15 years old.  It 
was found that APOE ɛ4 carriers (n = 28) performed better than non-carriers on a visual-
motor integration task, with no group differences evident on other tasks.  These findings 
suggest that APOE ɛ4 is not deleterious, and may confer an advantage in paediatric cohorts, 
thus aligning with the study by Mannix and colleagues (2011).  Conversely, it must be 
acknowledged that studies assessing general outcome using the extended Glasgow Outcome 
Scale (GOS-E) after TBI report that paediatric APOE ɛ4 carriers display poorer outcomes 
(Kurowski, Martin, & Wade, 2012).  However, the GOS-E is not a sensitive 
neuropsychological measure and there is some question as to the appropriateness of using this 
scale in paediatric cohorts (Liehlai et al., 1992).  
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Evidence from adult TBI cohorts. 
 
While research exploring the effect of APOE ɛ4 in adult TBI cohorts is more frequent, 
the findings remain equivocal and contradictory.  The following two tables provide a 
condensed summary of the literature to date, and are followed by a more integrative 
description of the key findings.  Table 1 summarises the evidence that indicates APOE ɛ4 has 
a detrimental effect post-TBI in adult cohorts, and Table 2 summarises research that indicates 
APOE ɛ4 has no effect, or may provide a beneficial effect in adults.  In order to further 
clarify the relationship between APOE status and cognitive function effect sizes are also 
included for adult TBI studies.  Where an effect size has been provided by the authors, these 
are reported, and where effect size has not been reported, either Cohen’s d or r has been 
calculated, depending on the nature of the data (for formulae see Dunlap, Cortina, Vaslow, & 
Burke, 1996; Rosenthal & Rubin, 2003).  Magnitude of effect is also estimated, and findings 
deemed to be clinically relevant have been identified, based on Ferguson’s (2009) guidelines 
for interpreting effect size for the social sciences. 
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Table 1   
 
Neuropsychological evidence for the detrimental effect of APOE ɛ4 allele on cognitive outcome following TBI  
Author 
(year) 
N 
APOE  
ɛ4 carrier 
n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Anderson et 
al. (2009) 
51 15 Mild to 
severe 
1, 6, 12, 
months & 
10 years 
 Verbal memory 
 Visual-Spatial 
ability 
 Psychomotor Speed 
 Verbal ability 
 Once adjusted for education APOE ɛ4 
carriers performed significantly poorer 
in tests of verbal IQ at 1 and 12 months 
after TBI, and verbal recall at 1, 6, and 
12 months after TBI. 
d = 0.01 - 0.73 
(d = 0.51 a -0.73 a 
for significant 
tests) 
(Small) 
Ariza et al. 
(2006) 
77 10 Moderate 
to severe 
6-9 months  Verbal memory 
 Visual memory 
 Executive function 
 Psychomotor speed  
 APOE ɛ4 carriers significantly poorer 
on 6/9 measures of verbal memory, 
executive function, and psychomotor 
speed. 
d = 0.27-0.77 
(0.50 a - 0.77a for 
significant tests) 
(Small) 
Crawford et 
al. (2002) 
110 30 Mild to 
severe 
Within 6 
months 
 Verbal learning and 
memory 
 Executive function 
 APOE ɛ4 carriers performed worse on 
verbal memory and learning measures  
 No significant differences in episodic 
memory or executive function tasks.  
R2 = .045a 
(Small) 
Eramudug-
olla et al.  
(2014) 
489 unknown Mild to 
severe 
Long term   Verbal learning and 
memory 
 Verbal ability 
 Attention 
 Working memory 
 Psychomotor speed 
 TBI sufferers in early adulthood 
(approx. 20 years old) with APOE ɛ4 
performed worse on tests of episodic 
memory than non-carriers  
 Middle-aged TBI sufferers with APOE 
ɛ4 (approx. 40 years old) performed 
poorer than non-carriers of the same 
age on reaction time tasks, but only 
when childhood TBI had occurred. 
 No differences in the cognitive 
performance in the older age group 
(approx. 60 years old). 
Insufficient data 
to estimate 
Continued overleaf… 
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Author 
(year) 
N 
APOE  
ɛ4 carrier 
n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Friedman et 
al. (1999) 
69 27 Mild to 
severe 
6 - 8 
months 
 General ability  Possession of APOE ɛ4 was predictive 
of sub-optimal outcome. A higher 
percentage of APOE ɛ4 carriers 
displayed severe behavioural and 
cognitive abnormalities, however these 
didn’t reach significance. 
 No significant interaction between age 
and APOE. 
Behaviour 
abnormalities 
OR = 2.71   
Severe cognitive 
abnormalities OR 
= 2.79a 
(Small) 
Müller et al. 
(2009) 
37 13 Mild Baseline 
(described 
as before 
discharge) 
and at 6 
months 
 Verbal learning and 
memory 
 Working memory 
 Executive function 
 Attention 
 All tasks were combined to determine a 
global cognitive impairment rating. 
APOE did not predict initial 
neuropsychological impairment, but 
APOE ɛ4 carriers were slower to 
recover, and at 6 month follow-up 
APOE ɛ4 carriers showed 
approximately half the improvement of 
the non- ɛ4 group.  
d = .45 
(Small) 
Noé et al. 
(2010) 
126 23 Moderate 
to severe 
Week after 
emergence 
from PTA 
then at 6 
months 
 Verbal learning and 
memory 
 Working memory 
 APOE ɛ4 carriers were initially more 
impaired but improved faster on some 
working memory tasks. 
 Authors suggested APOE genotype 
effects speed of recovery but not 
amount of recovery.  
d = 0.10 – 1.25a 
(Small – Med) 
 
 
 
Continued overleaf… 
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Author 
(year) 
N 
APOE  
ɛ4 carrier 
n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Sundström 
et al. (2004) 
30 11 Mild Within 5 
years 
 Attention  
 Verbal learning and 
memory 
 Visual learning and 
memory 
 Visual-Spatial 
ability 
 Executive function 
 Comparison of pre and post injury 
cognitive performance revealed that 
APOE ɛ4 carriers had a significant 
post-injury decline in three out of nine 
tasks (divided attention, recognition and 
recall), whereas there were no 
significant declines in the non- ɛ4 
carriers. 
 
d = 0.03 - 0.78 
Divided attention 
d = .78a 
Recognition d = 
.67a 
Recall d = .36 
(Small) 
a = Effect size is considered to be clinically significant, as recommended by Ferguson (2009) 
OR = Odds Ratio  
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Table 2   
 
Neuropsychological evidence of no effect of APOE ɛ4 allele on cognitive outcome following TBI  
Author 
(year) 
N 
APOE  ɛ4 
carrier n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Ashman et 
al. (2008) 
54 15 Mild to 
severe 
1-58 years 
(M = 12.8 
years) 
 Verbal memory 
and learning 
 Visual memory 
and learning 
 Processing Speed 
 Executive Function 
 Attention 
 Verbal 
ability/fluency 
 No significant differences in cognitive 
decline based on APOE status. 
Insufficient data 
to estimate 
Chamelian 
et al. (2004) 
90 19 Mild 6 months  Working memory 
 Verbal memory 
and learning 
 Visual memory 
and learning 
 Processing Speed 
 Attention 
 Executive function 
 No significant differences for any 
measures.  
d = 0.11 - 0.40 
(Small) 
Han et al. 
(2007) 
78 16 Mild to 
moderate 
1 month  Working memory 
 Processing Speed 
 Attention 
 Visual-Spatial 
ability 
 Executive function 
 Verbal memory 
and learning 
 APOE ɛ4 carriers performed better than 
non-APOE ɛ4 carriers on some 
measures of working memory and 
verbal learning, with trends for better 
performance on a number of other 
executive function, working memory 
and verbal learning measures.  
ηp2 = 0.00 - 0.14ab 
(Small) 
Continued overleaf… 
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Author 
(year) 
N 
APOE  ɛ4 
carrier n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Hodgkinson 
et al. (2009) 
58 13 
 
Severe 12 months  Verbal memory 
and learning 
 Visual memory 
and learning 
 Attention 
 Working memory 
 Visual-spatial 
ability 
 No significant differences between 
APOE ɛ4 and non- ɛ4 carriers on any 
tasks except DS, where APOE ɛ4 
carriers performed better than non- ɛ4 
carriers. 
d = 0.03 - 0.80 ab 
(Small) 
 
Isoniemi et 
al. (2006) 
61 19 Mild to 
severe 
Approx. 30 
years 
 Verbal memory 
and learning 
 Visual memory 
and learning 
 Verbal 
fluency/ability 
 General ability 
 Although initial analysis revealed 
APOE ɛ4 carriers performed 
significantly worse than non APOE ɛ4 
carriers, this result was attributed to six 
individuals who had developed 
dementia related symptomology.   
d = .04 – 1.00a 
(Small) 
Liberman et 
al. (2002) 
80 18 Mostly 
mild 
3 and 6 
weeks 
 Psychomotor speed 
 Attention 
 Processing speed 
 Executive function 
 Verbal memory 
and learning 
 Visual memory 
and learning 
 After controlling for age, sex, education 
and ethnicity, APOE ɛ4 carriers were 
found to perform poorer on 12 out of 13 
tasks, as compared to non- ɛ4 carriers, 
however only two tasks reached 
significance (PASAT and grooved 
pegboard).  A similar finding was 
reported for the second visit, where 
APOE ɛ4 carriers performed worse on 
11 out 13 tasks for visit 2, however 
none were significant. 
 Authors suggest presence of APOE ɛ4 
may impact on initial severity of 
impairment, but not rate of recovery. 
d = 0.004 - 0.61 
(0.59a and 0.61a 
for significant 
tasks) 
(Small) 
Continued overleaf… 
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Author 
(year) 
N 
APOE  ɛ4 
carrier n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Lichtman et 
al. (2000) 
31 7 Mild to 
Severe 
6 months  General ability 
 
 Significant differences between APOE 
ɛ4 and non- ɛ4 carriers for FIM total 
and motor subscale, but not FIM 
cognitive subscale 
FIM Total d = 
0.5a 
Cognitive 
Subscale d = 0.2 
(Small) 
Millar et al. 
(2003) 
396 117 Mild to 
severe 
15-25 years  Verbal memory 
and learning 
 Visual memory 
and learning 
 Attention  
 Verbal 
ability/fluency 
 Executive function 
 APOE ɛ4 status was not predictive of 
overall cognitive function, or for any of 
the specific cognitive domains.   
 APOE ɛ4 carriers who were initially 
classified with severe disability at time 
of injury demonstrated significantly 
poorer cognitive function than non-
APOE ɛ4 carriers who were also rated 
as being severely disabled. 
OR 0.83 – 1.54  
(Small) 
Ponsford et 
al. (2007) 
120 28 Moderate 
to severe 
3, 6, and 12 
months 
 Verbal memory 
and learning 
 Attention 
 Executive function 
 No significant differences due to APOE 
status on any tasks at any time point 
with the exception of the SMDT at 3 
months post injury.  
SMDT r = .20a 
(Small) 
Pruthi et al. 
(2010) 
73 12 Mild to 
moderate 
6 months  Attention 
 Visual learning 
and memory 
 Psychomotor speed 
 Verbal ability 
 No significant differences between 
APOE ɛ4 and non- ɛ4 carriers on any 
tasks. 
Insufficient data 
to estimate 
Rapoport et 
al. (2008) 
69 Unknown Mild to 
moderate 
12 and 24 
months 
 Working memory 
 Verbal learning 
and memory 
 Visual learning 
and memory 
 Executive function 
 No significant differences between 
APOE ɛ4 and non- ɛ4 carriers on 
performance on neuropsychological 
tasks, or clinician assessment of 
cognitive impairment. 
Insufficient data 
to estimate 
cognitive tasks. 
Clinician 
assessment d = 
0.37 (Small) 
Continued overleaf… 
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Author 
(year) 
N 
APOE  ɛ4 
carrier n  
Injury 
severity 
Time of 
assessment 
Cognitive function Summary of relevant findings 
Effect size 
(magnitude) 
Shadli et al. 
(2011) 
19 6 Mild to 
Moderate 
6 weeks and 
6 months 
 Visual-spatial 
ability 
 Verbal learning 
and memory 
 Executive function 
 APOE ɛ4 carriers did not perform 
worse than non-carriers who sustained 
TBI on any neuropsychological tasks. 
η2 = .002 - .087a 
(Small) 
Teasdale et 
al. (2000) 
39 10 Severe  Approx 1.9 
years post 
injury and 
12 months 
later 
 Attention 
 Verbal memory 
and learning 
 Visual memory 
and learning 
 Comparison of cognitive function at the 
commencement and cessation of a 
rehabilitation programme revealed that 
performance was the same for both 
APOE ɛ4 carriers and non-carriers, with 
the exception that APOE ɛ4 carriers had 
greater improvement on one memory 
task.   
d = 0.00 – 0.85ab 
(Small) 
 
a = Effect size is considered sufficient to be of clinical significance, as recommended by Ferguson (2009) 
b = APOE ɛ4 carriers performed significantly better than APOE non-ɛ4 carriers on at least one task 
LR = Likelihood ratio 
OR = Odds Ratio 
η2 = Eta Square 
ηp2 = Partial Eta Square 
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Although the literature regarding the effect of APOE ε4 on cognitive function after 
TBI is mixed, the above findings do offer some insights.  Firstly, the effect sizes reported 
above demonstrate that the magnitudes of effect are consistently small.  Nonetheless, many of 
these findings would still be considered clinically relevant based on the guidelines provided 
by Ferguson (2009).  Secondly, significant differences are most frequently reported in the 
first 12 months following injury, with a number of authors observing that APOE ɛ4 carriers 
displayer poorer cognitive performance in this period. The following sections describes the 
findings relating to recovery in the first 12 months after TBI, and this is followed by a 
summary of research relating to later outcomes. 
 
APOE ɛ4 and cognitive function in the first 12 months following TBI in adults. 
 A number of researchers have reported that APOE ɛ4 is associated with either greater 
cognitive impairment, or reduced recovery trajectories in the 12 months following TBI. 
Crawford and colleagues (2002) reported that verbal memory was significantly more 
impaired in APOE ɛ4 carriers than in non-carriers at 6 months following TBI, however there 
were no significant differences in measures of executive function.  Similarly, Ariza and 
colleagues (2006) found that APOE ɛ4 carriers performed poorer on tasks of verbal memory, 
as well as psychomotor speed, visual tracking and attention, and executive function, at 6 to 9 
months post injury.  It is noteworthy that in the study by Ariza et al there were no significant 
differences on the GOS-E despite poorer performance on a large number of 
neuropsychological tasks, suggesting that general measures of function such as the GOS-E 
are not sufficiently sensitive to detect cognitive impairment.  Friedman et al (1999) also 
assessed cognitive function at 6-8 months following TBI, and reported that APOE ɛ4 carriers 
had more serious behavioural and cognitive abnormalities, although it in not clear which 
cognitive domains were evaluated. 
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Although the above findings indicate APOE ɛ4 carriers may have greater impairment 
than non-carriers during the first year after TBI , a number of investigations have failed to 
find any significant differences in the same time period (Table 2; Chamelian, Reis, & 
Feinstein, 2004; Hodgkinson, Gillett, & Simpson, 2009; Liberman, Stewart, Wesnes, & 
Troncoso, 2002; Lichtman, Seliger, Tycko, & Marder, 2000; Pruthi et al., 2010; Shadli, 
Pieter, Yaacob, & Rashid, 2011), although it is noteworthy that when Liberman et al 
compared the performance of APOE ɛ4 carriers and non-carriers on a battery of 13 
neuropsychological tests 3 and 6 weeks after TBI, they observed that, although not reaching 
significance, the APOE ɛ4 group displayed poorer performances than the non-carrier group 
on all but one task at the first visit, and all but two tasks at the second visit.  The consistency 
in direction of effects suggests that a larger sample size may have revealed significant 
differences. 
There is also some evidence that possession of APOE ɛ4 might lead to reduced 
recovery trajectories.  Müller and colleagues (2009) compared APOE ɛ4 carriers and non-
carriers cognitive performance at time of injury and at 6 months following mild TBI and 
reported that although there were no differences between APOE ɛ4 and non-carriers at the 
baseline assessment, APOE ɛ4 carriers displayed a lower global score at 6 months. It was 
reported that non-carriers had approximately twice the rate of recovery of the APOE ɛ4 
group, indicating a significantly slower recovery trajectory associated with APOE ɛ4.  The 
authors also observed that APOE genotype was a better predictor of 6 month outcome than 
Glasgow Coma Scale score (GCS) or other neurological indicators.   
Interestingly, others have reported the opposite effect.  Despite using similar tasks to 
Müller et al., Noé, Ferri, Colomer, Moliner and Chirivella (2010) found that APOE ɛ4 
carriers initially displayed greater cognitive impairment than non-carriers, but then recovered 
at a faster rate, and by 6 months there were no significant differences between the two 
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groups.  While this finding appears to be at odds with Müller et al (2009), there are two 
distinctions that should be noted.  Firstly, Müller et al recruited participants with mild TBI 
(classified as 13-15 on the GCS), whereas the participants in Noé et al’s study had moderate 
to severe TBI (GCS < 12).  Therefore it is possible that the effect of APOE ɛ4 is accentuated 
by other factors associated with more severe neuropathology during early recovery; a finding 
which aligns with the previously described animal study by Mannix et al (2013), but does not 
explain the faster recovery rate reported by Noé.  Secondly, in Noé et al’s study the 
differences were only apparent in the some of the working memory tasks; the APOE ɛ4 group 
did not display superior rates of recovery across the majority of tasks.  Given that Müller and 
colleagues used a global score, it is difficult to compare these two findings in terms of 
whether similar domains were affected.   
Anderson and colleagues (2009) also employed a longitudinal design when they 
assessed neuropsychological performance at 1, 6, and 12 months, and 10 years post-TBI.  
When education was controlled for, APOE ɛ4 carriers performed significantly worse than 
non-carriers on tasks of verbal memory at 1, 6 and 12 months following injury, and on the 
verbal intelligence quotient subscale of the Wechsler Adult Intelligence Scale at 1 and 12 
months post TBI.  No significant differences were found on any tasks at the 10 year time-
point, suggesting that possession of the APOE ɛ4 allele may be associated with delayed 
recovery for a period of time following injury, but not necessarily progress into chronic 
impairment.  This supports the findings reported in the shorter-term studies (Ariza et al., 
2006; Crawford et al., 2002; Friedman et al., 2009) described above. In contrast, Ponsford, 
Rudzki, Bailey and Ng (2007) failed to find any differences using similar tasks at 3, 6 and 12 
months post-injury, with the exception of a single attention task at 3 months.  It is difficult to 
reconcile these conflicting findings given the sample characteristics and measures used in 
both studies are relatively similar.   
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While the majority of published adult TBI studies indicate that APOE ɛ4 carriers 
either have poorer cognitive outcomes or no differences in cognitive outcomes to non- ɛ4 
carriers, Han et al (2007) report contradictory findings. In an examination of the 
neuropsychological performance of young adults within a military population 1 month 
following a mild to moderate TBI, Han et al (2007) found that APOE ɛ4 carriers performed 
significantly better than non-carriers on several measures of working memory, verbal 
learning and recall, and executive function. Although this finding implies APOE ɛ4 may have 
a beneficial effect for young adult TBI sufferers, it must be noted that for the majority of 
tasks, there were no significant differences.   
 
APOE ɛ4 and long-term cognitive function following TBI in adults. 
There is less evidence that APOE ɛ4 is associated with longer-term cognitive 
impairment, however, some long-term studies have also reported a detrimental effect of 
APOE ɛ4 on cognitive function. Sundström et al (2004) compared pre- and post-injury 
neuropsychological performance by recruiting through an ongoing longitudinal health study.  
Individuals who reported sustaining a TBI within the 5 year period between assessments 
(approx. 19 months after TBI) were grouped according to APOE genotype, and the authors 
reported greater cognitive decline in the APOE ɛ4 group following TBI on attention and 
memory tasks.  It should be noted that significant post-injury decline in the APOE ɛ4 group 
was only observed on three out of nine measures.  In another retrospective study, 
Eramudugolla et al (2014) compared cognitive decline following self-reported TBI in three 
adult cohorts (early, middle and old-aged groups – aged approx. 20, 40 and 60 years 
respectively) who were assessed three times across an 8 year period.  When APOE ɛ4 carriers 
and non-carriers were compared within each age cohort, it was found that APOE ɛ4 carriers 
in early adulthood experienced greater declines in episodic memory than non-carriers, and 
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that the APOE ɛ4 carriers in the middle aged cohort had significantly greater declines in 
reaction time than non-carriers.  Those in older adulthood showed no significant differences 
based on APOE ɛ4 status. It was also noted that there were significant differences between 
the sexes, with females performing worse than males in the middle and later adulthood 
groups, however the interaction between sex and genotype was not investigated.  The reliance 
on self-report of the timing and severity of the TBI reduces the reliability of this finding, as 
many participants were self-reporting and estimating injury from many years previous.  
Furthermore, the substantial variation in time of follow-up assessment in both Sundström et 
al and Eramudugolla et al’s studies may also have obscured effects should there be differing 
recovery trajectories as reported in other literature (Anderson et al., 2009; Noé et al., 2010; 
Müller et al., 2009).    
Alternatively, Teasdale and colleagues (2000) compared APOE ɛ4 carriers and non-
carriers cognitive function on a range of tasks at the commencement of a rehabilitation 
programme (approximately 1.9 years after injury) and 12 months later.  Despite subjective 
reports by APOE ɛ4 carriers and their relatives indicating they had poorer cognitive recovery, 
actual performance on neuropsychological tasks was the same for both APOE ɛ4 carriers and 
non-carriers, with the exception that APOE ɛ4 carriers showed greater improvement on one 
verbal memory measure; a result the authors thought likely to be spurious. 
Very long term studies have found no significant differences based on APOE status 
following TBI (Anderson et al 2009; Ashman et al, 2008; Isoniemi, Tenovou, Portin, 
Himanen & Kairisto, 2006; Millar, Nicholl, Thornhill, Murray, & Teasdale, 2003; Rapoport 
et al, 2008). However, Millar and colleagues observed that the APOE ɛ4 carriers with severe 
TBI had poorer cognitive function than non-carriers who had also sustained a severe TBI, 
suggesting that increasing injury severity may pronounce the effect of APOE ɛ4.  Isoniemi et 
al also assessed individuals who had sustained a TBI 30 years earlier (age at testing approx. 
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60 years), and reported that APOE ɛ4 carriers had significantly poorer cognitive outcomes 
than non-carriers, although further analysis revealed this was solely due to a subgroup of six 
individuals who had developed dementia symptoms.  These findings are somewhat surprising 
given the hypothesised relationship between APOE ɛ4 and AD incidence (Corder et al., 
1993); if the relationship between APOE and AD is due to APOE ɛ4 carriers having 
increased age-related cognitive decline it would be expected that APOE ɛ4 carriers in this age 
group would display greater cognitive decline than non- ɛ4 carriers, regardless of whether or 
not a TBI had been sustained. Collectively, the above findings indicate that although the 
APOE ɛ4 allele may be associated with delayed recovery, particularly within the first year 
following injury, this does not appear to progress into chronic impairment.   
 
Issues associated with APOE ɛ4 research in TBI populations. 
 
Given the mixed findings reported to date, it is suggested that a more nuanced 
approach to exploring the role of APOE status in the TBI population is needed.  For example, 
there have been calls for more detailed investigations of all three APOE alleles, rather than 
focus on APOE ɛ4 (Ponsford, 2013; Weaver et al., 2014).  To date, it has been routine 
practice to categorise participants as either ε4-carriers (possessing a genotype of ɛ2/ɛ4, ɛ3/ɛ4 
or ɛ4/ɛ4) or non-carriers (ɛ2/ɛ2, ɛ2/ɛ3, or ɛ3/ɛ3).  However, there is emerging evidence that 
the ε2 allele is dominant over the ε3 and ε4 alleles, and may confer protection following 
insult or injury (Corder et al., 1994; Laskowitz, Horsburgh, & Roses, 1998; Mahley & Rall 
2000; Miller et al., 2010).  Thus, inclusion of individuals with an ɛ2/ɛ4 genotype may mask 
any deleterious effects of ε4, and alternately the inclusion of ε2 carriers in the non-carrier 
cohort may inflate differences between ε4-carriers and non-carriers.  It has also been 
suggested that APOE ε2 carriers should be grouped separately, given the potential protective 
properties of this allele (Suri, Heise, Trachtenberg, & Mackay, 2013).   
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It has also been claimed that the expression of APOE may be influenced by biological 
and environmental factors (Ordovas, 2007).  Specifically, there is emerging evidence that sex 
may interact with APOE ɛ4 in relation to risk of developing AD (Altman et al., 2014; Ungar, 
Altmann & Greicius, 2014),  and that both age and sex might interact with APOE ɛ4 in 
relation to cognitive function (Beydoun et al., 2012; Jack et al., 2015).  Despite this, there are 
yet to be any investigations employing neuropsychologically-sensitive tasks to investigate the 
relationship between sex and APOE status, and there are very few published studies 
exploring of the interaction between age and APOE status in TBI populations.  The focus of 
this thesis is therefore to more fully explore the role of APOE ɛ4 in post-TBI cognitive 
function by comparing the effects of APOE ɛ4 to the predominant genotype; APOE ɛ3, and if 
possible, also exploring the effect of the APOE ɛ2 allele.  Additionally, the relationship 
between sex and age and the APOE gene is of interest in the current thesis, and the following 
section provides a brief review of the evidence regarding these issues.  
 
The effect of age on APOE ɛ4 expression: Evidence of antagonistic pleiotropy? 
It is possible that any detrimental effect of APOE ɛ4 is moderated by age, and that 
APOE ɛ4 may even be beneficial in young individuals.  For example, animal studies have 
found that APOE ɛ4 may be associated with poorer cognitive performance in both injured 
and non-injured older adults, but not in juvenile animals (Mannix et al., 2011; Raber et al., 
1998; Veinbergs et al., 1999).  And, as noted previously, there is evidence that the APOE ɛ4 
allele may be associated with improved cognitive performance in paediatric TBI cohorts 
(Blackman, Worley, & Strittmatter, 2005; Moran et al., 2009), and in young adult TBI 
populations (Han et al, 2007).  However, in adult TBI populations, there are only two studies 
that have explored the effect of age; one reporting no age-related interactions (Friedman 
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1999), and the other reporting a decreased difference in cognitive impairment between APOE 
ɛ4 carriers and non-carriers post TBI in later life (Eramudugolla et al, 2014).   
The difference between findings in juvenile and young adults, as compared to older 
cohorts, might be reconciled by considering the concept of antagonistic pleiotropy.  The 
antagonistic pleiotropy hypothesis proposes that gene(s) may exert beneficial effects upon a 
given trait before and during the reproductive phase of life, and have a deleterious effect in 
post-reproductive life (Carter & Nguyen, 2011), and some authors have suggested this 
explains the relationship between APOE polymorphism and Alzheimer’s Disease (Han & 
Bondi, 2008; Leroi et al, 2005; Tuminello & Han, 2011).  There is a growing body of 
evidence that APOE does indeed have an antagonistic pleiotropic effect on a range of non-
cognitive traits (Jasienska, Ellison, Galbarczyk, Jasienski, & Kalemba-Drozdz, 2015; 
Kulminski et al., 2013; Kulminski et al., 2011; Wierenga et al., 2013), and possibly has a 
similar effect on cognitive function in some clinical cohorts (Chang et al., 2011).  However 
the evidence for an antagonistic effect on cognitive function remains inconclusive, with some 
finding evidence to support this mechanism (Jochemsen, Muller, van der Graaf, & Geerlings, 
2012; Marchant, King, Tabet, & Rusted, 2010; Mondadori et al., 2007; Nichols et al., 2012; 
Rusted et al., 2013; Yu, Lin, Chen, Hong, & Tsai, 2000), and others finding no effect (Bunce, 
Anstey, Burns, Christensen, & Easteal, 2011; Bunce et al., 2014; Jorm et al., 2007).  The 
antagonistic pleiotropic hypothesis is yet to be applied to cognitive impairment for APOE ɛ4 
carriers versus non-carriers following TBI, but may prove to be a fruitful line of research 
given some of the age effects described above. 
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The effect of sex on APOEɛ4 expression: Are female APOE ɛ4 carriers more 
vulnerable to cognitive impairment? 
It has been established that higher levels of oestrogen increase production of apoE 
(Horsburgh, Macrae, & Carswell, 2002; Struble, Nathan, Cady, Cheng, & McAsey, 2007), 
with evidence indicating that allelic variations of APOE may influence this relationship 
(Lambert, Coyle, & Lendon, 2004).  There is also tentative evidence to suggest that there are 
sex differences which may interact with APOE status to influence cognitive function, with 
Raber and colleagues (1998) reporting that older APOE ɛ4 carrying female mice displayed 
poorer cognitive performance than their male counterparts (Raber et al., 1998).  Furthermore, 
in both healthy and cognitively impaired human populations, females who possess APOE ɛ4 
have been found to have greater age related cognitive decline than APOE ɛ4 males (Bartres-
Faz et al., 2002; Fleisher et al., 2005; Mortensen & Hogh, 2001).   Other researchers have 
reported that oestrogen use by post-menopausal females reduces age related cognitive decline 
in non-carriers, but does not slow cognitive decline in APOE ɛ4 carriers, suggesting that the 
interaction between sex and APOE is less efficacious for APOE ɛ4 carriers (Yaffe, Haan, 
Byers, Tangen, & Kuller, 2000).  Interestingly, Ponsford and colleagues (2011) also reported 
that following TBI, female APOE ɛ4 carriers over the age of 55 had poorer outcomes (as 
measure by the GOS-E) than males of the same age, or than female non-carriers. These 
findings may indicate that in female APOE ɛ4 carriers, premenopausal levels of oestrogen 
ameliorate the detrimental effect of APOE ɛ4 by increasing apoE levels, but when oestrogen 
levels drop following menopause, apoE production also declines, and therefore the 
detrimental effect of the poorly structured apoE ɛ4 isoform is increased.  However this 
hypothesis is yet to be tested and is thus highly speculative. 
Although none of the neuropsychological studies reviewed above investigated 
potential sex differences in relation to APOE ɛ4, Eramudugolla and colleagues (2014) 
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observed in their long term retrospective study that young adult females tended to outperform 
males of the same age, and older females performed worse than their male counterparts on a 
number of measures memory and reaction time, however the authors did not investigate the 
interaction between sex and genotype. In contrast, Alexander and colleagues (2007a) reported 
no interaction between APOE and sex in their investigation of general functional outcome 
during the first two years after severe TBI.  Given the relationship between sex hormones and 
APOE described in the above, investigation of the interaction between sex and APOE, using 
sensitive neuropsychological tasks, rather than functional outcome measures, is needed.   
 
 
Thesis Aim and Chapter Outline 
The aim of the thesis was to provide a more nuanced and rigorous exploration of the 
effect of APOE ɛ4 on cognitive function following TBI than has previously occurred. This 
was done firstly by conducting a meta-analysis of the extant literature, as no such analysis 
had been published at the time of writing.  Based on the conclusions drawn from the meta-
analysis, and from the broader review of literature, two studies were undertaken; one during 
the acute recovery period, and a second longitudinal study at 3, 6 and 12 months after TBI, 
both of which employed sensitive neuropsychological tasks.  
In order to provide a more focused exploration of the impact of APOE ɛ4 on post-TBI 
cognitive function, the majority of the research undertaken in this thesis compares ɛ4 carriers 
who did not also possess the APOE ɛ2 allele (thus, those with either an ɛ4/ɛ3 or ɛ4/ɛ4 
genotype) to participants who were homozygous for APOE ɛ3 allele (those with a 
homozygous ɛ3/ɛ3 genotype), due to the potentially opposing effects of the APOE ɛ2 and 
APOE ɛ4 alleles.  Beyond exploring the relationship between APOE status and post-TBI 
cognitive function, there were additional objectives of investigating the potential interactions 
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between APOE ɛ4 and age, APOE ɛ4 and sex, and APOE ɛ4 and TBI severity. While it was 
planned to examine the effect of the APOE ɛ2 allele, due to the relative population 
infrequency of this allele it was not certain that sufficient participants with this allele would 
be identified.  Thus, there were five hypotheses: 
 
 Hypothesis 1:  That APOE ɛ4 carriers (ɛ4/ɛ3 and ɛ4/ɛ4) who had sustained a TBI 
would experience poorer cognitive function than APOE ɛ3 homozygotes in the first 
12 months after injury.  This is the primary hypothesis of this thesis and is explored in 
the studies reported in chapters 2, 5, and 6. 
 
 Hypothesis 2: That age would interact with APOE ɛ4 via an antagonistic pleiotropic 
mechanism, whereby young adult APOE ɛ4 carriers (ɛ4/ɛ3 and ɛ4/ɛ4) would not 
experience cognitive impairment (or may even display superior performance) as 
compared to APOE ɛ3 homozygotes of the same age, whereas older APOE ɛ4 carriers 
would demonstrate poorer cognitive function than APOE ɛ3 homozygotes of the same 
age, following TBI.  This question is addressed in chapter 6. 
 
 Hypothesis 3: That there would be an interaction between APOE ɛ4 and sex, 
resulting in females being more vulnerable to the effect of APOE ɛ4 than males, in 
relation to post-TBI cognitive function.  This hypothesis is investigated in chapter 6. 
 
 Hypothesis 4: In severe TBI that APOE ɛ4 carriers (ɛ4/ɛ3 and ɛ4/ɛ4) would 
experience more pronounced cognitive impairments than APOE ɛ3 homozygotes.  
This hypothesis is explored in chapter 5. 
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 Hypothesis 5: Contingent on sufficient recruitment of ɛ2 carriers, that APOE ɛ2 
carriers would outperform both APOE ɛ4 carriers and APOE ɛ3 homozygotes.  This 
question is addressed in chapter 5.  
 
Chapter 2 contains the meta-analysis of the research to date.  This meta-analysis 
incorporates literature from adult TBI populations in which neuropsychological assessment 
was undertaken within the first 12 months following injury.  As will be demonstrated, despite 
conducting separate analyses for general cognitive function and domain-specific cognitive 
function, there was no evidence of APOE ɛ4 having a detrimental impact on cognitive 
function.  Possible reasons for this finding and directions for future research, are offered.  The 
content of this chapter is currently in press: 
 
Padgett, C. R., Summers, M. J., & Skilbeck, C. E. (in press).  Is APOE ɛ4 associated with 
poorer cognitive outcome following traumatic brain injury? A meta-analysis. 
Neuropsychology. 
 
Chapters 3 and 4 provide the general method for this thesis.  Given the longitudinal 
nature of the research, it was foreseen that missing data would be likely, and although not 
directly related to the research questions described above, it was therefore also decided that 
using the clinical data collected for this thesis would provide a valuable opportunity to 
explore the effect of missing data on clinical data. Specifically, a series of traditional and 
more sophisticated statistical approaches used to compensate for the effects of missing data 
were applied to a sub-set of the data to determine the relative effects of each technique.  The 
findings from this were also published in a peer reviewed journal, which forms the basis of 
chapter 4: 
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Padgett, C. R., Skilbeck, C. E., & Summers, M. J. (2014). Missing data: The importance and 
impact of missing data from clinical research. Brain Impairment, 15, 1-9.  
 
Chapter 5 reports the findings on the effect of APOE ɛ4 on cognitive function during  
the acute recovery period following TBI once other injury and demographic-factors were 
accounted for.  An advantage of this study over previous studies which have used 
neuropsychological assessment during the acute recovery phase were the additional analyses 
in which of APOE ɛ2 carriers were treated a separate group, and an investigation of the effect 
of APOE ɛ4 specifically in moderate to severe TBI.  This series of analyses indicated that 
APOE ɛ4 was unlikely to influence initial cognitive recovery, even where injury was more 
severe, and provided tentative evidence that APOE ɛ2 did not appear to influence recovery.  
These findings are currently in press: 
Padgett, C. R., Summers, M. J., McCormack, G. H., Vickers, J. C. & Skilbeck, C. E (in 
press). Exploring the effect of the APOE gene on executive function, working 
memory and processing speed during the early recovery period following traumatic 
brain injury.  Journal of Clinical and Experimental Neuropsychology. 
  
Chapter 6 contains the final study for this thesis, in which the interaction between 
APOE ɛ4, sex, and age, are investigated in the context of cognitive impairment at 3, 6 and 12 
months post-injury.  In this study, no interactions were found between APOE ɛ4 and age or 
sex, however APOE ɛ4 carriers performed worse than non-carriers on the Trail-Making Task 
B (TMTB) at 6 months post-TBI, and there was a trend for poorer performance on the 
Controlled Oral Word Association Task (COWAT).  This may provide evidence for a 
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domain-specific effect of APOE ɛ4, whereby APOE ɛ4 carriers experience poorer executive 
function, however this finding must be interpreted cautiously unless confirmed by future 
research.  This study has been submitted and is undergoing review: 
Padgett, C. R., Summers, M. J., Honan, C. A.,  McCormack, G. H.,  Vickers, J. C., & 
Skilbeck, C. E. (under review).  Does Apolipoprotein ɛ4 interact with age or sex in 
cognitive function after traumatic brain injury? Brain [BRAIN-2016-00203]. 
 
Chapter 7 concludes with a general discussion which summarises the key findings, 
and describes the limitations and applications of this thesis.  The final section of this chapter 
aims to provide directions for future research. 
 
 
 
 
 
 
 
 
 
 
 
  
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2:  Is APOE ɛ4 Associated with Poorer Cognitive Outcome Following 
Traumatic Brain Injury? A Meta-analysis. 
 
 
 
 
 
 
 
 
 
 
Published as: 
Padgett, C. R., Summers, M. J., & Skilbeck, C. E. (in press).  Is APOE ɛ4 associated with 
poorer cognitive outcome following traumatic brain injury? A meta-analysis. 
Neuropsychology. 
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Abstract 
 
Objective:  Cognitive impairment is a common sequelae of traumatic brain injury (TBI), 
however predicting who will experience poorer outcomes remains challenging.  A potential 
risk factor that has gained attention is the APOE gene, with the ɛ4 allele hypothesised to have 
a detrimental effect on post-TBI cognitive outcome.  The aim of this meta-analysis was to 
evaluate the effect of APOE ɛ4 both in terms of general cognitive function and within 
specific domains known to be prone to impairment following TBI (executive function, 
working memory, verbal memory and visual memory). 
Method:  A literature search was undertaken in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA), resulting in the inclusion of ten 
studies (ɛ4-carriers n = 143, non-carriers n = 510).  Neuropsychological tasks were identified 
and Cohen’s d was calculated and pooled.  Meta-analyses were conducted on general 
cognitive functioning, and for the specific cognitive domains of interest.  
Results: No significant differences were found between APOE ε4-carriers or non-carriers, 
either in general cognitive function, or in the cognitive domains of executive function, 
working memory, verbal memory or visual memory.   
Conclusions: This meta-analysis indicates that APOEɛ4 does not have a detrimental effect on 
cognitive performance following TBI.  We propose that the relationship between APOE and 
cognitive function following TBI is complex, and a more nuanced exploration of APOE 
genotypes is needed.   
 
 
Keywords: Traumatic Brain Injury, Apolipoprotein E, Cognitive Function, Executive 
Function, Working Memory, Visual Memory, Verbal Memory.  
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Introduction 
 
Investigations of candidate gene-environment interactions (cGxE) have become 
increasingly popular within psychological research.  The initial proliferation of significant 
findings in a broad range of cGxE investigations attracted widespread attention, with recent 
advances and greater cost-efficiency of genotyping technologies resulting in a burgeoning 
number of publications in recent years.  An emerging area of research is the exploration of 
gene-related effects following traumatic brain injury (TBI), including the possibility that 
cognitive impairment may be impacted by the expression of a given gene.  Cognitive 
impairment is considered the most common and enduring complaint following TBI, and is 
often reported to be the greatest impediment to resumption of normal life (Draper & Ponsford 
2008; Konrad et al., 2011; Spitz, Ponsford, Rudzki, & Maller, 2012).  The ability to predict 
who will experience impairment remains poor, with physiological measures of injury severity 
and pre-morbid characteristics offering limited prognostic value, especially in mild TBI 
(Azouvi 2000; Jacobs et al., 2013; Lannsjo, Backheden, Johansson, af Geijerstam, & Borg, 
2013; de Oliveira Thais et al., 2014).  The APOE gene has received attention as a potential 
predictor of injury severity and outcome, with research focussing on the ɛ4 allele.   
 
The APOE gene: General characteristics and function. 
 
The APOE gene is located on the long arm of chromosome 19, and expresses the 
amino-acid glycoprotein Apolipoprotein E (apoE; Scott, Knott, Shaw, & Brook, 1985).  
ApoE is considered to be the primary lipid transporter within the central nervous system, 
providing cholesterol and other lipids which are essential for maintaining neurological 
integrity and facilitation of post injury repair (Mahley, 1988), and is also believed to play a 
role in lipid clearance and recycling (Ignatius et al. 1986; Leoni, Solomon, & Kivipelto, 
2010; Mahley & Huang, 1999).  Consistent with this, it has been shown that levels of apoE 
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increase dramatically in response to TBI (Horsburgh, McColl, White, & McCulloch, 2003; 
Poirier, Hess, May, & Finch, 1991).  ApoE has also been reported to be involved in multiple 
processes implicated in cellular recovery following TBI, including: maintaining the integrity 
of the blood brain barrier (Methia et al., 2001); neural growth and regeneration (Horsburgh, 
Graham, Stewart, & Nicholl, 1999; Mahley & Rall, 2000); reactive synaptogenesis (Poirier et 
al., 1991); acute and long-term sprouting and synaptogenesis (Orihara & Nakasono 2002; 
Snipes, Mcguire, Norden, & Freeman, 1986; White, Nicholl, & Horsburgh, 2001); and 
reduction of oxidative stress and oedema, particularly in hippocampal regions (Han & Chung 
2000; Lynch et al., 2002).  In short, there is strong evidence to indicate that apoE is a crucial 
protein that is associated with a wide range of neurobiological responses to TBI.  
In humans, there are three common APOE alleles; ɛ2, ɛ3, and ɛ4, with population 
frequencies of approximately 11%, 72%, and 17% respectively (Eisenberg, Kuzawa, & 
Hayes, 2010; Zannis, Just, & Breslow, 1981), with each allele synthesising a structurally 
different form of protein (Utermann, Langenbeck, Beisiegel, & Weber, 1980).  The protein 
synthesised by the APOE ɛ4 allele has been demonstrated to be the least stable of the three, 
with evidence of increased misfolding in the resultant protein, which is believed to contribute 
to neurodegeneration and apoptosis (for a review see Mahley & Huang, 2012).  APOE ɛ4 has 
been associated with increased incidence and poorer outcomes in Alzheimer’s disease and 
other neuropathological events (Saunders et al., 1993; Strittmatter et al., 1993; Verghese, 
Castellano, & Holtzman, 2011), particularly when present in the homozygous condition, 
indicating a possible dose-dependent effect (Corder et al, 1993; Engelborghs et al, 2006; 
Hostage et al, 2013).   
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APOE ɛ4 and cognition. 
 
While there is convincing evidence that APOE ɛ4 is associated with 
neurodegenerative disorders in which cognitive decline is a defining feature, there are mixed 
findings regarding the nature of the relationship between APOE ɛ4 and cognitive function in 
other clinical populations.  For example, Louko, Vilkki, and Niskakangas (2006) reported 
that ɛ4-carriers performed worse than non-carriers on tasks of visual memory, verbal fluency 
and attention following aneurysmal subarachnoid haemorrhage, and Wagle et al (2010) found 
that ɛ4-carriers performed worse than non-carriers on tests of verbal memory and learning 
following stroke.   There is also evidence that APOE ɛ4 is associated with a more rapid 
progressive cognitive decline in HIV and Parkinson’s disease (Chang et al, 2014; Mata et al, 
2014).  However, others have found no meaningful differences between the cognitive 
performance of ɛ4-carriers and non-carriers in the same clinical populations (Becker et al, 
2015; Bour et al, 2010; Federoff, Jimenez-Rolando, & Singleton, 2012; Morris, Wilson, 
Dunn & Nicholl, 2004).   
The relationship between APOE ɛ4 and cognition is equally contentious in healthy 
populations.  Small et al (2004) and Wisdom, Callahan and Hawkins (2011) conducted meta-
analyses on the effect of APOE ɛ4 on cognition in healthy adults, both finding that ɛ4-carriers 
demonstrated poorer performance than non-carriers on measures of global cognitive function, 
executive function, and episodic memory. Additionally, Wisdom et al reported that 
perceptual speed was reduced for ɛ4-carriers. However, both these meta-analyses included 
predominately older-aged adults, and other age-stratified studies have failed to find an effect 
of APOE on cognitive function within any age group (Bunce et al, 2014; Jorm et al 2007).  
Rather than a detrimental effect, Rusted and colleagues (2013) reported superior cognitive 
function in young adult ɛ4-carriers.  Tuminello and Han (2011) reviewed the literature from 
both healthy and dementia-related cohorts across the lifespan and found that young ɛ4-
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carriers may have greater neural recruitment than non-carriers, but it was unclear whether this 
translated into improved cognitive function.  There was also evidence of earlier and more 
rapid cognitive decline in older ɛ4-carriers, but preserved cognitive function in non-demented 
very-old (> 90 years) ɛ4-carriers, as compared to non-carriers.  These contradictory findings 
have led some authors to suggest that any effect of APOE genotype on cognition may be 
domain-specific, and /or may be moderated by other environmental or biological factors 
(Jochemsen, Muller, van der Graff & Geerlings, 2012; Rusted et al., 2013; Small et al, 2004; 
Tuminello & Han, 2011, Wisdom et al., 2011).   
Evidence for APOE ɛ4 impacting cognitive outcome following TBI is also mixed.  
While some reports have indicated that possession of APOE ε4 results in a detrimental effect 
on cognitive outcome following TBI (Anderson et al., 2009; Ariza et al., 2006; Crawford et 
al., 2002; Eramudugolla et al., 2014; Friedman et al., 1999; Müller et al., 2009; Noé, Ferri, 
Colomer, Moliner, & Chirivella, 2010; Sundström et al., 2004), others have failed to find any 
effects (Ashman et al., 2008; Chamelian, Reis, & Feinstein, 2004; Hodgkinson, Gillett, & 
Simpson, 2009; Isoniemi, Tenovuo, Portin, Himanen, & Kairisto, 2006; Liberman, Stewart, 
Wesnes, & Troncoso, 2002; Miller et al., 2010; Ponsford et al., 2011; Ponsford, Rudzki, 
Bailey, & Ng, 2007; Pruthi et al., 2010; Rapoport et al., 2008; Shadli, Pieter, Yaacob, & 
Rashid, 2011; Teasdale, Jorgensen, Ripa, Nielsen, & Christensen, 2000), and there have been 
reports that ε4-carriers may even display better cognitive outcomes following TBI than non-
carriers (Han et al., 2007; Noé et al., 2010).   
Unfortunately, there are a number of factors which make interpretation and 
comparison of the findings from the TBI literature problematic. Firstly, although TBI was 
recently defined as ‘an alteration on brain function, or other evidence from brain pathology, 
caused by an external force’ (Menon, Schwab, Wright & Maas, 2010, p.1637), it is 
recognised that alteration to function can be difficult to confirm when TBI is mild, or when 
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there has been a delay in the person presenting for medical assessment.  Additionally, altered 
function may not become apparent until later in the recovery process and it can be unclear 
whether some symptoms have occurred as a direct result of a TBI, or are due to other events, 
such as orthopaedic injury or pharmacological treatment (Menon et al, 2010).   These issues 
may lead to systematic differences between studies depending on the assessment protocols 
used at a given research/medical center, or as a result of differences in individual 
presentations. Furthermore, as there is no reliable biomarker of injury severity for TBI, it is 
necessary to estimate injury severity by using scales such as the Glasgow Coma Scale (GCS) 
or length of post-traumatic amnesia (PTA), which are based on behavioural responses post-
injury, rather than underlying clinical pathology.  While both are relatively reliable estimates 
of injury, there is a lack of correlation between severity estimates obtained from GCS as 
compared to PTA (Sherer, Struchen, Yablon, Wang, & Nick, 2008), and both have been 
found to have limited ability to predict functional outcomes both in early and later recovery 
(Ponsford, Draper, & Schonberger, 2008; Thornhill et al, 2000).  Confounding factors such as 
poly-trauma, intoxication, existing premorbid conditions, medical interventions, or reliance 
on self-report can also impact negatively on injury estimation (Kemp, Agostinis, House, & 
Coughlan, 2010; Sherer et al., 2015; Zuercher, Ummenhofer, Baltussen, & Walder, 2009).   A 
final issue in comparing studies is the substantial number of cognitive tests reported in the 
TBI literature, with a recent review revealing that a total of 263 cognitive tests had been 
employed in the adult TBI literature in the period between the years 2000 and 2012 alone 
(Tate, Godbee, & Sigmundsdottir, 2013).  This array of tasks, in conjunction with the 
abovementioned injury and assessment-related issues, makes comparison both at an 
individual and group level, challenging.  
As well as the issues relating to assessment of TBI severity and outcome, there have 
been growing concerns that the influence of genes on psychological function has been 
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exaggerated.  Duncan and Keller (2011) found compelling evidence of a publication bias 
towards significant results in novel cGxE studies within psychiatric research, with further 
evidence that replication studies are more likely to be published either when positive results 
have been found, or when a novel finding is reported alongside a null finding.  The authors 
also reported replication biases, insofar as samples sizes needed to be substantially larger for 
publication of non-significant replication studies.  These findings indicate the effect of 
various genes may be being over-estimated.  It has also been noted that many gene studies are 
underpowered, due to a combination of small samples sizes and/or small to modest effect 
sizes, and as a result may be prone to Type I errors (Dick et al., 2015; Duncan & Keller, 
2011).   
Cumming (2012) states that even when meta-analyses only include two studies, the 
margin of error is typically reduced by approximately 30%, and thus a meta-analytic 
approach may be particularly beneficial in cGxE studies to compensate for the issues 
described above (Dick et al., 2015).  To date, two meta-analyses have investigated the effect 
of APOE ε4 on broad functional outcomes following TBI. One concluded that APOE ε4 may 
be associated with poorer outcomes in severe TBI, and that its detrimental effect may be 
pronounced in Asian populations (Zeng et al., 2014), with the second reporting that any 
detrimental effect of APOE ɛ4 may be more apparent in the post-acute recovery phase (Zhou 
et al., 2008).  Both meta-analyses relied on broad or non-cognitive outcome measures, and 
were not intended to identify differences in cognitive function.  Lawrence, Comper, 
Hutchison and Sharma (2015) recently conducted a systematic review of the effect of APOE 
ɛ4 across a range of outcomes, including neuropsychological function.  The authors identified 
studies that included neuropsychological assessment, classifying each as providing evidence 
for APOE ɛ4 being hazardous, non-contributory, or protective.  Of the 18 studies reviewed, 
the authors concluded that nine revealed no effect, seven reported a hazardous effect, and two 
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indicated a protective effect of APOE ɛ4 possession. Lawrence and colleagues also observed 
that memory impairment was found in all studies that identified APOE ɛ4 as being hazardous, 
and that APOE ɛ4 appeared to be more deleterious when TBI was classified as severe.  
Although memory was identified as a domain that may be more at risk of decline, it was not 
clear which other cognitive domains were assessed, or the magnitude of effect for any of the 
neuropsychological functions that were assessed.    
The aim of our study is to explore the effect of APOE ε4 on cognitive recovery in the 
first 12 months following TBI, in adult populations.  Using a meta-analytic approach will 
enable us to explore whether there is any effect of APOE ɛ4 on cognitive impairment 
following TBI, beyond the memory deficits identified in Lawrence et al.’s review, and to 
estimate the magnitude of effect within both general cognitive function and specific cognitive 
domains.  Given the aforementioned issues regarding the range of tasks employed in this 
area, we attempted to attain a balanced approach by undertaking a series of meta-analyses.  
First, we explored the effect of APOE ɛ4 in general cognitive function by including all 
studies which have employed neuropsychologically validated tests.  Second, to address the 
issue of heterogeneity, we conducted domain-specific meta-analyses in which we selected 
tasks that have been recommended for cognitive assessment following TBI (Bagiella et al, 
2010; Lezak, Howison & Loring, 2004; Wilde et al., 2010).  The domains of interest were 
executive function, working memory, visual memory and verbal memory, as these are known 
to be the most commonly impaired in TBI (Mathias & Wheaton, 2007; Rabinowitz & Levin, 
2014; Rohling et al., 2011). 
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Method 
Literature search and selection 
 
The search and selection of articles was conducted according to the Preferred 
Reporting Items for Systematic Review and Meta-analyses (PRISMA; Moher, Liberati, 
Tetzlaff, & Altman, 2009). Pubmed (MEDLINE), Web of Science, and Proquest (inc 
PsychINFO) were searched for articles published between 1980 and 29th April 2015. The 
search terms used were ‘apolipoprotein e’ ‘APOE’ ‘brain injury’ ‘TBI’ ‘head injury’ 
‘cognitive’ ‘memory’ ‘executive function’ and ‘neuropsychological’,  with both long and 
short versions included (a wildcard term was added pre and post word stem for short 
versions).  A total of 445 publications were obtained, and were screened for duplications (n = 
134), resulting in 311 studies.   
Inclusion criteria were as follows; the study must be an original report in full text, 
containing adult TBI participants categorised by APOE genotype (ε4-carriers versus non-
carriers), with neuropsychological assessments undertaken within 12 months of injury.  
Publications reporting any level of TBI severity (mild, moderate, and/or severe) were 
included.  A total of 258 studies were excluded as they did not use adult TBI participants, or 
participants had not been APOE genotyped, 24 were found to be either non-original studies, 
or were not full-text.  Another 11 studies either did not use cognitive-specific outcome 
measures, or did not measure the domains of interest within 12 months of injury, and one 
study was excluded as it used a duplicate population that was already included in the meta-
analysis.  This resulted in 17 publications meeting the inclusion criteria.  Seven studies did 
not have sufficient data published to calculate effect size, and attempts were made to contact 
corresponding authors.  We were unable to obtain data for these studies and so ten studies 
were included in the meta-analysis. A flowchart for the search strategy and study selection is 
available in the supplemental information section which follows the chapter discussion.  We 
49 
 
 
 
also contacted authors when the included studies did not stratify demographic and injury data 
by APOE ɛ4 status. 
Where a longitudinal design had been employed, only baseline measurements were 
included.  One study (Noé et al., 2010) reported separately on the cognitive function of 
participants who were still in PTA, and those who had emerged from PTA.   Only the 
findings for those participants who had emerged from PTA are reported here.   
 
 
Test selection 
 
General cognitive function.  
All ten studies were included in the general cognitive function analysis.  Validated 
tests of general ability, psychomotor function, attention, executive function, working 
memory, verbal memory, and visual memory were included, resulting in a total of 33 tasks 
across the seven domains, as shown in Table 3.   
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Table 3  
 
Cognitive domains, tests, and associated studies included in the general cognitive functioning meta-analysis                                           
Domain Testa Studies 
General Ability FIM (Cognition) 
MR 
NRS-R (Executive/cognition) 
WAIS PIQ 
WAIS VIQ 
Hodgkinson et al; Lichtman et al. 
Han et al; Hodgkinson et al; Shadli et al. 
Ariza et al. 
Anderson et al. 
Anderson et al. 
Psychomotor Speed CALCAP 
CRT  
Digit Symbol 
Grooved Pegboard 
SDMT 
SRT 
Tapping 
Hodgkinson et al. 
Chamelian et al; Liberman et al. 
Han et al. 
Ariza et al; Liberman et al. 
Liberman et al. 
Chamelian et al; Liberman et al. 
Anderson et al. 
Attention PASAT 
Divided Attention 
Number Vigilance 
Chamelian et al; Han et al; Liberman et al. 
Liberman et al. 
Liberman et al. 
Executive Function Fluency - Animal 
              - Design 
              - Word 
SCWT 
Sorting Test 
TMT B 
WCST 
Crawford et al. 
Han et al. 
Ariza et al; Chamelian et al; Crawford et al; Han et al; Shadli et al. 
Han et al; Liberman et al. 
Han et al. 
Ariza et al; Han et al; Shadli et al. 
Chamelian et al; Shadli et al. 
Continued overleaf… 
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aBVMT, Brief Visuospatial Memory Test;  CALCAP California Computerised Assessment Package; CFT, Complex Figure Test; CRT, Choice Reaction Time; CVLT, 
California Verbal Learning Test; DS, Digit Span; DS-B, Digit Span Backwards; FIM, Functional Independence Measure; MR, Matrix Reasoning; NRS-R, Neurobehavioral 
Rating Scale – Revised; PASAT, Paced Auditory Serial Addition Test; RAVLT, Rey’s Auditory Verbal Learning Test; SCWT, Stroop Colour-Word Test; SDMT, Symbol 
Digit Modalities Test; SRCL, Selective Reminding Test; SRT, Simple Reaction Time;  TMT B, Trail-Making Test B; WAIS PIQ, Wechsler Adult Intelligence Scale – 
Performance Intelligence Quotient; WAIS VIQ, Wechsler Adult Intelligence Scale – Verbal Intelligence Quotient; WCST, Wisconsin Card Sorting Test; WMS, Wechsler 
Memory Scale
Working Memory 
 
DS 
DSB 
WMI 
Han et al; Hodgkinson et al. 
Hodgkinson et al. 
Chamelian et al; Noé et al. 
Verbal Memory CVLT (immediate and delayed) 
CVLT Trial 5 total 
RAVLT (immediate and delayed) 
SRCL 
WMS (logical memory, immediate and 
delayed) 
Word recall  
Crawford et al (immediate only); Chamelian et al; Han et al.; Noé 
et al. 
Crawford et al. 
Ariza et al; Hodgkinson et al; Shadli et al. 
Anderson et al. 
Chamelian et al; Han et al. 
Liberman et al. 
Visual Memory CFT (immediate and delayed) 
BVMT (immediate and delayed) 
Ariza et al (immediate only); Hodgkinson et al. 
Chamelian et al. 
Domain Testa Studies 
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In order to reduce heterogeneity, only tasks recommended for assessment of outcome 
in TBI were selected for the specific cognitive domains of interest (Bagiella et al, 2010; 
Lezak, Howison & Loring, 2004; Wilde et al., 2010). These domains were chosen a priori as 
they are reported to be most sensitive to change following TBI, regardless of severity of 
injury (Mathias & Wheaton, 2007; Rabinowitz & Levin, 2014; Rohling et al., 2011). The 
studies and tasks included for each cognitive domain are described below:   
 
Executive function. 
Five studies were included in the executive function meta-analysis (Ariza et al, 2006; 
Chamelian et al, 2004; Crawford et al, 2002; Han et al, 2007, Shadli et al, 2011).  Three tests 
were employed; the Trail Making Test B (TMTB), the Controlled Oral Word Association 
Task (COWAT; verbal fluency only), and Wisconsin Card Sorting Test (WCST).  For the 
WCST two measures (total and number of perseverative errors) were obtained, resulting in a 
total of four measures being included in this domain.  As higher scores on the TMTB and 
WCST perseverative errors indicate poorer performance, the direction of effect size was 
reversed on these tasks. 
 
Working memory. 
Four studies were included in the working memory meta-analysis (Chamelian et al, 
2004; Han et al, 2007; Hodgkinson et al, 2009; Noé et al, 2010).  Digit Span (DS) score was 
obtained from Han et al., and Hodgkinson et al., with Hodgkinson et al also providing a Digit 
Span Backwards (DSB) score.  Chamelian et al. and Noé et al. provided a composite working 
memory index score (WMI) based on Digit Span, Letter-Number Sequencing, and Arithmetic 
scores from the Wechsler Adult Intelligence Scale. 
 
53 
 
 
 
Verbal memory. 
Seven studies were included in the verbal memory meta-analysis (Ariza et al, 2006; 
Chamelian et al, 2004; Crawford et al, 2002; Han et al, 2007, Hodgkinson et al, 2009; Noé et 
al, 2010; Shadli et al, 2011).  Three tests were used; the Californian Verbal Learning Test 
(CVLT), the Rey Auditory Verbal Learning Test (RAVLT), and the Wechsler Memory Scale 
Logical Memory Task (WMS).  Immediate and delayed recall scores were obtained for each 
task, resulting in a total of six measures. 
 
Visual memory. 
Three studies were included in the visual memory meta-analysis (Ariza et al, 2006; 
Chamelian et al, 2004; Hodgkinson et al, 2009).  Two tasks were included; the Complex 
Figure Test (CFT) and the Brief Visuo-Spatial Memory Test (BVMT).  Immediate and 
delayed recall scores were obtained for each task, resulting in four measures. 
 
Statistical analysis 
 
Between group means and standard deviations were used to calculate Cohen’s d. 
Ariza et al., (2006) and Han et al., (2007) did not have raw descriptive data for some tasks, 
and so Cohen’s d was calculated using the F or t statistic and sample size in these instances 
(for formulae see Lipsey & Wilson, 2001).  Meta-analysis was conducted using the 
Exploratory Software for Confidence Intervals programme (ESCI; Cumming, 2012).  Effect 
size estimates for each domain in the general cognition meta-analysis, and for each task in the 
domain-specific meta-analyses were pooled, and were also combined to determine the overall 
effects.  Due to the relatively small sample size, a fixed effects model was used.  It is 
important to note that random effects models are generally recommended where 
heterogeneity is expected (Cumming, 2012).  However, random effects models are also 
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associated with reduced power (Howell, 2013), and given the small number of studies 
included in our meta-analysis it was decided that a fixed effects model, reporting the 
heterogeneity, was the most pragmatic approach.   The Q statistic and associated I2 value 
were calculated to test the assumption of homogeneity of effect sizes (Howell, 2013).  A 
significant Q value indicates heterogeneous effect sizes, and I2 estimates the percentage of 
variation across the studies occurring as a result of heterogeneity.   
 
 
Results 
 
Demographic and injury-related characteristics 
 
The ten studies that were included in the analysis resulted in a combined sample of 
143 ε4-carriers and 510 non-carriers.  While genotype frequencies were reported for most 
studies, all studies analysed data by classifying participants as either APOE ɛ4 carriers or 
non-carriers.  Demographic and injury-related characteristics for each study are provided in 
Table 4.  As can be seen, we were unable to ascertain the average age of APOE ɛ4 and non-
carriers for one study (Liberman et al., 2002), sex ratio for two studies (Crawford et al., 2002; 
Shadli et al., 2011), or ethnicity for four studies (Anderson et al, 2009; Ariza et al., 2006; 
Hodgkinson et al., 2009; Shadli et al., 2011), as stratified by APOE ɛ4 status. 
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Table 4  
 
Demographic and injury-related characteristics of studies included in the meta-analysis 
Author Country n Injury severity 
Mean time 
since injury  Mean age (SD) % Female % Caucasian 
  
ε4-
carriers 
non-
carriers   
ε4-
carriers 
non-
carriers 
ε4-
carriers 
non-
carriers 
ε4-
carriers 
non-
carriers 
Anderson et al. 
(2009) 
USA 15 36 Mild to severe 1 month 
38.2  
(10.1) 
33.9  
(11.8) 
13.00 11.00 NR NR 
Ariza et al. 
(2006) 
Spain 10 67 
Moderate to 
severe 
215  
(23) days 
34.70 
(18.31) 
28.87 
(11.47) 
30.00 20.90 NR NR 
Chamelian et al. 
(2004) 
Canada 19 71 Mild 6 months 
31.20  
(13.3) 
34.10  
(12.3) 
47.40 38.00 73.70 77.50 
Crawford et al. 
(2002) 
USA 30 80 Mild to severe 
41  
(33) days 
32.25 
(11.57) 
33.56 
(14.18) 
NR NR 53.33 35.00 
Han et al. (2007) USA 16 62 
Mild to 
moderate 
38  
(13) days 
22.56  
(3.76) 
25.26  
(5.78) 
18.70 3.23 75 79.50 
Hodgkinson et al. 
(2009) 
Australia 13 45 
Moderate to 
severe 
12 months 
40.33 
(14.12) 
31.08 
(13.96) 
38.5 22.2 NR NR 
Liberman et al. 
(2002) 
USA 18 62 
Mild to 
moderate 
3 weeks NR NR 27.80 43.50 83.30 80.60 
Lichtman et al. 
(2000) 
USA 7 24 
Moderate to 
severe 
6 months 
39.8 
 (18.1) 
34.3 
 (18.1) 
28.57 29.16 85.14 87.50 
Noé et al. (2010) Spain 9 50 
Moderate to 
severe 
312  
(431) days 
28.45  
(8.96) 
29.70 
(10.92) 
28.57 42.86 100 100 
Shadli et al. 
(2011) 
Malaysia 6 13 
Mild to 
moderate 
6 weeks 
25.00  
(8.63) 
26.15  
(6.84) 
NR NR NR NR 
NR = Not reported. 
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One study compared the TBI groups to healthy controls, matched on age, education, 
and general ability (Shadli et al., 2011); the remaining nine studies included only TBI 
sufferers.  All studies compared age of ε4-carriers and non-carriers, with only Ariza et al. 
reporting significant age differences, which were controlled for by ANCOVA.  With the 
exception of Crawford et al. (2002) and Shadli et al. (2011), all studies reported that they 
compared sex ratios for ε4 carriers and non-carriers, with no significant differences found.  
Education level was also compared for each group, other than Hodgkinson et al. (2009), with 
no significant differences being reported.   Six studies recruited from North American 
populations (Anderson et al., 2009; Chamelian et al., 2004; Crawford et al., 2002; Han et al., 
2007; Liberman et al, 2002; Lichtman et al, 2000), two studies were undertaken in a 
Mediterranean population (Ariza et al., 2006; Noé et al., 2010), one study was undertaken in 
an Asian population (Shadli et al., 2011), and one in an Australian population (Hodgkinson et 
al., 2009). 
Injury severity was estimated by GCS and/or PTA in most studies, however Anderson 
and colleagues (2009) used time to follow commands.  There was also variation in how injury 
severity was classified.  Ariza et al. (2006), Chamelian et al. (2004) and Han et al. (2007) 
used GCS score to categorise injury severity as mild (13-15) moderate, (9-12) or severe (<8), 
with Chamelian et al. and Han et al. also incorporating PTA into their estimates of severity 
(<24 hrs = mild, 1-7 days = moderate, > 7 days = severe).  Liberman et al (2002) stratified 
GCS scores into three levels (9-12, 13-14, and 15) but did not identify these in terms of 
severity. Noé et al. (2010) also categorised their participants as having sustained a moderate 
or severe TBI based on GCS, however, while mean GCS scores are provided, it is not clear 
what cut-offs were employed.  Similarly Shadli et al. (2011) report a mild-moderate cohort 
based on mean a GCS of 13.21 (SD = 1.99).   Crawford et al. (2002) stratified each group 
based on length of PTA (< 1 hr, 1-24 hrs, 1-7 days, 7-30 days, and > 30 days), but did not 
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explicitly categorise severity.  Hodgkinson et al. (2009) estimated injury severity based on 
PTA using the Modified Oxford PTA scale (1-7 days = severe, 7-28 days = very severe, > 28 
days = extremely severe).   As all of the participants in Hodgkinson et al’s study had PTA >1 
day, they were classified as having severe TBI, however, as others have consistently 
classified 1-7 days as moderate, the injury severity of this cohort has been identified as 
moderate to severe in Table 1.  There were no significant differences in injury severity 
between APOE ɛ4 carriers and non-carriers reported in any of the studies with the exception 
of Lichtman et al (2000), who reported that non-carriers had significantly longer coma period 
than ɛ4-carriers.  This was adjusted for in the subsequent analysis. 
 
Meta-analysis results. 
 
Ten studies were included in the general cognitive function meta-analysis (ɛ4-carriers 
n = 143, non-carriers n = 510).  There was an overall effect of d = 0.038 (95% CI [-0.028, 
0.105]) indicating that there were no differences in overall cognitive function.  Although 
there was substantial variability between the domains, heterogeneity was not significant (Q 
(6) = 6.686, p = .351; I2 = 10.26%).  Figure 2 depicts the forest plots for general cognitive 
function. 
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Figure 2. Forest plot for general cognitive outcome Cohen’s d effect sizes and 95% CIs.  
Dotted vertical line indicates overall pooled effect size. 
 
The executive function tasks of interest in the domain specific studies (TMTB, 
COWAT, and WCST) were employed in five studies (ε4-carriers n = 81, non-carriers n = 
293).  There was an overall effect of d = -0.118 (95% CI [-0.305, 0.069]), suggesting no 
difference between the performance of ε4-carriers and non-carriers.  There was a significant 
effect for heterogeneity (Q (10) = 33.038, p = .001; I2 = 69.7%).  The only task found to have 
significant heterogeneity was the COWAT, and so this was removed and the data was re-
analysed, resulting in an increase in overall effect; d = -0.145 (95% CI [-0.394, 0.105]).  
However, heterogeneity remained significant (Q (6) = 21.738, p = .001; I2 = 72.4%).  The 
forest plots for executive function tasks are depicted in Figure 3. 
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Figure 3. Forest plot for executive function Cohen’s d effect sizes and 95% CIs.  Dotted 
vertical line indicates overall pooled effect size. 
 
Four studies assessed working memory (ε4-carriers n = 57, non-carriers n = 228), 
using the DS and/or DSB, or the WMI.  A small overall effect of d = 0.210 (95% CI [-0.055, 
0.476]) was found, indicating no differences between ε4-carriers and non-carriers. There was 
also a significant effect for heterogeneity (Q (4) = 10.600, p = .031; I2 = 62.3%).  Figure 4 
displays the forest plots for the working memory tasks. 
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Figure 4.  Forest plot for working memory Cohen’s d effect sizes and 95% CIs.  Dotted 
vertical line indicates overall pooled effect size. 
 
Verbal memory was the domain most frequently assessed, with seven studies 
including a verbal memory measure of relevance to the domain-specific meta-analysis (ε4-
carriers n = 90, non-carriers n = 343).  These being the CVLT (immediate and delayed 
recall), the RAVLT (immediate and delayed recall), or the WMS logical memory tasks 
(immediate and delayed recall).  There was a small overall effect of d = 0.061 (95% CI [-
0.081, 0.204]), indicating negligible differences between ɛ4-carriers and non-carriers. There 
was also a significant effect for heterogeneity (Q (16) = 49.719, p = .001; I2 = 67.8%). Figure 
5 demonstrates the forest plots for verbal memory tasks. 
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Figure 5.  Forest plot for verbal memory Cohen’s d effect sizes and 95% CIs.  Dotted vertical 
line indicates overall pooled effect size. 
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Three studies used tasks assessing visual memory (ε4-carriers n = 42 non-carriers n = 
183), using either the CFT (immediate and delayed recall) or BVMT (immediate and delayed 
recall).  There was an overall effect size of d = 0.152 (95% CI [-0.104, 0.409]), suggesting no 
significant differences between ε4-carriers and non-carriers.  There was a non-significant 
effect for heterogeneity (Q (4) = 5.200, p = .267; I2 = 23.1).  The forest plots for visual 
memory are shown in Figure 6.  
 
 
Figure 6.  Forest plot for visual memory Cohen’s d effect sizes and 95% CIs.  Dotted vertical 
line indicates overall pooled effect size. 
 
Given the evidence of variation of ε4 frequency and expression in different ethnic 
groups (Corbo & Scacchi, 1999; Farrer et al., 1997; Zeng et al., 2014), additional analysis 
was conducted in which Shadli et al’s (2011) study was excluded as the study recruited from 
an Asian population.   As Shadli et al did not use measures of working memory or visual 
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memory, re-analysis was only conducted on the executive function and verbal memory 
domains.  This resulted in a non-significant increase in effect size for executive function (d = 
-0.122 [-0.323, 0.078]), and a slight reduction in effect size for verbal memory (d = 0.069, 
95% CI [-0.082, 0.221]), suggesting there was minimal effect due to ethnicity.  
 
 
Discussion 
This is the first meta-analysis to be conducted on the effect of APOE ɛ4 on cognitive 
function following TBI.  Meta-analytic approaches are known to reduce margin of error 
(Cumming, 2014),   and therefore it is hoped that the current findings provide a more accurate 
estimation of the effect of APOE ɛ4 on post-TBI cognitive function.  The findings from the 
general cognitive function meta-analysis and the domain-specific meta-analyses revealed 
similar results.  There were no significant differences between APOE ε4-carriers and non-
carriers in general cognitive function, and the domain-specific meta-analyses revealed no 
significant differences between ɛ4-carriers and non-carriers for any of the domains, despite 
the selection of tasks known to be sensitive to change following TBI. Our findings do not 
appear to align with the recent review by Lawrence et al (2015), in which possession of 
APOE ɛ4 was found to be associated with poorer memory function following TBI.  However 
it must be noted that half the studies described by Lawrence and colleagues found a non-
contributory effect of APOEɛ4, thus is it is possible that using a meta-analytic approach was 
able to provide a more integrative interpretation of the literature to date.  Lawrence et al also 
included studies of late outcome, whereas we focussed on outcomes in the first 12 months 
post injury.  Therefore another possible explanation for the difference between our and 
Lawrence et al’s findings is that any detrimental effect of APOE ɛ4 may be more apparent in 
later recovery.  
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A number of factors must be considered in interpreting this finding.  Firstly, the small 
effect sizes and relatively small sample sizes that our meta-analyses are based upon means 
that the current study may be underpowered, and it must also be acknowledged that when 
there is publication bias in a given topic, meta-analysis will reflect the inflated positive 
findings (Duncan & Keller, 2011).   Thus, while this analysis offers a more considered 
interpretation of the findings to date, the results reported here must be viewed cautiously. 
Our meta-analysis also included studies in which injuries ranged from mild to severe, 
but there is evidence from both animal and human studies indicating that APOE ε4 may have 
a greater impact when TBI is severe (Mannix et al., 2013; Millar et al., 2003), and a recent 
meta-analysis comparing general prognosis for APOE ɛ4 carriers and non-carriers also noted 
that APOE ɛ4 carriers only appeared to be disadvantaged when injury was severe (Zeng et al., 
2014). This was also observed by Lawrence and colleagues (2015) in their recent review. 
Interestingly, Maxwell and colleagues (2011) report that ɛ4-carriers may be at greater risk of 
experiencing brain micro-bleeds, and there is evidence that the presence of micro-bleeds in 
TBI sufferers is a strong predictor of cognitive impairment (Fagerholm, Hellyer, Scott, 
Leech, & Sharp, 2015).  There is also emerging evidence that APOE ɛ4 is associated with 
greater neuro-inflammation (Cudaback, Yang, Montine, & Keene, 2015; Tai et al., 2015), 
although this is yet to be demonstrated in TBI populations.  Whether such allele-specific 
effects translate to more severe initial pathology in TBI, and/or a protracted recovery period, 
remains unknown.  Should the effects of APOE ε4 be more pronounced when injury is 
severe, or alternatively, lead to more severe pathology, it is possible that these effects would 
not be uncovered when mild to moderate TBI cohorts are included in analyses. 
Demographic data obtained from the included studies also indicates that participants 
were primarily young to middle-aged adults.  It has long been established that APOE ε4 is 
associated with age-related neurological disorders such as Alzheimer’s disease (Corder et al., 
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1993), indicating that any detrimental effect of the ε4 allele may be only be apparent in older 
adults.  Thus, the apparent contradiction between the findings in this meta-analysis and the 
evidence for a detrimental effect of APOE ε4 might be due to age-associated effects, which 
we were unable to assess.  A potential explanation for the apparent age-associated variation is 
that the APOE gene operates via an antagonistic pleiotropic mechanism, whereby it exerts 
beneficial effects upon a given characteristic before and during the reproductive phase of life, 
but is deleterious in post-reproductive life (Carter & Nguyen, 2011).  This mechanism is yet 
to be clearly demonstrated for the APOE gene, however some authors have suggested this 
explains the relationship between APOE ε4 and Alzheimer’s disease (Han & Bondi, 2008; 
Leroi et al., 2005; Tuminello & Han, 2011), and there is some evidence that APOE ε4 has an 
antagonistic pleiotropic effect on a range of non-cognitive traits (Kulminski et al., 2013; 
Kulminski et al., 2011; Wierenga et al., 2013), and possibly on cognitive function in some 
clinical cohorts (Chang et al., 2011).   
A further issue for our meta-analysis is the differences between studies in method of 
assessing injury severity.  The majority of studies included here provided GCS scores, 
however two studies relied on PTA to classify injury severity (Crawford et al., 2002; 
Hodgkinson et al., 2009), and a third used time to follow commands as an estimate of 
severity (Anderson et al., 2009).  While both GCS and PTA have been shown to be adequate 
estimates of injury severity, severity scores obtained from the GCS have been found to be 
poorly correlated with severity estimated by PTA (Sherer et al., 2008), and there is often 
variation in the timing of GCS administration, which can lead to over- or under-estimation of 
injury severity (Zuercher et al., 2009).  As a result there may be substantial variation in the 
level of injury severity both between and within individual studies, and caution must be 
applied when comparing injury severity classifications between studies. 
66 
 
 
 
A previous meta-analysis by Zeng and co-workers (2014), using non-cognitive 
outcome measures, also indicated that ethnicity can influence both frequency and expression 
of the APOE ε4 allele, with some evidence that APOE ε4 is associated with greater risk of 
neurological dysfunction in some Asian populations.  When we removed the only study in 
our meta-analysis that had recruited from an Asian population (Shadli et al., 2011), there was 
no evidence of systematic changes.  Although this suggests that ethnicity was unlikely to 
have influenced this meta-analysis, given the small sample size, this finding should not be 
applied to the broader TBI population.  
 
Directions for future research.  
 
There are a number of issues that need to be addressed in future research, and a key 
theme is that reporting demographic, injury and outcome-related data, stratified by APOE 
genotype (or at least by APOE ɛ4 status) will allow better understanding of the role of APOE 
in cognitive recovery following TBI.  Inclusion of this information (either in publications or 
attached as supplementary information) will be of benefit to meta-analytic or other integrative 
approaches. 
As stated previously, the wide range of tasks employed to assess cognitive function 
after TBI has made comparison of findings challenging.  Ideally, as well as using 
neuropsychological tasks that are psychometrically validated, repeatable, and sensitive to 
change following TBI, routine incorporation of a set of core neuropsychological tests would 
mean that individual studies can be included into meta-analytic or other approaches, 
permitting more rigorous exploration of the cognitive domains known to be impacted by TBI.  
Wilde and colleagues (2010) propose a three tier approach to functional assessment following 
TBI, with specific recommendations for neuropsychological assessment. In the Wilde et al 
protocol, the first tier contains a number of core tasks, allowing a time-efficient but broad 
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coverage of cognitive domains known to be impacted by TBI; the second supplemental tier 
provides additional tasks to allow a more in-depth exploration when specific domains are of 
interest; and the third tier includes emerging, less well-established tests, thus allowing newer 
tests to become validated.  While it is beyond the scope of the current study to describe Wilde 
et al’s protocol in detail, it is suggested that future researchers routinely incorporate the core 
tasks recommended by Wilde et al, and preferably the supplemental and emerging tasks, 
alongside any other measures of interest.     
We also recommend the inclusion of both GCS and PTA when possible.  While the 
GCS is the most frequently used scale, recent evidence indicates that PTA may be a more 
accurate estimation of injury severity, and a better predictor of functional outcome (Perrin et 
al., 2015; Schonberger, et al., 2009), although caution must be applied where PTA has been 
self-reported (Kemp et al., 2010; Sherer et al., 2015).  Given that GCS is routinely 
administered in the emergency medicine setting, it is likely that this will remain the most 
commonly used measure for some time, however inclusion of both GCS and PTA will permit 
investigation of the relationship between GCS and PTA, and will improve the ability to 
interpret and compare injury severity between studies, and clarify the relationship between 
each scale and functional outcome. 
Given the evidence that possession of APOE ε4 may be associated with reduced 
cognitive function in the general population (Tuminello & Han, 2011; Wisdom, Callahan, & 
Hawkins, 2011), further research is needed to establish whether any differences in cognitive 
impairment between ε4-carriers and non-carriers are a result of interaction between TBI and 
APOE genotype, or are a reflection of premorbid differences in cognitive function. To date, 
only one study has compared pre and post-TBI cognitive function of ε4-carriers (Sundström 
et al., 2004), and another (included in our analysis) has compared healthy ε4-carriers to ε4-
carriers who had sustained a TBI (Shadli et al., 2011).  In the pre- and post-TBI comparison 
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by Sundström and colleagues, it was found that ε4-carriers displayed greater post-injury 
cognitive declines than non-carriers, as compared to their pre-injury test performance, 
suggesting that APOE ε4 confers a greater vulnerability to cognitive impairment arising from 
TBI (Sundström et al., 2004).  Alternatively, Shadli et al. (2011) compared the cognitive 
function of healthy controls to a mild-moderate TBI sample, with both groups categorised as 
either ε4-carriers or non-carriers.  Shadli and colleagues reported no significant differences 
across a range of cognitive tasks, with the exception of poorer performance of the ε4-TBI 
group as compared to the ε4-healthy control group on the TMTB.  However, as stated above, 
it is possible that any detrimental effects of APOE ɛ4 may be more pronounced in severe 
TBI, and it is therefore recommended that further exploration of this issue is needed to clarify 
the interaction between APOE genotype and TBI.   
It is also recommended that a more nuanced approach to exploring the APOE gene is 
needed.   In particular, we suggest that moderating factors need to be further explored.  As 
mentioned in the previous section, injury severity may influence the effect of APOE ɛ4 on 
cognitive function after injury (Lawrence et al., 2015; Mannix et al., 2013; Millar et al., 
2003), and this warrants further exploration. Furthermore, if APOE ε4 is expressed via an 
antagonistic pleiotropic mechanism, it is possible that TBI would have more severe effects 
for APOE ε4 carriers if sustained in later life, but this hypothesis is yet to be tested in the TBI 
population.  There is tentative support for this mechanism from animal studies, where it has 
been reported that APOE ε4 is associated with poorer cognitive performance in older injured 
animals, but not in juveniles (Mannix et al., 2011).  Others have reported that APOE ɛ4 may 
be associated with improved cognitive performance in paediatric TBI cohorts (Blackman et 
al., 2005; Moran et al., 2009).  However, there have only been two studies which specifically 
explored the interaction between age and APOE genotype in adult TBI cohorts.  One reported 
no age-related interactions (Friedman et al., 1999), and the other which revealed decreased 
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differences between ε4-carriers and non-carriers cognitive function in later life 
(Eramudugolla et al., 2014).  Additionally, Rapoport and colleagues (2008) reported no 
significant differences in cognitive function in ε4-carriers and non-carriers who had sustained 
a TBI in later life.  There is also some evidence from animal and in-vitro studies which 
indicates the expression of APOE is moderated by sex hormones (Koutseff, Mittelhaeuser, 
Essabri, Auwerx, & Meziane, 2014; Raber et al., 1998; Struble, Nathan, Cady, Cheng, & 
McAsey, 2007).  To date, only two studies have directly investigated the potential interaction 
between sex and APOE, both of which used broad outcomes measures and therefore were not 
included in the current meta-analysis.  Ponsford et al. (2011) reported that in their TBI 
sample, female ε4-carriers over the age of 55 had poorer outcomes than males of the same 
age, or than female non-carriers (as measured by the Extended Glasgow Outcome Scale). In 
contradiction, Alexander and colleagues (2007a) report no interaction between sex and APOE 
status using the same outcome measure.  While we acknowledge that individual studies may 
lack the power to detect such interactions, routine inclusion of basic demographic and injury 
related data, stratified by genotype (or at least by presence/absence of APOE ɛ4), will allow 
exploration by meta-analysis or other integrative approaches once a sufficient number of 
studies are published.  These factors should be included routinely, regardless of whether there 
is any a priori evidence, as the effect of a given characteristic may not initially be apparent.  
There has also been minimal exploration of APOE ε4 dose-dependent effects on 
cognition in the TBI population.  In the only study comparing ε4-homozygotes to ε4-
heterozygotes to date, Ponsford and colleagues (2007) observed that ε4 homozygotes 
appeared to have greater initial cognitive impairment following TBI, although interpretation 
was hampered by a small sample size.  As the majority of ε4-carriers are heterozygous there 
may be limits to determining the effect of the ε4 allele in isolation.  Nevertheless, comparison 
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of ε4-homozygotes to other groups may assist in determining whether the ε4 allele is indeed 
detrimental to cognitive recovery following TBI.  
The majority of studies also dichotomise participants as either ε4-carriers (possessing 
a genotype of ɛ2/ɛ4, ɛ3/ɛ4 or ɛ4/ɛ4) or non-carriers (ɛ2/ɛ2, ɛ2/ɛ3, or ɛ3/ɛ3).  However, there is 
emerging evidence that the ε2 allele is dominant over the ε3 and ε4 alleles, and may confer 
protection following insult or injury (Corder et al., 1994; Laskowitz, Horsburgh, & Roses, 
1998; Mahley & Rall 2000; Miller et al., 2010).  Thus, inclusion of individuals with an ɛ2/ɛ4 
genotype may mask any deleterious effects of ε4, and alternately the inclusion of ε2 carriers 
in the non-ε4 carrier cohort may attenuate differences between ε4-carriers and non-carriers.  
It could be argued that given the rarity of the ε2 allele it is unlikely to have a meaningful 
impact, but given the small sample sizes often used, and the modest effect sizes that have 
been reported here, it may be appropriate to exclude such individuals, as indeed has been 
done in some more recent studies (Eramudugolla et al., 2014; Isoniemi et al., 2006; Ponsford 
et al., 2007).  It has also been suggested that the potential effect of APOE ε2 should be 
considered separately, given the potential protective properties of this allele (Suri, Heise, 
Trachtenberg, & Mackay, 2013).  The relative scarcity of the ɛ2 allele may make analysis of 
results from an individual study questionable, however if data for ε2-carriers is treated 
separately (and either reported or made available upon request) this will at the very least 
permit future meta-analytic approaches to be conducted on this allele.  
It is also becoming increasingly apparent that combinations of genes may operate 
synergistically to either delay or enhance cognitive recovery post-TBI, and that identification 
of genes that exert a small but specific effect is an important avenue of research (Weaver et 
al., 2014). There have been a number of genes that have be implicated in cognitive change 
post-TBI, and therefore consideration of the interaction between APOE and other genes such 
as the brain-derived neurotropic factor (BDNF), catechol-O-methyl transferase (COMT), and 
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kidney and brain expressed protein (KIBRA) may elucidate the impact of genotype on 
cognitive recovery (Dardiotis, Grigoriadis, & Hadjigeorgiou, 2012; McAllister, 2010; 
Wagner et al., 2012; Weaver, Chau, Portelli, & Grafman, 2012).      
Finally, there are broader methodological issues that are particularly pertinent in this 
area of research.  The American Psychological Association (2012) has stressed that effect 
sizes, confidence intervals and complete demographic data should be routinely included in all 
publications, and full disclosure of results and increased replication studies are also needed to 
address concerns regarding publication and replication bias (Cumming, 2014).  While more 
recent studies have incorporated some of these elements, given the small effect sizes often 
reported in the literature to date, and recent concerns regarding publication bias specifically 
in this field (Dick et al., 2015; Duncan & Keller, 2011), these issues are worth emphasising 
here.  In relation to the concerns regarding sample size, the most apparent solution is 
increased collaboration and multi-centre research.  While the benefits of multi-centre and 
multi-disciplinary collaborations are well-known, this is particularly apposite for behavioural 
genetics, where comprehensive, discipline specific knowledge of current advances in genetic 
research and neuropsychological assessment is crucial for robust investigations.  Dick and 
colleagues (2015) identify a number of associations that provide opportunities to foster such 
collaborations and could also lead to improved standardisation of measures, and the 
interested reader is directed to their excellent review and recommendations of the broader 
issues in cGxE research.  
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Conclusion. 
 
This is the first meta-analysis exploring the effect of APOE ɛ4 on cognitive function 
following TBI, and reveals that APOE ɛ4 may not be detrimental in terms of post-TBI 
cognitive function.  However, while our meta-analysis provides a more comprehensive 
picture of the research to date, given the small effects and modest sample size, and recent 
concerns regarding the prevalence of publication and replication biases in cGxE research 
(Dick et al., 2015; Duncan & Keller, 2011), our findings must be interpreted cautiously.  We 
suggest that the relationship between APOE genotype and cognitive function following TBI 
may be better understood with more consistent assessment of injury severity and 
neuropsychological function, in conjunction with a more nuanced approach to exploring the 
APOE gene.  This would include investigation of moderating factors, consideration of dose-
dependent effects APOE ε4 and the possible ameliorative effects of APOE ε2, and 
exploration of potential interactions between APOE and other genes.  While it may not be 
possible for individual studies to explore these factors, routine reporting of demographic and 
injury related data, stratified by APOE genotype, or at least the presence/absence of APOE 
ɛ4, may clarify the disparate finding to date, and reveal a more complex interaction between 
APOE and TBI than is currently evident. 
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Participants  
 
Participants for the present study were recruited through the Tasmanian Neurotrauma 
Register (TNTR); a prospective population study of TBI in the Australian state of Tasmania.  
Located at the Royal Hobart Hospital, Tasmania, the TNTR was established as a joint research 
unit between the University of Tasmania and the Tasmanian Department of Health and 
Human Services, with the primary objective of assessing neuropsychological and psychosocial 
outcomes up to five years following TBI. The TNTR was funded by the Motor Accidents 
Insurance Board (MAIB), a state-governed scheme which provides compulsory third-party 
insurance for all Tasmanian registered motor vehicles.  The MAIB operates on a common 
law/no fault basis and provides medical and income compensation and benefits in the event of 
a motor accident.  Ethics approval for the TNTR was obtained from the Tasmanian Human 
Research Ethics Committee (H0007116), and additional approval for the current studies was 
provided on the 2nd of September 2010 (see Appendix A for ethics approvals, information 
sheets and consent forms for both TNTR and APOE study).   
All patients aged 16 years and older presenting to the accident and emergency 
department, or admitted/transferred to the Royal Hobart Hospital (RHH) with a principal or 
additional diagnosis of TBI, between December 2003 and June 2008 were invited to 
participate.  A total of 2,382 people presented at the RHH within the recruitment period, with 
1,226 (51%) agreeing to participate. For those who were unconscious or incapable of giving 
informed consent at time of admission, next of kin provided initial consent, with the 
participant consenting on remission of PTA or when appropriate.  As the TNTR was a 
population study there were no inclusion or exclusion criteria, and assessments were 
undertaken at time of injury, and at 2 weeks, 3, 6, and 12 months, and annually thereafter up 
to 5 years post injury.   
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The current research used data obtained at time of injury, 3, 6, and 12 months, and 
inclusion criteria were as follows:   
 The participant must have been aged between 18-75 at time of injury  
 No premorbid history of neurological or neurodegenerative disorder 
 No previous history of TBI 
 No premorbid history of medicated psychological disorders 
 Estimated premorbid FSIQ > 70.   
 
Recruitment for the current research occurred between September 2010 and October 
2011, with participants being invited to participate in the APOE study when they were 
contacted for follow-up assessments for the larger TNTR study.  A total of 173 participants 
consented to be in the APOE study, however 3 were unable to be genotyped resulting in a 
final sample of 170 participants.  The APOE genotype distribution is shown in Table 5, and 
was found to be in Hardy-Weinberg equilibrium [χ2 (5) = 6.050, p = .30].  
Table 5  
 
APOE Genotype Frequencies (N = 170) 
APOE Genotype Frequency 
 ɛ4/ɛ4 5 (2.95%) 
ɛ4/ɛ3 37 (21.76%) 
ɛ4/ɛ2 4 (2.35%) 
ɛ3/ɛ3 106 (62.36%) 
 ɛ3/ɛ2 15 (8.82%) 
 ɛ2/ɛ2 3 (1.76%) 
 
Given the reported opposing effects of APOE ɛ4 and APOE ɛ2 (Corder et al., 1994; 
Suri et al., 2013), participants with a ɛ2/ɛ4 genotype were excluded (n = 4), resulting in a total 
of 166 participants in the APOE study.  The demographic and injury-related details for the 
participants in the current study, and total TNTR sample are provided in Table 6.  As can be 
seen, there were significant differences between the APOE study and the larger TNTR study, 
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with the only exception being differences in GCS.   However, the effect sizes reported are 
small and indicate that there is little meaningful difference between the two cohorts. Table 7 
shows the demographic and injury-related characteristics for the remaining 166 participants, 
with ANOVA and Chi-square analyses revealing no significant differences between APOE ɛ4, 
ɛ3, and ɛ2 carriers. 
Table 6  
Demographic and Injury-Related Data for APOE Study and all TNTR Participants 
 
Characteristic 
APOE Study 
Total (n = 166a) 
TNTR Total 
(n = 1226b) 
t-test / 
χ2 
 
p-value 
Cohen’s d/ 
Cramer’s 
V 
Sex n (%) 
     Male  
     Female 
 
91 (54.82%) 
75 (45.18%) 
 
796 (65%) 
430 (35%) 
 
 
6.46 
 
 
.011 
 
 
0.04 
Age at injury (years) 
     Mean (SD) 
 
40.09 (16.71) 
 
36.90 (17.81) 
 
2.18 
 
.029 
 
0.18 
Premorbid IQ 
     Mean (SD) 
 
103.10 (9.78) 
 
97.71 (11.87) 
 
5.39 
 
.001 
 
0.46 
Injury Severity (PTA) 
     Mild (< 24 hours) 
     Moderate (< 1 week) 
     Severe (> 1 week) 
 
108 (65.06%) 
32 (19.28%) 
26 (15.66%) 
 
872 (74%) 
187 (16%) 
115 (10%) 
 
 
 
7.45 
 
 
 
.024 
 
 
 
0.04 
Injury Severity (GCS) 
     Mild (13-15) 
     Moderate (9-12) 
     Severe (3-8) 
 
147 (91.30%) 
5 (3.11%) 
9 (5.59%) 
 
1,045 (92.72%) 
29 (2.58%) 
53 (4.70%) 
 
 
 
0.41 
 
 
 
.813 
 
 
 
0.01 
Injury Mechanism  
     Motor accident 
     Fall 
     Assault 
     Sports 
     Other 
 
74 (44.58%) 
43 (25.90%) 
21 (12.65%) 
22 (13.25%) 
6 (3.61%) 
 
472 (39%) 
264 (22%) 
335 (27%) 
68 (5%) 
87 (7%) 
 
 
 
 
 
31.04 
 
 
 
 
 
.001 
 
 
 
 
 
0.06 
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a APOE data for premorbid IQ n = 162; GCS n = 161 
b TNTR data for premorbid IQ n = 887; PTA n = 1174; GCS n = 1127 
Table 7  
 
Demographic and Injury-Related Data for APOE Study Stratified by APOE Status 
 
Characteristic 
APOE ɛ4 
(ɛ4/ɛ4 ɛ4/ɛ3) 
n = 42a 
APOE ɛ3 
(ɛ3/ɛ3) 
n = 106b 
APOE ɛ2 
(ɛ2/ɛ2 ɛ2/ɛ3) 
n = 18 
ANOVA/
χ2 p-value 
Partial ƞ2/ 
Cramer’s 
V 
Sex n (%) 
     Male  
     Female 
 
21 (50%) 
21 (50%) 
 
58 (54.72%) 
48 (45.28%) 
 
12 (66.67%) 
6 (33.33%) 
 
 
1.41 
 
 
.493 
 
 
0.09 
Age at injury (years) 
     Mean (SD) 
 
40.45 (16.59) 
 
39.58 (16.52) 
 
42.19 (18.79) 
 
.19 
 
.820 
 
0.01 
Premorbid IQ 
     Mean (SD) 
 
104.51 (9.69) 
 
102.19 (10.19) 
 
104.90 (6.96) 
 
1.18 
 
.307 
 
0.01 
Injury Severity (PTA) 
     Mild (< 24 hours) 
     Moderate (< 1 week) 
     Severe (> 1 week) 
 
27 (64.29%) 
8 (19.05%) 
7 (16.67%) 
 
66 (62.26%) 
21 (19.81%) 
19 (17.92%) 
 
15 (83.33%) 
3 (16.67%) 
0 (0.00%) 
 
 
 
4.33 
 
 
 
.363 
 
 
 
0.11 
Injury Severity (GCS) 
     Mild (13-15) 
     Moderate (9-12) 
     Severe (3-8) 
 
36 (87.80%) 
2 (4.88%) 
3 (7.32%) 
 
93 (91.18%) 
3 (2.94%) 
6 (5.88%) 
 
18 (100%) 
0 (0.00%) 
0 (0.00%) 
 
 
 
2.43 
 
 
 
.657 
 
 
 
0.08 
Injury Mechanism  
     Motor accident 
     Fall 
     Assault 
     Sports 
     Other 
 
20 (47.62%) 
13 (30.95%) 
5 (11.90%) 
4 (9.52%) 
0 (0.00%) 
 
43 (40.57%) 
29 (27.35%) 
13 (12.26%) 
16 (15.09%) 
5 (4.72%) 
 
11 (61.11%) 
1 ((5.55%) 
3 (16.67%) 
2 (11.11%) 
1 (5.55%) 
 
 
 
 
 
8.05 
 
 
 
 
 
.429 
 
 
 
 
 
0.16 
a APOE ɛ4 GCS n = 41 
b APOE ɛ3 premorbid IQ n = 102; GCS n = 102 
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Materials 
 
Demographic and screening materials. 
Demographic information including age, sex, premorbid medical history, and 
pharmaceutical/substance use was collected at the initial assessment.  Information regarding 
the TBI was also collected, including injury mechanism, and measures of severity as described 
below.  Premorbid intellectual function was estimated using the National Adult Reading Test 
(NART).  The NART is comprised of 50 phonetically irregular words which participant reads 
aloud, with the number of correctly pronounced words being converted to an estimate of FSIQ 
based on the WAIS-III norms (Nelson, 1991).   Although there is some evidence that more 
severe injury is associated with underestimation of FSIQ, performance on the NART has been 
found to reliably estimate premorbid FSIQ in TBI populations (Morris, Wilson, Dunn, & 
Teasdale, 2005; Watt & O'Carroll, 1999).   
While both PTA and GCS are reported throughout the thesis, injury severity was 
estimated by length of PTA for all analyses.  PTA has been found to be an accurate estimate 
of injury severity in both mild-to-moderate and severe TBI populations, is considered a more 
sensitive estimate of injury severity in mild TBI than GCS (Teasdale & Jennett, 1974; van der 
Naalt, 2001), and is less influenced by factors such as substance use and medical intervention, 
which may inflate acute GCS scores (Lezak, Howieson, & Loring, 2004; Zuercher et al., 
2009). For participants admitted to the RHH (n = 57), PTA was estimated using the Westmead 
PTA Scale (Shores, Marosszeky, Sandanam, & Batchelor, 1986).  PTA for remaining 
participants (n = 109) was estimated by self-report using the Galveston Orientation and 
Amnesia Test (GOAT; Levin, Odonnell, & Grossman, 1979).  PTA was classified as either 
mild (less than 24 hours), moderate (1-7 days) or severe (more than 7 days).   
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Cognitive test battery. 
 
Five neuropsychological tasks were selected, yielding a total of seven measures, as 
described below.  All tasks have been recommended for routine use in assessing post-TBI 
cognitive function as they are sensitive to neuropsychological impairment following TBI 
(Atchison et al., 2004; Bagiella et al., 2010; Donders, Tulsky, & Zhu, 2001; Hanks et al., 
2008; Henry & Crawford, 2004).  These tasks are reported to have minimal practice effects for 
the time-periods in which assessment was conducted, and/or have alternate versions for 
repeated administration (Basso, Bornstein, & Lang, 1999; Basso, Carona, Lowery, & Axelrod, 
2002; Beglinger et al., 2005).   
 
Adult Memory and Information Processing Battery Information Processing     Form 
A (IP Speed). 
The IP Speed task is a subtest from the Adult Memory and Information Processing 
Battery (Coughlan & Hollows, 1985).  It is a speed-based pen and paper task which is a 
measure of cognitive processing speed which controls for motor speed.  The participant first 
completes a motor speed task, in which they must cross out as many digits as possible in 30 
seconds.  They are then presented with 105 rows of 5 digits, and have to cross out the second 
highest number in each row, for as many rows as possible, in 4 minutes.  The IP speed score 
can then be adjusted based on the initial motor speed task (Coughlan & Hollows, 1985).  This 
task has been found to reliably detect information processing deficits in clinical populations 
(Vlaar & Wade, 2003).  Higher values on the IP Speed task indicate better performance. 
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Trail-making Task B (TMT-B). 
The TMT-B is a speed-based paper and pen task in which the participant is required to 
connect a randomly distributed series of letters and numbers in alternate sequential order 
(starting with 1-A-2-B…) as quickly as possible.  The TMT-B has been reported to measure 
attention, psychomotor speed, and cognitive flexibility, and is considered to reflect both 
working memory and executive function (Kortte, Horner, & Windham, 2002; Sanchez-Cubillo 
et al., 2009; Strauss, Sherman, & Spreen, 2006).  Time is measured in seconds, thus a lower 
score indicates better performance. 
Controlled Oral Word Association Task (COWAT). 
The COWAT is a speed-based verbal task, in which the participant has 60 seconds to 
name as many novel words as possible, starting with a particular letter (pronouns and word 
extensions are not permitted).  Three trials are undertaken, each with a different letter.  The 
COWAT is a measure of verbal fluency, and has been shown to indicate executive 
dysfunction in TBI populations (Henry & Crawford, 2004).  Although practice effects for the 
COWAT have been reported to be minimal (Basso et al., 1999), two parallel versions were 
administered using either the letters F, A, S, or B, H, T, at alternate assessments (Borkowsk, 
Benton, & Spreen, 1967).  Performance was measured by total number of words across the 
three trials, thus higher scores indicate better performance. 
Digit Span (DS). 
The digit span (DS) task from the Wechsler Adult Intelligence Scale III is a measure of 
short-term memory, attention and immediate verbal recall (Lezak et al., 2004; Wechsler, 
1996).  For the current study three measures were obtained:  
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Digit span forwards (DS-F): The DS-F requires the participant to repeat back to the 
examiner a series of random numbers, in the same order that the examiner presented 
them.  There are two sets for each span, starting with three digits and terminating with 
nine digits, or when the participant fails two series of equal length.  The DS-F score is 
the longest series of digits correctly recalled, thus higher scores represent better 
performance. 
Digit span backwards (DS-B):  The DS-B has an identical structure to DS-F, however 
the participant must repeat the series of digits in reverse order.  Although the DS-B 
overlaps with the DS-F in terms of function (Bowden, Petrauskas, Bardenhagen, 
Meade, & Simpson, 2013), due to the additional effort required to reverse the order, 
the DS-B is considered more challenging and is considered to be more sensitive to 
neurological impairment than DS-F (Lezak et al., 2004).   As for the DS-F, the score is 
derived from the number of digits correctly recalled and higher values indicate better 
performance. 
Digit Span forward-backwards (DS-FB): Subtracting a participant’s total DS-B from 
the DS-F provides a measure of the discrepancy between of an individual’s 
performance on the DS-F and DS-B.  It has been reported that TBI sufferers are likely 
to have greater divergence between the DS-F and DS-B than normal controls (Lezak et 
al, 2004).  In this measure, lower values indicate better performance. 
Letter-Number Sequencing (LNS). 
In the letter-number sequencing task (LNS), the examiner reads out a random 
combination of letters and numbers, and the participant is required to repeat them by 
providing the letters first, in alphabetical order, then the numbers, in numerical order.  Similar 
to the DS tasks, the LNS is considered to primarily measure attention and short term memory, 
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however it has also been reported to have a visuo-spatial component (Crowe, 2000).  The 
score for the LNS is the longest sequence correctly recalled; therefore larger values indicate 
better performance. 
 
Procedure 
 
Participants who were registered in the TNTR study as of 2010 were invited to 
participate in the current study during routine follow-up contact.  Those who agreed 
completed an additional consent form, and were provided with an additional information sheet 
(see Appendix A). The neuropsychological tasks used in this research were administered as 
part of a larger battery of psychosocial, cognitive, and general outcome measures, which took 
approximately 60 minutes to complete, and participants were invited to take rest-breaks if 
fatigued.  For this study participants were assessed at time of injury, then at 3, 6 and 12 
months following TBI, and assessors were blind to APOE status.  Table 8 shows the number 
of participants who completed each task at each time-point, grouped by APOE status.   
Table 8  
 
Completion rate for each task at each time-point 
 Acute 3 months 6 months 12 months 
IP Speed 128 (77.1%) 127 (76.5%) 130 (78.3%) 107 (64.50%) 
TMT-B 125 (75.3%) 130 (78.3%) 127 (76.5%) 115 (69.3%) 
COWAT 139 (83.7%) 133 (80.1%) 131 (78.9%) 112 (67/5%) 
DS-F 139 (83.7%) 134 (80.7%) 132 (79.5%) 115 (69.3%) 
DS-B 139 (83.7%) 134 (80.7%) 132 (79.5%) 115 (69.3%) 
DS-FB 139 (83.7%) 134 (80.7%) 132 (79.5%) 115 (69.3%) 
LNS 134 (80.7%) 134 (80.7%) 130 (78.3%) 113 (68.1%) 
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As demonstrated in the above table, approximately 80% of participants completed 
tasks at the acute, 3 and 6 month time periods, and completion rate drops to approximately 
69% at 12 months post injury.  In chapter 4 this impact of missing data is explored, and is also 
addressed in the subsequent research chapters (5 and 6). 
 
DNA Analysis 
 
DNA was obtained from saliva samples via buccal swab.  Participants rinsed mouth 
with water, and rubbed the sterile applicator against the buccal mucosa (inner cheek) for 10 
seconds, and repeated on opposing side.  Applicators were air dried for 30 minutes, then 
sealed and stored at 4°c until extraction stage.  For DNA extraction, 100μl tissue extraction 
solution ES and 12.5 μl tissue preparation solution was pipetted into tube containing swab.  
The sample was centrifuged for 5-10 seconds, then swab manually twirled 10-12 times, and 
excess fluid removed, after which the swab was discarded.  Sample was then incubated at 
room temperature for 10 minutes, and then further incubated at 95°c for 3 minutes.  100μl of 
neutralisation solution B was then added and sample was again centrifuged for 10 seconds.  
Samples were then stored at 4°c until PCR could be performed.  
Amplification refractory mutations system (ARMS) PCR was used for genotyping, as 
described by Donohoe, Salomaki, Lehtimaki, Pulkki, and Kairisto (1999).  Two reactions 
were used for each sample (see Appendix B for mixes).  Cell extract was added to each 
reaction, and centrifuged for 10 seconds.  11μl of master mix from reactions A and B were 
pipetted into a 96 well plate, covered and then PCR was performed using the APOEARMS 
programme (see Appendix B for description).  An agarose (1.5%) gel tray containing SYBR 
Safe DNA gel stain (5μl/100μl) was submerged in TAE buffer and loaded with 8μl of DNA 
samples and 4.5 μl of DNA ladder (100 bp, 50 μg/ml).  Gel electrophoresis was then 
performed at 100 volts for 35 minutes (using Bio-Rad Power/Pac 300).  Images were captured 
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using Quantity One (version 4.6) Chemidoc XRS programme and APOE genotypes were 
identified from images.  An example of an electrophoresis image from the study is shown in 
Figure 7.   
 
 
 
 
 
 
Figure 7. Examples of electrophoresis patterns for APOE genotypes ɛ3ɛ4, ɛ2ɛ3, ɛ3ɛ3 and 
ɛ4ɛ4, using modified ARMS PCR (ɛ2ɛ2 and ɛ2ɛ4 not shown).  
 
  
 
100 bp 
Ladder 
 
 
 
 
 
ε3ε4 
 
 
 
ε2ε3 
 
ε3ε3 
 
ε4ε4 
86 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4:  Missing Data - The Importance and Impact of Missing Data from Clinical 
Research 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as: 
 
Padgett, C. R., Skilbeck, C. E., & Summers, M. J. (2014). Missing data: The importance and 
impact of missing data from clinical research. Brain Impairment, 15, 1-9.  
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Abstract 
 
There is compelling evidence that traditional methods used to address the detrimental 
impacts of missing data are inadequate.  Despite this, researchers have been slow to utilise 
newer statistical approaches known to be more effective.  The aim of the current article is to 
offer a conceptual explanation of the rationale for using newer missing data techniques, with a 
focus on multiple imputation (MI).  To illustrate the relative efficacy of deletion, single 
imputation and multiple imputation techniques in the clinical setting, 20 cases were randomly 
selected from a population study investigating the cognitive sequelae of traumatic brain injury 
(TBI), and 8 out of 20 cases had scores on one variable deleted to simulate a missing dataset.  
Comparing the parameter estimates obtained by each technique to the known parameters of 
the complete dataset revealed that MI outperformed deletion and single imputation 
approaches.  It is therefore recommended that more sophisticated techniques such as MI 
should be considered in clinical research.   
 
 
  
88 
 
 
 
Introduction 
 
Missing data (often referred to as missingness) is commonplace in clinical research, 
where participants may miss appointments, refuse certain tasks, drop out of or die during the 
course of longitudinal studies.  Statistical techniques do not enable the analysis of data in 
which there are missing cases, consequently different approaches for dealing with the issue of 
missing values have evolved. Traditionally, the most commonly used approaches for dealing 
with missing values are deletion or single imputation.  Deletion techniques exclude the 
missing data from analyses, thus statistical analysis is conducted only on complete sets of 
observed scores.  Whilst this may appear to be the most pragmatic approach, ignoring missing 
data is known to be problematic and has been criticised by methodologists as being one of the 
most dubious approaches to analysis (Wilkinson & American Psychological Task Force on 
Statistical Inference, 1999).  Imputation techniques involve substituting the missing value with 
an estimated value.  Single imputation techniques provide estimates based on the observed 
scores on the variable for which the data is missing.  The most commonly used single 
imputation techniques are mean imputation and regression imputation.  (Stochastic regression 
can also be used, however this is rarely employed in clinical research, and is not addressed in 
this paper.)  Mean imputation involves substituting the mean of the observed scores of a given 
variable for the missing value.  Alternatively, where it is possible to conduct a regression 
analysis, a missing value can be estimated based on a regression equation for the variable. 
It has been argued for some time that deletion and single imputation techniques fail to 
adequately address the impact missing data may have on analysis, with the primary concern 
being that such approaches do not account for the increased variance that may occur had the 
actual score(s) been obtained (Allison, 2002; Enders, 2010; Graham, 2012; Schafer & 
Graham, 2002; Schafer & Olsen, 1998).  An additional consequence of deletion techniques is 
the reduction of statistical power that occurs from the reduction in sample size (Graham, 2009; 
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McKnight, McKnight, Sidani, & Figueredo, 2007).  Therefore missing data has the potential 
to introduce bias and reduce the integrity of results. With the emergence of increasingly 
powerful statistical software it is increasingly easy to employ more sophisticated missing data 
techniques that better compensate for the problems associated with traditional missing data 
approaches. Two of the more sophisticated approaches are multiple imputation (MI) and 
maximum likelihood (ML) (Allison, 2002; Baraldi & Enders, 2010; Sinharay, Stern, & 
Russell, 2001).  This report focuses on MI, as it has been suggested this is the most 
generalisable and flexible missing data technique. MI is robust to breaches of the assumption 
of normality, is impacted less by the nature of the missing data than other approaches, and 
performs relatively well even in small samples (Graham, 2012; Graham & Schafer, 1999; 
Jelicic, Phelps, & Lerner, 2010; McKnight et al., 2007; Sinharay et al., 2001).   
Despite repeated recommendations for employing newer missing data techniques such 
as MI, these approaches are rarely used in clinical/psychological research (Enders, 2010; 
Jelicic, Phelps, & Lerner, 2009; Roth, 1994; Schafer & Graham, 2002).  This is possibly due 
to a lack of awareness of such approaches, and because the literature regarding these newer 
approaches can appear daunting for non-statisticians.  Furthermore, the detrimental effect that 
missing data has on analysis is also often underestimated by researchers, thus methods that 
ameliorate the impact of missing data are not considered necessary.  With this in mind, the 
aim of this report is to offer a conceptual demonstration of how deletion, single imputation 
and MI compare in estimating missing data when applied in clinical research, in order to 
demonstrate the impact missing data can have.  Firstly, to clarify the effect of missing data on 
analysis, a description of the nature of missing data, and the limitations of various approaches 
in addressing missing data, is provided. 
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Why does missing data matter? 
 
In order to understand why missing data can bias results, it is necessary to briefly 
explain the nature of missingness itself.  The underlying premise of missing data theory is that 
missingness is often not random in nature.  Rubin (1976) proposed that there are three types of 
missing data.  Firstly, data can be missing completely at random (MCAR).  MCAR occurs in 
instances where missing data is not related to the scores on the variable in question, and is also 
not related to scores on any other variables under analysis.  The second category proposed by 
Rubin is missing at random (MAR).  Missing data in this category is not related to scores on 
the variable with the missing data, however there may be systematic missingness in relation to 
another variable also being measured.  For example, if assessing cognitive function during the 
acute phase following traumatic brain injury (TBI) it may be that individuals that also 
experienced orthopaedic injuries when the TBI was sustained would be less likely to complete 
a design-learning task, due to restricted mobility.  In this case, missingness is systematic on 
one variable (presence of orthopaedic injury/polytrauma) but not on the variable being 
measured (word-learning), and is therefore MAR. Finally, missing values can be said to be 
missing not at random (MNAR).  This occurs when the missing values are directly related to 
values of the variable in question.  For example, if only participants who are experiencing 
high levels of depression refuse to complete a questionnaire assessing depression, high scores 
will be systematically missing on the variable with the missing data.   
Missing data therefore has the potential to influence analysis in a number of ways.  
Clearly, where there is a relatively large amount of missing data and only the complete cases 
are analysed, the sample size may be seriously reduced.  This results in a loss of power, 
leading to increased risk of Type II errors, whereby meaningful differences are missed 
(McKnight et al., 2007).  An equally pressing concern, long recognised by statisticians but 
often unrecognised by clinical researchers, is that traditional techniques (deletion, single 
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imputation) are based on an assumption that missing data occurs randomly, or is MCAR.  
However, data is often not MCAR, especially in the clinical setting where often there are one 
or more variables that have the potential to influence which scores are missing.  As such, 
missingness is typically either MAR and MNAR, and therefore bias can occur (Graham, 
2009).  A further limitation of both deletion and mean and regression imputation is that they 
only utilise the variance of the observed data set. These methods assume that missing data will 
fall within the variance range of the existing data set.  This is concerning as the missing data is 
likely to introduce greater variability, and as such ignoring missing data may reduce variance.  
This attenuates differences where scores are being compared, increasing the likelihood of a 
Type I error occurring; identifying a significant effect when one is not present (Schafer & 
Olsen, 1998).  Alternately, where correlational analysis is conducted, if mean imputation is 
used the strength of association becomes weaker, whereas employing regression imputation 
will strengthen the association, again increasing the risk of misinterpretation of results 
(Baraldi & Enders, 2010; Schafer & Olsen, 1998).  In short, traditional approaches to 
replacing missing values are based on the frequently erroneous assumption that data is 
MCAR; increasing the risk of bias and errors in interpretation.  Furthermore, the use of 
traditional techniques such as deletion and single imputation may lead to loss of power, and/or 
increased risk of Type I or Type II errors.   
 
A conceptual explanation of multiple imputation (MI). 
 
A brief conceptual description of the processes involved in MI is provided below. For 
more detailed explanations see Enders (2010), Graham (2012), Schafer (1999), and/or 
Sinharay et al. (2001).  
Three separate phases occur in MI; imputation, analysis, and pooling.  The imputation 
phase involves the creation of multiple datasets where missing scores are replaced by scores 
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obtained from regression equations that are computed from the variable in question and other 
related variables, as selected by the researcher. Generally, all variables that will be used in 
final analysis, and any variable expected to interact with the variables under investigation, 
should be included in the MI (Enders, 2010).  Indeed, including additional auxiliary variables 
(those which may interact with the outcome variable, but may not be of relevance to the 
research question) is recommended and does not mean that such variables need to be used in 
later analysis (Enders, 2010).  There are a number of algorithms available for use when 
conducting the imputation phase, however, data augmentation is the most commonly used as it 
assumes multivariate normality (Enders, 2010; Graham, 2009), and is the focus of the 
following description.   
The imputation phase involves two steps; the imputation step (I-step) and posterior 
step (P-Step).  In the I-step one or more regression equations (based on observed scores of 
selected variables) are calculated to estimate missing values.  To increase variability, an error 
term derived from the regression is added to each imputed score.  From this set of scores, the 
P-Step calculates new means and co-variances, and again a residual error term is added.  The 
dataset obtained in the P-step can then be used to create another imputed set of scores.   In 
order to ensure that each imputed dataset is independent, a large number of iterations (I-Steps 
and P-Steps) are run before the next imputed dataset is selected for use in the analysis phase.  
Because each dataset is based on different regression equations, and generates a different set 
of parameter estimates, the amount of variance is increased. Thus, MI techniques better 
account for the impact of unknown variance in the missing data than if a single imputation 
technique were to be employed.  Parenthetically, by comparing the variability of parameters 
between each of the datasets, the researcher can also estimate the relative impact of the 
missing data -greater variation between datasets indicating a greater impact of missingness 
(McKnight et al., 2007).  It should also be noted that the number of imputed datasets needed 
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will vary depending on the amount and nature of the missing data, and predicted effect size 
(Graham, Olchowski, & Gilreath, 2007; Graham & Schafer, 1999)   
When the required number of imputed datasets have been created, the analysis phase is 
performed, in which the desired analysis is conducted on each dataset separately.  In other 
words, whatever analysis had been planned (regression, ANOVA) can be conducted 
separately on each of the multiple datasets.  Finally, in the pooling phase, the results obtained 
for each imputed dataset during the analysis phase are combined to obtain a single value 
reflective of all datasets.  For example, means and standard errors could be calculated for each 
imputed dataset during the analysis phase, and then combined to create a pooled mean and 
standard error, which can then be reported in the final analysis.  The process of pooling varies 
in complexity, depending on the statistic being calculated.  In some situations such as pooling 
means, the formula for pooling results is the same as for any other data.  However, in other 
situations the process is more complicated, for example pooling standard errors employs a 
formula in which the variance between and within each imputed dataset is taken into account 
(for further detail on method of reporting MI results and formulae for pooling see Enders, 
2010).   
Despite the conceptual nature of the above description, it may appear that MI is a 
complicated process.  However, these steps are automated in many statistical software 
packages, and therefore MI can be conducted with relative ease.  Nevertheless, it should be 
noted that popular statistical programmes vary in capacity to perform the various stages of MI.  
For example, whilst SPSS conducts the imputation and analysis phases automatically, it 
currently doesn’t always pool test statistics (for example, if F-tests are performed).  Where the 
test statistic is not calculated, it is possible to create syntax or calculate manually (Enders, 
2010; Howell, 2012; Schafer & Olsen, 1998), although clearly this is not ideal and it is hoped 
that forthcoming versions will soon be more user-friendly.  SAS does routinely pool test 
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statistics, and there are also a number of MI specific programmes such as NORM which also 
have better functionality.   
It is also important to have some understanding of the processes involved in MI as the 
researcher may need to modify the default settings in some software.  Of particular importance 
are decisions regarding the number of iterations allowed to run between each dataset selected 
for analysis, and the total number of imputed datasets that should be obtained.  For example, 
in SPSS (version 21) the default number of iterations when choosing the custom setting is 10, 
whereas it is likely that many more iterations may be necessary, with current 
recommendations suggesting 100 to 200 iterations are typically required (Baraldi & Enders, 
2010; Graham & Schafer, 1999).   Furthermore, in SPSS the default number of imputations is 
5, and whilst some authors suggest this is acceptable (Sinharay et al., 2001), others suggest 
that 10 to 20 imputations are required, although this is dependent on the amount of missing 
data and predicted effect size (Enders, 2010; Graham et al., 2007; Graham & Schafer, 1999).  
 
The current study 
 
Baraldi and Enders (2010) offer a coherent and insightful demonstration that clearly 
illustrates traditional and newer techniques and their effect.  The current study replicates this 
approach, but rather than create a simulated dataset, the data reported here has been extracted 
from an existing clinical research project investigating cognitive and psychosocial function 
following traumatic brain injury (TBI).  In order to demonstrate the application of missing 
data approaches within the clinical research setting a small number of complete cases were 
randomly selected from the dataset.   Parameter estimates (means and standard 
deviation/error) were calculated, and then some scores were excluded to create a hypothetical 
missing dataset.  The means and standard deviation obtained by deletion, mean imputation, 
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regression imputation, and MI were then compared to the known mean and standard deviation 
of the complete dataset in order in order to determine the relative efficacy of each approach. 
 
 
Method 
 
Description of data set 
 
Data was obtained from the Tasmanian Neurotrauma Register; a population study 
investigating cognitive and psychosocial recovery following TBI (ethics approval obtained).  
Individuals with TBI presenting at the Royal Hobart Hospital, Tasmania from 2003-2007 were 
invited to participate in the Register.  At total of 1227 (m = 798 f = 429) individuals consented 
and underwent a battery of psychosocial and neuropsychological assessments at admission, 
with follow-up assessments at 3, 6, and 12 months, and annually up to 5 years post injury.  For 
the purpose of the current study, a random draw of 20 participants was selected (m = 11, f = 
9), and scores obtained at the initial assessment were used.  The injury and demographic 
variables of the sample are shown in Table 9. 
 
Table 9  
 
Injury and Demographic Characteristics of Participants (n = 20) 
      Range  M  SD 
Age at injury (years)    21-70  45.56  14.71  
Post Traumatic Amnesia (days)  .003 – 9.00 1.11  2.15  
Premorbid FSIQa    75 – 121 104.35  11.27  
aPremorbid full scale IQ was estimated using the National Adult Reading Test (NART). 
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Materials 
 
Two cognitive measures were selected from the assessment battery.  The Controlled 
Oral Word Association Task (COWAT; Benton & Hamsher, 1989) requires participants to list 
as many words as possible, starting with a particular letter, within 60 seconds.  Three trials, 
using the letters ‘F’, ‘A’, and ‘S’ were used for all participants, with the total number of words 
across all three conditions being used in analysis.  Coughlan’s Information Processing Speed 
Task (IP Speed; Coughlan & Hollows, 1985) is a measure of processing speed, in which the 
participant identifies the second highest number in each row of 5 numbers over a set of 105 
rows of numbers. The total number of lines in which the correct number is crossed out was the 
score used in the current analysis.   
 
Procedure 
 
From the 20 selected cases, participants who had attended between June 2005 and June 
2006 had their scores on the COWAT deleted, thereby simulating a dataset in which some 
data was missing due to a hypothetical data entry error.  As such, the simulated missing 
dataset can be said to have data missing at random (MAR), as the likelihood of any given 
score being missing is not directly related to the variable being measured. Deletion, mean and 
regression imputation, and MI were then conducted.   
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Results 
 
SPSS (version 21) was used for all analysis.  Means and standard deviations were 
calculated for the complete set, and then COWAT scores for individuals assessed between 
June 2005 and June 2006 were excluded, resulting in a total of 8 out of the 20 scores being 
deleted.   Standard approaches to missing data (deletion, and mean and regression imputation) 
were conducted, and the means and standard deviations obtained using each approach were 
compared to the known values of the full dataset (Table 10).  Scatterplots for the complete 
dataset (Figure 8), the deletion dataset (Figure 9), mean imputation (Figure 10) and regression 
imputation (Figure 11), are also provided to enhance illustration. 
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Table 10  
Means and Standard Deviations Obtained Using Deletion, Mean and Regression Imputation 
Techniques for Hypothetical Missing Dataset, Compared to Complete Dataset  
Complete (Observed) Data 
Hypothetical Missing COWAT Dataset 
IP Speed COWAT Deletion 
Technique 
Mean 
Imputation 
Regression 
Imputationa 
38.00 23.00 - 41.67 30.07 
67.00 19.00 - 41.67 43.93 
60.00 26.00 - 41.67 40.59 
59.00 44.00 - 41.67 40.11 
52.00 31.00 - 41.67 36.76 
38.00 26.00 - 41.67 30.07 
72.00 65.00 - 41.67 46.32 
58.00 46.00 - 41.67 39.63 
50.00 36.00 36.00 36.00 36.00 
39.00 18.00 18.00 18.00 18.00 
63.00 50.00 50.00 50.00 50.00 
42.00 32.00 32.00 32.00 32.00 
87.00 54.00 54.00 54.00 54.00 
67.00 45.00 45.00 45.00 45.00 
86.00 63.00 63.00 63.00 63.00 
87.00 47.00 47.00 47.00 47.00 
41.00 28.00 28.00 28.00 28.00 
68.00 34.00 34.00 34.00 34.00 
36.00 44.00 44.00 44.00 44.00 
79.00 49.00 49.00 49.00 49.00 
Mean 39.00 41.67 41.67 40.37 
SD 13.76 12.45 9.48 10.26 
a Regression Imputation Equation: Ŷ = 11.989 + 0.478 (IPSpeed) 
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Figure 8. Scatterplot of observed dataset. ▲ Denotes observed data point deleted to create 
missing data set. 
 
            
Figure 9.  Scatterplot of the hypothetical dataset cases with missing values removed using the 
deletion technique. 
 
When the deletion technique was used, there was a slight increase in the mean and 
reduction in variance, as compared to the known parameters (Table 10).  The mean obtained 
from the deletion dataset was then used for the mean imputation approach.  Unsurprisingly, 
 
Figure 1  Scatterplot of Observed Dataset.  
 Denotes observed data point deleted to 
create missing data set. 
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this resulted in the mean remaining the same as for the deletion technique, with a further 
decrease in variance (Table 10). A bivariate regression analysis was conducted using the IP 
Speed scores and the COWAT scores from the hypothetical missing dataset (Table 10), with 
the resulting regression equation being used to imputate the missing COWAT values (see 
footnote Table 10).  The regression imputation mean was closer to the true mean than either 
the deletion or mean imputation technique.  However while the variance was slightly more 
accurate than variance obtained by mean imputation, it was not as close to the observed SD as 
when the deletion technique was employed.   
  
 
Figure 10.  Scatterplot of the hypothetical dataset missing values replaced with mean 
imputation. ▲ Denotes mean imputed data point. 
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Figure 11.  Scatterplot of the hypothetical dataset missing values replaced with regression 
imputation. ▲ Denotes regression imputed data point. 
 
MI was then conducted, using IP Speed and COWAT scores in the missing dataset.  
Although it has been recommended that at least 20 imputations be used in most situations 
(Graham et al., 2007), for the purpose of demonstration a total of 5 imputations were 
performed (Table 11).  In order to increase independence of each imputation, the number of 
iterations between each imputation was increased from the SPSS default setting 10 to 200, 
consistent with Baraldi and Enders’ demonstration (2010).  As is evident in Table 11, each 
imputation generates different values for a given missing score, thus creating differing means 
and standard errors (SE). The mean and standard error are pooled for the final analysis. When 
comparing the pooled mean and standard error to the complete dataset, it is apparent that MI 
has yielded both a mean and variance very similar to the known parameter estimates, and is 
closer on both measures than the deletion or single imputation techniques.  
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Figure 4  Scatterplot of the hypothetical dataset with 
missing values replaced by regression imputation.  
 Denotes regression imputed data point. 
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Table 11  
Comparison of Means and Standard Deviations (SDs) for Complete Dataset, and 
Hypothetical Missing Datasets Employing Multiple Imputation Techniques 
 
Original Data Missing 
Data 
Imputed COWAT Scores 
IP 
Speed 
COWAT COWAT MI 
Set 1 
MI 
Set 2 
MI 
Set 3 
MI 
Set 4 
MI 
Set 5 
MI 
Pooled 
38.00 23.00 - 10.31 33.95 22.94 23.09 50.17  
67.00 19.00 - 33.66 51.92 32.77 26.33 33.12  
60.00 26.00 - 43.81 42.86 38.59 36.45 49.10  
59.00 44.00 - 25.14 52.26 50.86 25.12 34.03  
52.00 31.00 - 35.16 34.57 35.31 0.04 47.08  
38.00 26.00 - 37.51 35.46 25.69 24.30 23.13  
72.00 65.00 - 48.43 32.17 17.29 60.61 27.59  
58.00 46.00 - 16.13 61.45 16.31 43.04 54.99  
50.00 36.00 36.00 36.00 36.00 36.00 36.00 36.00  
39.00 18.00 18.00 18.00 18.00 18.00 18.00 18.00  
63.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00  
42.00 32.00 32.00 32.00 32.00 32.00 32.00 32.00  
87.00 54.00 54.00 54.00 54.00 54.00 54.00 54.00  
67.00 45.00 45.00 45.00 45.00 45.00 45.00 45.00  
86.00 63.00 63.00 63.00 63.00 63.00 63.00 63.00  
87.00 47.00 47.00 47.00 47.00 47.00 47.00 47.00  
41.00 28.00 28.00 28.00 28.00 28.00 28.00 28.00  
68.00 34.00 34.00 34.00 34.00 34.00 34.00 34.00  
36.00 44.00 44.00 44.00 44.00 44.00 44.00 44.00  
79.00 49.00 49.00 49.00 49.00 49.00 49.00 49.00  
Mean 39.00 41.67 37.51 42.23 36.98 36.95 40.96 38.93 
SD/SE 13.76 12.45 13.46 11.58 13.23 15.45 11.93 13.47a 
a As SPSS does not pool SE this was calculated manually using the formula provided in Baraldi & Enders 
(2010).      
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Discussion 
 
In the current study, a random sample of 20 cases was drawn from a clinical research 
study to compare the means and variance obtained from a complete dataset to an identical 
dataset, except with missing values.  As demonstrated, MI yielded parameter estimates closer 
to the known estimates than any of the traditional missing data approaches.  Each of the 
deletion and single imputation procedures was limited in its capacity to reflect the complete 
sample parameters, yielding means and/or variance estimates that were markedly different to 
the original data set.  In contrast, MI was found to provide both a mean and standard error that 
was close to identical to the known values, and therefore outperformed the deletion or single 
imputation approaches. 
This finding provides similar results to Baraldi and Enders (2010), who used a 
hypothetical dataset to compare missing data techniques.  Indeed, when considering the 
traditional approaches, in both studies the regression imputation yielded the closest mean, and 
deletion yielded the closest standard deviation when compared to the complete datasets.  An 
advantage of the current study was that the parameter estimates obtained by each missing data 
technique were able to be compared to the known parameters of a complete dataset which has 
been obtained in the clinical setting, thus indicating that missing data techniques such as MI 
can be applied in this context.   
Whilst the above results indicate that MI is an effective method for addressing missing 
data, it must be acknowledged that the problems associated with missing data cannot be 
entirely ameliorated by any missing data techniques.  MI and other new missing data 
procedures are useful for data that is MCAR or MAR, however they are less reliable when 
data is MNAR. Unfortunately, although there are methods to determine if data is MCAR (see 
Enders, 2010), it is not possible to determine whether data is MAR and MNAR, and to date 
there is no effective technique for addressing data that is MNAR (Enders, 2010; Graham, 
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2012).  Nevertheless, MI has been found to work relatively well in the MNAR setting (Enders, 
2011), and may remain a better alternative than traditional approaches, or even techniques 
specifically designed to deal with data that is MNAR, as techniques designed for MNAR data 
rely on untestable and stringent assumptions (Enders, 2010; McKnight et al., 2007; Schafer & 
Graham, 2002).  However, where there are strong violations of the MAR assumption, use of 
MI or other modern techniques may be questionable. 
It should also be noted that even where missingness is MCAR or MAR, MI may not be 
the most appropriate approach.  McKnight and colleagues (2007) state that that small sample 
sizes may reduce the reliability of MI , however others have suggested this likely to be a 
reflection of the inherent limitations of small samples, rather than inefficiency of MI per se 
(Graham, 2009; Graham & Schafer, 1999).  Using standard MI in some longitudinal designs 
and with multilevel data may also be problematic, requiring either the use of an MI algorithm 
other than data augmentation, or the use of a technique other than MI (Enders, 2010, 2011; 
Graham, 2012).   
A further limitation is that statistical packages still vary in terms of ease of use, 
especially in relation to pooling parameters and test statistics.  Given recent advances, and 
increased use of modern missing data approaches, it is likely that techniques such as MI will 
become better integrated into many software packages in the near future.  Nevertheless, it is 
important to be aware of the capacity of a given programme in regards to MI prior to 
commencing analysis. 
An issue not often addressed in the literature to date is the proportion of data missing 
from a dataset that can be reliably replaced when employing missing data techniques such as 
MI.  McKnight et al. (2007) observe that any such guideline would be arbitrary, and would 
also depend on the nature of the research.  However, it may be advantageous to clarify 
whether there is a proportion of missingness at which the efficacy of MI is reduced, and 
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whether there are any considerations specific to applying MI in the clinical research setting, as 
have been observed for other statistical techniques (Proust-Lima, Dartigues, & Jacqmin-
Gadda, 2011).  Furthermore, given that clinical researchers may have little experience with 
such techniques, some provisional guidelines may foster confidence and encourage greater 
utilisation of these approaches. 
It is hoped that by providing this comparison of the various missing data techniques, 
the benefit of utilising MI in the clinical setting is apparent.  It should also be clear that 
regardless of whether missing data is actively dealt with, it is important to have a sound 
understanding of the nature and impact of missing data. Ideally, whilst modern missing data 
approaches can address missingness on a post hoc basis, it is suggested that consideration 
should be given to the possible factors that may contribute to missing data prior to 
commencement of research.   Any factors that are likely to influence missingness can then be 
measured, allowing more rigorous analysis.  That being said, Graham (2012)  states that whilst 
it is useful to include and understand the key causes of missing data, it is not necessary to 
include all variables contributing to missing data for MI to be effective.  Finally, while beyond 
the scope of this paper, it should be noted that understanding the nature of missing data can 
also allow more effective research, both in terms of analysis, and in creating cost-effective 
studies by utilising a planned missingness design (for further explanation see Enders, 2010 
and Graham, 2012).   
In conclusion, the nature and detrimental impact of missing data, and the associated 
limitations of traditional methods of dealing with missingness, are often not fully appreciated.  
The above findings indicate that modern missing data approaches such as MI outperform 
traditional approaches by re-introducing the variance that was likely to have occurred should 
missing scores have been obtained.  This minimises the amount of bias caused by missing 
data, and increases the power to detect meaningful effects.  MI and other approaches are now 
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readily available in many statistical software programs, and are relatively fast and 
straightforward to use.  Whilst there may be some additional effort required to learn new 
techniques such as MI, it is suggested that the long term benefits make learning these 
techniques worthwhile, and it is hoped that approaches such as MI will routinely conducted in 
the clinical research setting.
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Chapter 5:  Exploring the Effect of the Apolipoprotein Gene on Executive Function, 
Working Memory and Processing Speed During the Early Recovery Period Following 
Traumatic Brain Injury. 
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Abstract 
 
Introduction: There is evidence that the ɛ4 allele of the APOE gene is detrimental to 
cognitive function, but results from traumatic brain injury (TBI) populations are mixed.  
A possible explanation is that APOE ɛ2 carriers have routinely been incorporated into 
APOE ɛ4 and non- ɛ4 groups, despite APOE ɛ2 being proposed to have an ameliorative 
effect. Our primary aim was to investigate the influence of APOE ɛ4 on cognitive 
impairment during early recovery following TBI, excluding the potential confound of 
APOE ɛ2 possession.  A secondary objective was to explore whether APOE ɛ4 displays 
more pronounced effects in moderate to severe TBI and to consider the potential post-
injury protective influence of the APOE ɛ2 allele.   
Methods: Participants who recently sustained a TBI (Post Traumatic Amnesia > 5 
minutes) were assessed on measures of information processing speed, executive 
function, and working memory upon remission of post-traumatic amnesia. APOE 
genotype was determined by buccal saliva DNA extraction (APOE ɛ4 n = 37, APOE ɛ3 
n = 92, APOE ɛ2 n = 13).    
Results: Stepwise multiple regressions were performed to compare APOE ɛ4 carriers to 
APOE ɛ3 homozygotes, with injury severity, age, and estimated premorbid IQ included 
in the first step.  This model was found to significantly predict performance on all tasks, 
accounting for 17.3% - 24.3% of the variance.  When APOE ɛ4 status was added for the 
second step, there were no significant changes on any tasks (additional variance <1%).  
The effect of APOE ɛ4 in moderate to severe TBI and the effect of APOE ɛ2 were 
explored by ANCOVA, with no significant effects revealed.   
Conclusions:  It is unlikely that APOE genotype influences cognitive function in the 
initial recovery period following TBI, regardless of injury severity.  However, a more 
nuanced and long-term exploration of the effect of APOE genotype in the TBI 
population is warranted. 
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Introduction 
Traumatic brain injury (TBI) is a relatively common injury, with some estimates suggesting 
that 12% of adults will experience a TBI in their lifetime (Frost, Farrer, Primosch, & Hedges, 
2013).  Those who survive the initial injury can experience deficits to cognitive, emotional 
and motor function that can be lifelong, with impaired cognitive function being one of the 
most common and enduring complaints (Draper & Ponsford, 2008; Konrad et al., 2011; Millis 
et al., 2001).  There is emerging evidence that some biological factors may influence 
cognitive function following TBI.  Of growing interest is the Apolipoprotein E (APOE) gene, 
which synthesises the glycoprotein apolipoprotein e (apoE).  ApoE is believed to be one of 
the key lipid transporters in the brain, and has also been implicated in lipid recycling and 
clearance (Mahley & Rall, 2000).  Lipids, especially cholesterol, are necessary to maintain 
neurological integrity and to assist in repair processes following TBI, and it has been reported 
that apoE levels rise dramatically in the initial response to TBI (Adibhatla & Hatcher, 2007).  
There is also evidence that apoE has antioxidant properties, and may be associated with 
maintaining the integrity of the blood brain barrier following injury (Horsburgh, McColl, 
White, & McCulloch, 2003; Methia et al., 2001).  Therefore apoE production is thought to be 
integral in neurological responses to TBI.   
Within the human population there are three APOE alleles – APOE ɛ2 APOE ɛ3 and 
APOE ɛ4, with frequencies of approximately 11%, 72% and 17% respectively (Zannis, Just, 
& Breslow, 1981).  Each allele synthesises structurally different versions of apoE. It has been 
reported that the protein arising from the APOE ɛ4 allele has increased misfolding and is less 
stable than the other two isoforms, and may have reduced efficacy as a result (Mahley & 
Huang, 2006). Furthermore, there is evidence that possession of the APOE ɛ4 allele increases 
risk of developing a number of neurological disorders, most notably Alzheimer’s disease 
(Mahley & Huang, 2006).  Given these findings, it has been proposed that possession of the 
APOE ɛ4 allele could be associated with greater cognitive impairment post TBI. By far, the 
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majority of research has focussed on the hypothesised detrimental effect of APOE ɛ4, but it 
has also been postulated that APOE ɛ2 may confer some protective effects in the presence of 
neuropathology (for a review see Suri, Heise, Trachtenberg, & Mackay, 2013).   The APOE 
ɛ3 allele is considered neither beneficial nor detrimental (Mahley & Huang, 2012), and is 
typically used as a reference group to compare APOE ɛ4 carrier performance against.   
Although interest in the relationship between the APOE ɛ4 allele and cognitive 
recovery following TBI has grown in recent years, the evidence to date is mixed.  When 
comparing the cognitive performance of APOE ɛ4 carriers and non-carriers during early 
stages of recovery (< six months post injury), some researchers report that possession of the 
APOE ɛ4 allele is associated with reduced cognitive performance (Anderson et al., 2009; 
Crawford et al., 2002; Noe, Ferri, Colomer, Moliner, & Chirivella, 2010), whereas others 
have found no effect of APOE genotype (Liberman, Stewart, Wesnes, & Troncoso, 2002; 
Müller et al., 2009; Ponsford, Rudzki, Bailey, & Ng, 2007; Shadli, Pieter, Yaacob, & Rashid, 
2011).  Indeed, findings by Han and colleagues (2007) even suggest that APOE ɛ4 may have 
an ameliorative effect following TBI.  
There are a number of factors that may contribute to these conflicting reports.  A 
recent review of the literature suggests that APOE ɛ4 may be associated with poorer cognitive 
outcomes when TBI is severe (Lawrence, Comper, Hutchison, & Sharma, 2015), but while 
there is tentative evidence that APOE ɛ4 may initially be associated with greater cognitive 
impairment following severe TBI (Liberman et al., 2002; Noe et al., 2010), others have found 
no such effect in the early recovery period (Ponsford et al., 2007).   
There are also methodological limitations inherent in investigations of genetic effects 
in clinical populations such as TBI which may explain some of the contradictions in research 
to date.  Specifically, the relative infrequency of the APOE ɛ4 allele has meant that studies are 
frequently hampered by small sample size for APOE ɛ4 carriers, with a number of studies 
having APOE ɛ4 groups of less than 20 participants (Anderson et al., 2009; Müller et al., 
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2009; Shadli et al., 2011).  Furthermore, to date existing research investigating short term 
recovery has included APOE ɛ2 allele carriers within the APOE ɛ4 carrier group and/or the 
non-APOE ɛ4 carrier group.  This may be problematic not only because of the evidence that 
APOE ɛ2 confers a protective effect against neurological impairment, but also because APOE 
ɛ2 is believed to be dominant over the other two alleles (Corder et al., 1994; Suri, Heise, 
Trachtenberg, & Mackay, 2013).  Given the allelic frequencies of APOE, an estimated 15% of 
the population would have an APOE ɛ3/APOE ɛ2 combination, whereas only 3% of the 
population are likely to have an APOE ɛ4/APOE ɛ2 combination.  As such, any protective 
effect of the APOE ɛ2 allele would be more likely to impact on the APOE ɛ3 group, thus 
having the potential to accentuate differences between APOE ɛ4 carriers and non-carriers.  
Due to concerns about the impact of the APOE ɛ2 allele, more recent long-term investigations 
have excluded APOE ɛ2 carriers (Eramudugolla et al., 2014), however, this approach has yet 
to be applied in studies exploring cognitive function during the initial recovery period 
following TBI. 
The aim of the current study was to determine whether or not APOE ɛ4 contributes to 
early (< six months) cognitive impairment, specifically in the domains of executive function, 
working memory, and processing speed, once other demographic and injury related factors 
are accounted for.  To clarify the effect of APOE ɛ4, APOE ɛ2 carriers were treated as a 
separate group, with the intention that all three alleles could be compared, should there be 
sufficient APOE ɛ2 carriers recruited, or allowing a direct comparison of APOE ɛ4 to the 
more prevalent APOE ɛ3 allele if there were insufficient APOE ɛ2 carriers.  The primary 
hypothesis was that APOE ɛ4 carriers (individuals who have an ɛ3/ɛ4 genotype or are 
homozygous for the APOE ɛ4 allele) would have poorer neuropsychological performance 
than those who are homozygous for APOE ɛ3, as measured by tests of information 
processing, executive function and working memory, during the initial recovery phase 
following TBI.  As ancillary hypotheses, we also predicted that the detrimental effect of 
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APOE ɛ4 would only occur in moderate to severe TBI, and that APOE ɛ2 carriers would 
perform significantly better than either the APOE ɛ4 or APOE ɛ3 groups, irrespective of 
injury severity.  Given the infrequency of both APOE ɛ2 carriers and moderate to severe TBI 
sufferers in the general population, we expect that sample sizes will be sufficient to permit 
only exploratory analyses of the two ancillary hypotheses.  
 
Method 
 
Participants 
The current investigation into APOE genotype was retrospectively incorporated into a 
larger longitudinal population study of TBI; the Tasmanian Neurotrauma Register (TNTR).  
The TNTR operated within the Royal Hobart Hospital, which is the only tertiary referral 
centre within the state of Tasmania, Australia.  Between the years 2003 and 2007, all patients 
with a diagnosis of TBI, who were admitted as inpatients or seen in the emergency 
department of the Royal Hobart Hospital, were invited to participate in the TNTR study.  (In 
Australia, a no-fault compensation system operates.)  Recruitment and testing protocols were 
established prior to the commencement of the current study, and participants who had already 
been recruited into the TNTR were invited to participate in the current study when contacted 
for their routine follow-up assessments.  Those who agreed completed additional informed 
consent.  Inclusion criteria for the current study were: The participant must have experienced 
more than 5 minutes post-traumatic amnesia (PTA, as measured by either Westmead Scale 
score, or self-report and the Galveston Orientation and Amnesia Test), been aged between 15-
75 years of age at time of injury, have no premorbid history of neurological or 
neurodegenerative disorders, no previous TBI, no premorbid history of medicated 
psychological disorders, and premorbid full-scale intelligence quotient (FSIQ)  > 70, as 
estimated by the National Adult Reading Test (NART).  Ethics approval was obtained both 
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for the TNTR study and subsequently for the current study.   
Of those who met the inclusion criteria, a total of 173 participants agreed to take part 
in the APOE study, however three participants were unable to be genotyped.  The remaining 
170 participants were determined to be in Hardy-Weinberg equilibrium (χ2 (5) = 6.050, p = 
.30), and the genotype frequencies are provided the supplementary material section (Table 
S1).  Four participants had a genotype of ɛ2/ɛ4, and given the opposing effects of each allele, 
these participants were also removed from the analysis.  A total of 24 participants did not 
have neuropsychological data for their initial assessment, resulting in a final sample of 142. 
 
Procedure 
Following consent, neuropsychological assessment was undertaken as soon as possible 
following remission from PTA.  As neuropsychological assessment occurred prior to DNA 
sampling, assessors were blind to APOE genotype.  DNA samples were collected via buccal 
swab during routine follow-up assessments and de-identified prior to genotyping.  
Amplification refractory mutations system polymerase chain reaction (ARMS PCR) was used 
for genotyping, as described by Donohoe, Salomaki, Lehtimaki, Pulkki, and Kairisto (1999).  
The neuropsychological test battery comprised of 5 tasks measuring information 
processing, executive function and working memory.  Information processing speed was 
measured by the Information Processing (IP) subtest of the Adult Memory and Information 
Processing Battery, and was adjusted for motor speed (Coughlan & Hollows, 1985).  Verbal 
fluency was measured by the Controlled Oral Word Association Task (COWAT), and 
cognitive speed and flexibility was assessed by the Trail Making Task B (TMTB), as both 
tasks have been found to assess executive function (Borkowski, Benton, & Spreen, 1967; 
Strauss, Sherman, & Spreen, 2006).  Scores were obtained by total number of words produced 
for COWAT and total time taken for TMTB. Working memory was assessed by the Digit 
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Span (DS) and Letter-Number Sequencing (LNS) subtests of the Wechsler Adult Intelligence 
Scale (WAIS-III), which were converted to scaled scores (Wechsler, 1996).  With the 
exception of the TMTB and information processing tasks, higher scores are reflective of 
superior performance.  All tests have been found to be reliable and sensitive measures for 
assessing cognitive recovery in the TBI population, and are predictive of functional outcome 
following TBI (Henry & Crawford, 2004; Karr, Areshenkoff, & Garcia-Barrera, 2013; Lezak, 
Howieson, & Loring, 2004; Malojcic, Mubrin, Coric, Susnic, & Spilich, 2008).   
 
Statistical analysis 
All analysis was conducted using SPSS version 21.  Tests of normality and skewness 
indicated that scores on the TMTB deviated from normal, however as logarithmic and square 
root transformations did not significantly alter results the untransformed data was analysed.   
Chi-Square and t-tests were used to compare APOE ɛ4, ɛ3, and ɛ2 groups on demographic 
and injury factors. Hierarchical multiple regressions were used to compare the performance of 
APOE ɛ4 carriers to APOE ɛ3 homozygotes for each of the five tasks.  In the first step, the 
variables of injury severity, age, and estimated FSIQ were included, as these are consistently 
found to influence cognitive recovery following TBI (Ponsford, 2013).  While we report both 
Glasgow Coma Scale Score (GCS) and PTA, only PTA was used in the multiple regressions 
to avoid multicollinearity.  PTA was chosen as the predictor as it has been shown to be a more 
accurate predictor of initial pathology (Schonberger, Ponsford, Reutens, Beare, & O'Sullivan, 
2009) and functional outcome (Perrin et al., 2015) than GCS.  Injury severity was estimated 
by PTA and was categorised as mild (<24 hours), moderate (< 1 week) or severe (>1 week), 
and dummy coded as <1 day versus <1 week, and <1 day versus > 1 week, as has been 
previously recommended (Lezak et al., 2004), and all levels of injury severity were included 
in the regression analysis.    For the second step, APOE genotype (APOE ɛ4 carriers versus 
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APOE ɛ3 homozygotes) was added. 
APOE ɛ2 carriers were not included in the multiple regressions due to the small 
number of participants (n = 13); instead ANOVA was considered to be a more robust 
approach to assess the effect of APOE ɛ2 as compared to APOE ɛ4 and ɛ3 (Howell, 2010), 
with age, PTA and estimated FSIQ included as covariates when there were significant 
correlations between these factors and a given task.  Similarly, given the modest number of 
moderate to severe TBI participants (APOE ɛ4 = 11, APOE ɛ3 = 31, APOE ɛ2 = 2), 
ANCOVAs were conducted to test the additional hypotheses relating to injury severity.  With 
only 2 APOE ɛ2 participants in the moderate-severe TBI category the APOE ɛ2 participants 
could not be analysed. The resultant analysis of moderate-severe TBI included only APOE ɛ4 
and APOE ɛ3 homozygotes. 
 
 
Results 
The demographic data for the final sample is provided in Table 12.  As demonstrated, 
there were no significant differences between any groups for age, sex, estimated FSIQ, injury 
severity (PTA or GCS) or injury mechanism.  However, while the ANOVA for time between 
injury and assessment was not significant, Games-Howell post-hoc analysis revealed that the 
APOE ɛ2 carriers were assessed significantly closer to time of injury than either the APOE ɛ4 
group (p = .014) or APOE ɛ3 group (p = .002).   
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Table 12  
 
Demographic and injury related variables by APOE status 
 
APOE ɛ4  
(n = 37) 
APOE ɛ3  
(n = 92) 
APOE ɛ2 
(n = 13) 
F-test/χ2 p value 
Age (years) 
     Mean (SD) 
 
40.62 (17.47) 
 
39.89 (16.89) 
 
41.37 (17.69) 
 
F(139) = .057 
 
.945 
Sex 
     Males 
     Females 
 
19 (51%) 
18 (49%) 
 
49 (53%) 
43 (47%) 
 
9 (69%) 
4 (31%) 
 
 
χ2 (2) = 1.337 
 
 
.513 
Estimated FSIQ 
     Mean (SD) 
 
103.81 (9.84) 
 
102.47 (10.12) 
 
105.88 (7.23) 
 
F (136) = .802 
 
.451 
Time between injury and assessment 
     Mean (SD) 
     Median (Range) 
 
14.84 (13.60) 
11.00 (2-73) 
 
14.14 (13.75) 
11.00 (1-81) 
 
7.31 (4.52) 
7.00 (1-17) 
 
 
F(139) = 1.720 
 
 
.183 
Post Traumatic Amnesia (PTA)  
Frequency (%age) 
     Mild (< 24 hours) 
     Moderate (< 1 week) 
     Severe (> 1 week) 
 
 
26 (70.27%) 
7 (18.92%) 
4 (10.81%) 
 
 
59 (64.13%) 
19 (20.65%) 
14 (15.22%) 
 
 
11 (84.62%) 
2 (15.38%) 
0 (0.0%) 
 
 
 
 
χ2 (4) = 3.154  
 
 
 
 
.532 
Glasgow Coma Scale Score (GCS) 
Frequency (%age) 
     Mild (13-15) 
     Moderate (9-12) 
     Severe (3-8) 
     Not Recorded 
 
 
34 (83.3%) 
1 (4.8%) 
1 (7.1%) 
1 (4.8%) 
 
 
82 (86.8%) 
3 (2.8%) 
4 (5.7%) 
3 (4.7%) 
 
 
12 (92.3%) 
0 (0.0%) 
0 (0.0%) 
1 (7.7%) 
 
 
 
 
 
χ2 (6) = 1.899 
 
 
 
 
 
.929 
Injury Mechanism (%age) 
     Motor vehicle accident 
     Fall 
     Assault 
     Sports 
     Other 
 
16 (43.2%) 
14 (37.9%) 
5 (13.5%) 
1 (2.7%) 
1 (2.7%) 
 
37 (40.2%) 
29 (31.5%) 
12 (13.1%) 
12 (13.1%) 
2 (2.1%) 
 
7 (53.8%) 
1 (7.7%) 
3 (23.1%) 
1 (7.7%) 
1 (7.7%) 
 
 
 
 
 
χ2 (8) = 8.347 
 
 
 
 
 
.401 
117 
 
 
 
Hierarchical multiple regression analysis 
Descriptive data (stratified by injury severity) for APOE ɛ4 and APOE ɛ3 groups is provided 
in Table 14 in the supplementary section of this chapter.  Hierarchical multiple regressions 
were conducted for each task, comparing APOE ɛ4 carriers to the APOE ɛ3 homozygotes. 
For the first step, the predictor variables of PTA, age and estimated FSIQ were included.  
Genotype (APOE ɛ4 vs APOE ɛ3) was added in the second step.  The results for the multiple 
regressions are shown in Table 13.  As can be seen, the first model was predictive of outcome 
for IP speed, F(4,108)= 5.984, p=.001 (18.1% of variance); TMTB F(4,106)= 7.116, p = .001 
(21.2% of variance); COWAT F(4,118)= 6.164, p=.001 (17.3% of variance); DS, 
F(4,118)=9.473, p=.001 (24.3% of variance); and LNS, F(4,113)=6.563, p=.001 (18.9% of 
the variance).  As can also be seen in Table 13, the addition of APOE genotype in the second 
step did not significantly improve any of the models, with an additional contribution of less 
than 1% for each task. 
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Table 13  
 
Hierarchical multiple regression data for IP speed, COWAT, TMTB, DS and LNS (APOE ɛ4 carriers vs APOE ɛ3 homozygotes) 
 
 Unstandardized 
coefficient 
Standardised 
coefficient  
   
Task Variable B SE β p value R2 ΔR2 
IP Speed 
    Step 1 
 
Age   
Estimated FSIQ 
PTA (<1 day vs < 1 week) 
PTA (<1 day vs > 1 week) 
 
 
-.355 
.467 
-10.171 
-13.885 
 
.115 
.195 
4.712 
5.805 
 
-.291 
.228 
-.198 
-.215 
 
 
.002 
.018 
.033 
.018 
 
.181 
 
.181* 
    Step 2 Genotype 6.212 4.093 .132 .132 .199 .017 
COWAT 
     Step 1 
 
Age   
Estimated FSIQ 
PTA (<1 day vs < 1 week) 
PTA (<1 day vs > 1 week) 
 
 
.270 
.563 
-10.719 
-19.663 
 
.149 
.257 
6.051 
7.255 
 
.164 
.201 
-.153 
-.234 
 
.072 
.030 
.079 
.008 
 
.173 
 
.173* 
     Step 2 Genotype -6.375 5.207 -.102 .223 .183 .010 
TMTB 
     Step 1 
 
Age   
Estimated FSIQ 
PTA (<1 day vs < 1 week) 
PTA (<1 day vs > 1 week) 
 
 
1.023 
-.623 
2.203 
15.066 
 
.201 
.335 
8.054 
10.293 
 
.478 
-.176 
.024 
.129 
 
.001 
.066 
.785 
.146 
 
.212 
 
.212* 
     Step2 Genotype -.563 6.734 -.007 .933 .212 .001 
 
Continued overleaf… 
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 Unstandardized 
coefficient 
Standardised 
coefficient  
   
Task Variable B SE β p value R2 ΔR2 
DS 
     Step1 
 
Age   
Estimated FSIQ 
PTA (<1 day vs < 1 week) 
PTA (<1 day vs > 1 week) 
 
 
-.005 
.119 
-.618 
-.704 
 
.013 
.022 
.525 
.612 
 
-.034 
.470 
-.097 
-.095 
 
.696 
.001 
.241 
.253 
 
.243 
 
.243* 
     Step2 Genotype .517 .455 .091 .258 .251 .008 
LNS 
     Step 1 
 
Age   
Estimated FSIQ 
PTA (<1 day vs < 1 week) 
PTA (<1 day vs > 1 week) 
 
 
-.010 
.098 
-.315 
-1.757 
 
.014 
.025 
.610 
.678 
 
-.061 
.368 
-.045 
-.225 
 
 
.508 
.001 
.607 
.011 
 
.189 
 
.189* 
     Step 2 Genotype .481 .502 .081 .340 .195 .007 
* p <.05 
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Ancillary analyses for moderate to severe TBI participants and for APOE ɛ2 
carriers.  
In order to explore whether APOE ɛ4 is increasingly detrimental to cognitive 
performance as TBI severity increases, ANCOVAs (with age, PTA and estimated FSIQ 
included as covariates when significant correlations were present) were conducted comparing 
the performance of APOE ɛ4 and APOE ɛ3 participants who were classified as sustaining a 
moderate to severe TBI. These revealed no significant differences between the performance 
of APOE ɛ4 carriers and APOE ɛ3 carriers on any tasks.  ANCOVAs were also conducted on 
all participants, including APOE ɛ2 carriers, to explore whether APOE ɛ2 carriers displayed 
superior performance to the other two groups.  This analysis also failed to find any significant 
differences between APOE ɛ2, ɛ3, and ɛ4 carriers on any tasks.  The descriptive statistics, F-
values and associated effects sizes for these analyses are provided in Table 14 and 15 which 
are in the supplementary section following this chapter’s discussion section. 
 
 
Discussion 
The hypothesis that possession of the APOE ɛ4 allele would be predictive of reduced 
executive function, working memory, or processing speed during the early recovery phase 
following TBI was not supported.  Adding APOE genotype to a multiple regression model 
did not improve the predictive ability of the model for any of the neuropsychological tasks 
after variance explained by age, estimated premorbid IQ, and severity of injury had been 
accounted for.  Although some previous studies have found evidence of an APOE ɛ4 
associated cognitive decline during the early recovery period following TBI (Anderson et al., 
2009; Crawford et al., 2002; Noe et al., 2010), the current finding aligns with previous 
research in which no significant effect of APOE ɛ4 on cognitive outcome was found during 
short term recovery (Liberman et al., 2002; Müller et al., 2009; Ponsford et al., 2007; Shadli 
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et al., 2011), suggesting that possession of the APOE ɛ4 allele does not lead to greater 
cognitive impairment following TBI. 
Additional analysis of participants with moderate to severe TBI reveal no detrimental 
effect on cognitive performance for APOE ɛ4 carriers as compared to APOE ɛ3 
homozygotes.  While this contradicts the recent review by Lawrence and colleagues (2015), 
who observed that poorer outcomes for APOE ɛ4 carriers were more frequently reported in 
studies in which severe TBI was investigated, it must be stressed that our analysis was highly 
exploratory due to the small sample, and as such requires cautious interpretation.  We also 
found that APOE ɛ2 carriers did not outperform the other two groups for any of the tasks, 
suggesting that APOE ɛ2 may not exert a protective influence following TBI. To our 
knowledge, this is the first report on the effect of APOE ɛ2 on cognitive function during the 
early recovery period following TBI.  While our findings may indicate that the inclusion of 
APOE ɛ2 into APOE ɛ4 non-carrier groups has not accentuated the differences between 
APOE ɛ4 carriers in previous reports, the tentative nature of our findings must be 
emphasised.   Given the evidence that APOE ɛ2 plays both a dominant and protective role in 
neurological integrity and cognitive function in non-TBI populations (Suri et al., 2013), 
future investigation with larger samples is needed to explore the role of the APOE ɛ2 allele in 
cognitive function following TBI.   
At the time of submission, this study has the advantage of containing the largest 
sample of APOE ɛ4 carriers of any study in which neuropsychological tasks have been used 
during the early recovery period.  However, there are some limitations to the current study.  
Most of our participants had sustained mild injuries (PTA < 24 hrs for 67.60% of the total 
sample), and although we explored the effect of injury severity, the small sample size for that 
analysis limits the robustness of the results.  We also note that had we used GCS as our 
measure of injury severity, 90% of participants would have been classified as sustaining a 
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mild TBI.  This highlights the discrepancy that can occur in estimating injury severity, 
depending on the measure used, as has been observed by others researchers (Sherer, 
Struchen, Yablon, Wang, & Nick, 2008).  We chose to use PTA as the primary measure of 
severity as GCS can be confounded by a number of factors (Zuercher, Ummenhofer, 
Baltussen, & Walder, 2009), and PTA has been reported to be more closely associated with 
measures of pathology and other functional outcomes following TBI than GCS (Perrin et al., 
2015).  Nonetheless, GCS remains a popular measure of severity, and we acknowledge that 
this reduces the ability to compare our study and previous literature using GCS.  
Additionally, while participants were assessed as soon as possible following injury, it is also 
possible that those with mild TBI had recovered prior to assessment.  However, time between 
injury and assessment was associated with severity of injury, insofar as assessments were not 
undertaken until PTA was resolved, and thus most mild TBI sufferers were seen relatively 
soon after injury. 
Animal and cellular studies also indicate that both levels of sex hormones and age 
influence apoE expression and the neurological response to apoE (Horsburgh, Macrae, & 
Carswell, 2002; Mannix et al., 2011; Struble, Nathan, Cady, Cheng, & McAsey, 2007).  Sex 
and age frequencies were equivalent between our APOE groups, therefore it is unlikely that 
there were any systematic between group effects, but we did not investigate whether there 
was any sex or age related differences within the APOE ɛ4 carrier group.  Furthermore, our 
sample was predominantly comprised of young and middle aged adults (approximately 70% 
being <50 years of age), and it has been well established that older age is related with poorer 
outcomes following TBI (Ponsford, 2013).  APOE ɛ4 is also associated with age-related 
neurological disorders such as Alzheimer’s disease (Mahley & Huang, 2006), in which 
cognitive impairment is a defining feature.  Thus, it is possible that when elderly APOE ɛ4 
carriers sustain a TBI, the effects of TBI and APOE ɛ4 may work synergistically to result in 
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poorer cognitive outcomes, or that when a TBI is sustained by APOE ɛ4 carriers prior to late-
adulthood, this augments disease-related pathology later in life, which would be unlikely to 
be detected in our sample. 
   There is also tentative evidence that APOE may be expressed via an antagonistic 
pleiotropic mechanism, whereby the APOE ɛ4 allele confers a protective effect before and 
during the reproductive life phase, but exerts a detrimental effect in the post-reproductive 
phase (Han & Bondi, 2008; Jochemsen, Muller, van der Graaf, & Geerlings, 2012; Rusted et 
al., 2013).  If this mechanism is demonstrated for APOE, it is possible that only APOE ɛ4 
carriers who sustain a TBI in later life will demonstrate poorer outcomes.  Such a mechanism 
would align with evidence from Han and colleagues (2007), who found in a young adult 
cohort that APOE ɛ4 carriers performed better than non-carriers on a broad range of 
neuropsychological tasks following TBI.  It is also noteworthy that Ponsford and colleagues 
(2011) observed that female APOE ɛ4 carriers over the age of 55 had poorer long term 
functional outcomes than age-equivalent APOE ɛ4 males, and non APOE ɛ4 females, 
suggesting a possible interaction between age, sex and APOE.  Others have not found such an 
effect, with Friedman et al. (1999) reporting no age-related differences in general cognitive 
function for APOE ɛ4 carriers, and a study Rapoport and coworkers (2008) revealing no 
differences between older (> 50 years) TBI sufferers on tasks of learning, memory, or 
executive function, based on APOE ɛ4 status.  Furthermore, Teasdale, Murray and Nicoll 
(2005) reported that APOE ɛ4 was more detrimental in terms of general functional outcome 
for young APOE ɛ4 carriers following TBI than for older APOE ɛ4 carriers. These 
contradictory findings suggest that further investigation is warranted to clarify whether age 
moderates the relationship between APOE and outcome following TBI.   
It is also possible that the effect of APOE ɛ4 is domain specific, and that our tasks did 
not capture some functional differences.  Specifically, both Crawford et al. (2002) and 
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Anderson et al. (2009) reported that verbal learning and memory functions were impaired 
during initial recovery in their cohorts, whereas performance on measures of executive 
function, psychomotor speed and visuo-spatial ability remained similar for both APOE ɛ4 
carriers and non-carriers.  Although DS has been argued to measure elements of short term 
verbal memory (Lezak et al., 2004), we did not employ any verbal learning tasks, as our 
study was part of a larger pre-existing longitudinal study which did not include these 
measures. Further investigations using measures of verbal learning and memory in APOE ɛ4, 
ε3 and ɛ2 carriers may therefore prove enlightening.   
Although this result bolsters the evidence that there is no effect of APOE ɛ4 on post-
TBI cognitive function, further research exploring later cognitive recovery, and more 
nuanced explorations of the APOE gene are warranted.  For example, some studies have 
found APOE ɛ4 to be deleterious to cognitive recovery during the 6-12 month recovery 
period (Ariza et al., 2006; Friedman et al., 1999; Müller et al., 2009).  This may suggest that 
any detrimental effect of APOE ɛ4 is initially masked by other acute neurobiological 
responses to injury, but may be revealed in later recovery.  It is also becoming increasingly 
evident that genetic expression is frequently impacted by biological and environmental 
factors, and there have been calls to consider such interactions when investigating the effect 
of APOE in the TBI population (Weaver et al., 2014).   
In conclusion, we did not find any evidence that APOE ɛ4 is associated with impaired 
in cognitive function during the acute recovery period following TBI, or that any detrimental 
effect of APOE ɛ4 is pronounced following more severe TBI.  However, exploration of later 
time-points, using a broader range of neuropsychological tasks, and investigation of the 
possible moderating effect of sex and/or age on APOE ɛ4, may clarify the role of the APOE 
gene in post-TBI cognitive outcomes.  We also did not find that APOE ɛ2 was associated 
with any significant differences in function, but given the tentative nature of these findings, 
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future research into the effect of APOE genotype would nonetheless benefit by employing a 
more considered approach to APOE ɛ2, with APOE ɛ2 carriers being either excluded, or 
treated as a separate group, when investigating the impact of APOE in cognitive function 
after TBI, and in other clinical and non-clinical populations.  
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Supplementary Material 
 
Table 14  
Descriptive data and ANCOVAs for performance by moderate to severe TBI (APOE ɛ4 and 
APOE ɛ3 only) 
 
Task APOE ɛ4 APOE ɛ3 ANOVA 
 n Mean (SD) n Mean  (SD) F p ƞp2 
IP Speeda 11 60.91  
(12.99) 
28 56.18  
(16.61) 
.512 .479 .014 
COWAT 11 28.82  
(15.28) 
30 24.67  
(9.86) 
.919 .344 .024 
TMTBa 10 105.00  
(31.17) 
26 97.77  
(44.55) 
.169 .683 .005 
DS (scale) 11 8.36  
(2.34) 
31 8.87  
(2.25) 
.677 .416 .017 
LNS (scale) 10 7.90  
(2.47) 
27 9.07  
(2.28) 
2.008 .166 .057 
a A lower score on these tasks is indicative of better performance. 
 
 
Table 15  
Descriptive data and ANCOVAs for performance on all tasks, grouped by APOE genotype 
 
Task APOE ɛ4 APOE ɛ3 APOE ɛ2 ANOVA 
 n Mean (SD) n Mean  (SD) n Mean (SD) F p ƞp2 
IP Speeda 32 63.31 
(19.47) 
83 68.52 
(22.20) 
13 66.92 
(12.73) 
 
1.531 
 
.220 
 
.025 
COWAT 36 34.17 
(13.72) 
90 31.22 
(11.54) 
13 37.46  
(8.86) 
 
.648 
 
.525 
 
.010 
TMTBa 36 90.06 
(32.31) 
78 91.76 
(41.07) 
11 79.36 
(325.80) 
 
.873 
 
.420 
 
.014 
DS  
(scale) 
35 9.20  
(2.29) 
91 9.37  
(2.76) 
13 10.00  
(2.61) 
 
.661 
 
.518 
 
.010 
LNS  
(scale) 
34 9.38  
(2.67) 
87 9.57  
(2.75) 
13 10.00  
(2.48) 
 
.415 
 
.661 
 
.007 
a A lower score on these tasks is indicative of better performance. 
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Chapter 6: Does Apolipoprotein ɛ4 Interact with Age or Sex in Post-Traumatic Brain 
Injury Cognitive Function? 
 
 
 
 
 
 
 
 
This chapter submitted for publication (under review) as: 
Padgett, C. R., Summers, M. J., Honan, C. A.,  McCormack, G. H.,  Vickers, J. C., & 
Skilbeck, C. E. (under review).  Does Apolipoprotein ɛ4 interact with age or sex in 
cognitive function after traumatic brain injury? Brain [BRAIN-2016-00203]. 
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Abstract 
 
Possession of the APOE ɛ4 allele has been suggested to lead to poorer cognitive 
function following traumatic brain injury relative to other allelic versions of the APOE gene, 
however, findings to date have proven equivocal.  For conditions other than traumatic brain 
injury, there is some evidence that the effect of APOE ɛ4 is influenced by age and/or sex, 
which may account for the mixed results in traumatic brain injury literature, but these 
relationships are yet to be systematically explored in the context of post-injury cognition.  
The aim of this study was to investigate the impact of APOE ɛ4 on cognitive function 
following traumatic brain injury, and to explore the influence of age and sex on the impact of 
APOE ɛ4 versus the most common APOE allele; ɛ3.  Participants diagnosed with traumatic 
brain injury were genotyped to determine APOE status (APOE ɛ4 n = 30, APOE ɛ3 n = 77, 
APOE ɛ2 n = 12)  and were assessed using a battery of cognitive tasks measuring executive 
function, working memory, and processing speed at 3, 6 and 12 months post-injury.  APOE 
ɛ2 carriers were excluded due to small sample and the possibility that APOE ɛ2 is both 
protective and dominant over APOE ɛ4 and ɛ3, and the cognitive function of APOE ɛ4 and 
APOE ɛ3 carriers was compared using a mixed model approach.  It was revealed that APOE 
ɛ4 carriers performed worse than the APOE ɛ3 group on only two of seven tasks (Trail 
Making Task B at 6 months, and the Controlled Oral Word Association Task), and therefore 
possession of APOE ɛ4 did not appear to systematically impair cognitive function.  To 
explore the relationship between APOE ɛ4 and age, participants were categorised as young 
(18-50 years) or older (51-70 years) adults, and the interaction between APOE ɛ4 and sex 
was also investigated.  There was no evidence of interactions between age and APOE ɛ4, or 
sex and APOE ɛ4.  Our findings indicate that the APOE gene is unlikely to significantly 
impact on cognitive function following traumatic brain injury, and that neither age nor sex 
interact with APOE ɛ4 in this population.  While the injury and demographic characteristics 
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of our sample were reflective of the broader traumatic brain injury population, further 
examination of these relationships in moderate to severe samples may be warranted.    
 
Keywords: traumatic brain injury, Apolipoprotein E, executive function, memory, gene-
environment interaction. 
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Introduction 
 
One of the most common and enduring outcomes following traumatic brain injury 
(TBI) is impaired cognition (Draper & Ponsford, 2008), and there has been increased interest 
in exploring the utility of a number of biomarkers in predicting cognitive outcome.  One such 
marker is the APOE gene.  The APOE gene synthesises apolipoprotein e (apoE) which is 
believed to be an essential factor in recovery following TBI due to its roles in lipid transport, 
recycling, and clearance (Mahley & Rall, 2000).  The APOE gene has three alleles; APOE ɛ2, 
APOE ɛ3 and APOE ɛ4, with estimated population frequencies of 11%, 72%, and 17% 
respectively (Zannis, Just, & Breslow, 1981).  To date, research has focussed on the 
hypothesis that the APOE ɛ4 allele may be deleterious, as it has been reported to synthesise 
an isoform of apoE that is less stable than the apoE ɛ2 or apoE ɛ3 isoforms, has been found to 
increase risk of developing Alzheimer’s disease (Corder et al., 1993; Kim, Basak, & 
Holtzman, 2009), and may be associated with poorer outcomes in other neuropathological 
events (Maxwell et al., 2011; Verghese, Castellano, & Holtzman, 2011).  Possession of 
APOE ɛ4 has also been demonstrated to be associated with both earlier accumulation and 
increased levels of amyloid pathology, even in the absence of disease processes (Jansen et al., 
2015), with animal studies indicating that the increased amyloid burden is associated with 
poorer cognitive function (Yin et al., 2014). Given the evidence that APOE ɛ4 may reduce 
neurological integrity, it has been proposed that TBI sufferers who possess the APOE ɛ4 
allele may experience greater cognitive impairment or delayed recovery following injury.   
Although animal studies consistently demonstrate that APOE ɛ4 leads to poorer 
neurological integrity and cognitive function post injury (Horsburgh, McCarron, White, & 
Nicoll, 2000; Sabo et al., 2000; White, Nicoll, Roses, & Horsburgh, 2001), the evidence is 
less clear in human TBI research. A number of researchers have reported that APOE ɛ4 
carriers experience greater cognitive impairment (Anderson et al., 2009; Ariza et al., 2006; 
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Crawford et al., 2002; Friedman et al., 1999; Noe, Ferri, Colomer, Moliner, & Chirivella, 
2010; Sundstrom et al., 2004), and reduced recovery trajectories (Müller et al., 2009) than 
non-carriers during the first 12 months of recovery, with Eramudugolla et al. (2014) reporting 
that APOE ɛ4 is also associated with poorer long-term cognitive outcomes. Conversely, 
others have found no differences in cognitive function either in the first 12 months following 
injury (Chamelian, Reis, & Feinstein, 2004; Hodgkinson, Gillett, & Simpson, 2009; 
Liberman, Stewart, Wesnes, & Troncoso, 2002; Ponsford, Rudzki, Bailey, & Ng, 2007; 
Pruthi et al., 2010; Shadli, Pieter, Yaacob, & Rashid, 2011), or in long-term recovery 
(Ashman et al., 2008; Isoniemi, Tenovuo, Portin, Himanen, & Kairisto, 2006; Rapoport et al., 
2008; Teasdale, Jorgensen, Ripa, Nielsen, & Christensen, 2000).  Indeed, there are some 
reports that APOE ɛ4 may be associated with reduced cognitive impairment after TBI (Han et 
al., 2007).   Thus, the findings to date are mixed, and consequently the establishment of the 
nature of the relationship between APOE ɛ4 and post-TBI cognition has proven difficult. 
It has been argued that interactions between biological and environmental factors 
need more consideration when investigating genetic effects in relation to psychological 
function, and specifically in TBI populations (Dick et al., 2015; Weaver et al., 2014).   A 
failure to explore such interactions may explain the equivocal findings in prior research 
relating to the impact of APOE ε4 in post-TBI cognition. Notably, there is emerging evidence 
that age and/or sex might influence the expression of APOE ɛ4, both in terms of cognitive 
function and risk for developing neurological disorders (Beydoun et al., 2012; Farrer et al., 
1997; Ghebremedhin et al., 2001; Jochemsen, Muller, van der Graaf, & Geerlings, 2012). 
Despite this, there has been minimal exploration of these factors in relation to cognitive 
function following TBI.   
There is some evidence from non-TBI literature that there is an interaction between 
APOE status and age.  For example, the reported relationship between APOE ɛ4 and 
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Alzheimer’s disease (which typically commences in late adulthood) has led some authors to 
propose that APOE operates via an antagonistic pleiotropic mechanism, whereby APOE ɛ4 
confers some benefits before and during the reproductive life phase, but becomes deleterious 
during the post-reproductive life phase (Carter & Nguyen, 2011; Han & Bondi, 2008; Leroi et 
al., 2005; Tuminello & Han, 2011).  In healthy human populations, some researchers have 
reported that young adult APOE ɛ4 carriers have superior cognitive function when compared 
to non-carriers (Alexander et al., 2007b; Marchant, King, Tabet, & Rusted, 2010; Mondadori 
et al., 2007; Puttonen, Elovainio, Kivimaki, Lehtimaki, & Keltikangas-Jarvinen, 2003; 
Rusted et al., 2013), and others have reported that APOE ɛ4 carriers have poorer cognitive 
function than non-ɛ4 carriers in late adulthood (Greenwood, Espeseth, Lin, Reinvang, & 
Parasuraman, 2014; Jochemsen et al., 2012; Shin et al., 2014), providing some support for an 
antagonistic pleiotropic mechanism.  However others have found no differences, either in 
young or old aged cohorts (Bunce, Anstey, Burns, Christensen, & Easteal, 2011; Deary et al., 
2003; Ihle, Bunce, & Kliegel, 2012; Jorm et al., 2007), thus this effect remains speculative. 
In the few studies which have considered the interaction between age and APOE 
status in the context of TBI, there is tentative support for an antagonistic pleiotropic effect.  
Animal models of TBI suggest that older APOE ɛ4 carriers may experience greater cognitive 
impairment following brain injury than younger APOE ɛ4 carriers, or young and old non-
carriers (Mannix et al., 2011), and in their investigation of cognitive performance following 
TBI in children aged 8-15 years, Moran and colleagues (2009) reported that APOE ɛ4 carriers 
performed better than non-APOE ɛ4 carriers on a visual motor integration task.  Han et al. 
(2007) also found that young adult (mean age 22 years old) APOE ɛ4 carriers performed 
significantly better than non-carriers on tasks of attention, executive function, and episodic 
memory, one month following mild to moderate TBI.   
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Conversly, Eramudugolla and colleagues (2014) reported that APOE ɛ4 carriers had 
poorer episodic memory in early adulthood, and poorer reaction time in middle-aged 
adulthood in TBI. In addition, they also found that if the brain injury was sustained during 
childhood, no genotypic differences in cognitive function were apparent by late adulthood.  
Also in contradiction to the antagonistic pleiotropic effect, Friedman et al. (1999) found that 
while APOE ɛ4 was predictive of a poorer cognitive performance 6-8 months following 
injury, an interaction between age and APOE status was not found.  Lastly, when comparing 
the cognitive function of APOE ɛ4 carriers and non-carriers aged 50 years and older, at 12 
and 24 months following mild to moderate TBI, Rapoport and co-workers (2008) also 
reported no significant differences.  In short, the role that age may play in the relationship 
between APOE e4 and cognitive function is not clear. 
It is also possible sex differences interact with APOE status.  Animal and in vitro 
studies have demonstrated that the expression of APOE is moderated by sex hormones 
(Koutseff, Mittelhaeuser, Essabri, Auwerx, & Meziane, 2014; Struble, Nathan, Cady, Cheng, 
& McAsey, 2007), and that the neuro-protective effects of apoE are enhanced by higher 
levels of oestrogen (Struble et al., 2007), with evidence that this relationship is less 
efficacious for the apoE ɛ4 isoform (Lambert, Coyle, & Lendon, 2004; Raber et al., 1998) 
and that androgens may be protective in the presence of APOE ɛ4 (Raber, Bongers, 
LeFevour, Buttini, & Mucke, 2002).  As a result, females may be more vulnerable to an 
APOE ɛ4 associated detrimental effect, and indeed studies in human populations indicate that 
female APOE ɛ4 carriers compared to males and non-carrying females may be at greater risk 
of cognitive impairment (Bartres-Faz et al., 2002; Beydoun et al., 2012; Mortensen & Hogh, 
2001), reduced hippocampal connectivity and volume (Fleisher et al., 2005; Heise et al., 
2014) and development of Alzheimer’s disease (Altmann, Tian, Henderson, Greicius, & Initi, 
2014; Farrer et al., 1997).  However, it must be noted that the aforementioned research was 
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undertaken in the context of risk of developing Alzheimer’s disease, and only recruited older 
participants.  In the only study we identified exploring this relationship in young adults, Yu, 
Lin, Chen, Hong, and Tsai (2000) found young APOE ɛ4 females had improved performance 
intelligence scores as compared to female non-carriers.  A limitation to the interpretability of 
this study is that males were not included, and although there were significant differences 
between groups, the mean scores for both fell within the normal intelligence range and would 
likely lack clinical relevance.  In summary, the moderating effect of sex on the relationship 
between cognitive function and APOE e4 is unknown. 
To date, there is no published literature examining the potential interaction between 
sex and APOE ɛ4 on cognitive function. However, Ponsford et al. (2011) reported that 
females APOE ɛ4 allele carriers over 55 years of age displayed poorer functional recovery at 
approximately 1 year post injury, as compared to their male counterparts. This result was 
interpreted by the authors as being related to post-menopausal declines in sex hormones.  In 
contrast, Ost et al. (2008) reported that male APOE ɛ4 carriers were more likely to have a 
worse outcome (death or severe disability) than female APOE ɛ4 carriers after severe TBI.  
However, given Alexander and colleagues (2007a) found no interaction between sex and 
APOE status in regards to general functional outcome, it remains possible that no such 
interaction exists. 
To summarise, there is tentative evidence that both age and sex may influence the 
expression of APOE ɛ4, with greater age, and being female, both likely to be associated with 
poorer outcomes in the presence of APOE ɛ4.  However, there has been limited exploration 
of the effect of age on APOE ɛ4, and no investigation of the effect of sex on the expression of 
APOE ɛ4, in relation to post-TBI cognitive function.  It has also been noted that although the 
APOE ɛ2 allele is relatively rare, there is evidence that it is dominant over ɛ3 and ɛ4 alleles, 
and may confer some protective effects (Corder et al., 1994; Suri, Heise, Trachtenberg, & 
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Mackay, 2013). As a result, it is possible that inclusion of APOE ɛ2 carriers into APOE ɛ4 
carrier and non-carrier groups may obscure any impact of APOE ɛ4. Although more recent 
studies have treated APOE ɛ2 carriers separately (Eramudugolla et al, 2014), this has not 
routinely occurred, and potentially may also contribute to the mixed findings to date.   
The primary aim of the current study was to examine the potential effect of APOE ɛ4 
on the cognitive function of adults with TBI, by longitudinally following recovery at 3, 6 and 
12 months following TBI. Here it was specifically hypothesised that carriers of APOE ɛ4 
would have poorer cognitive function than non-carriers.  A secondary aim was to examine the 
relationship between age and sex and APOE status on cognitive recovery from TBI.  In line 
with an antagonistic pleiotropic explanation, it was hypothesised that young adult APOE ɛ4 
carriers (ages 18-50 years) would retain better cognitive function and display faster recovery, 
than non-carriers of the same age, whereas older (51-70 years) APOEɛ4 carriers were 
predicted to experience poorer cognitive function post injury than non-carriers of the same 
age.  In relation to the effect of sex, it was hypothesised that female APOE ɛ4 carriers would 
perform worse than non-carriers and male APOE ɛ4 carriers.  Therefore, the aim of this study 
is to explore the interactions between age and APOE ε4, and sex and APOE ε4, in the context 
of post-TBI cognitive recovery, without potentially confounding effect of including the 
APOE ɛ2 carriers. 
 
Method 
 
Participants 
 
The current study was conducted within an existing longitudinal population study of 
TBI, the Tasmanian Neurotrauma Register (TNTR), located at the Royal Hobart Hospital in 
Tasmania, Australia (Australia operates under a no-fault compensation system).  Patients 
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with a diagnosis of TBI, who attended the Royal Hobart Hospital between the years 2003 and 
2007 were invited to participate in the TNTR study, and those recruited underwent 
neuropsychological assessment at time injury, or as soon as possible following remission of 
post traumatic amnesia (PTA), with follow up assessments at 3, 6 and 12 months following 
TBI, and then annually up to 5 years post injury.  Participants were recruited into the current 
study during routine follow-up within the larger TNTR study.  Institutional ethics approval 
was obtained for all aspects of this study. 
All participants met the following inclusion criteria: They were aged between 18 and 
70 years of age, had experienced more than 5 minutes of PTA as estimated by Westmead 
Scale score (Shores, Marosszeky, Sandanam, & Batchelor, 1986) or by the Galveston 
Orientation and Amnesia Test (Levin, Odonnell, & Grossman, 1979), and they had no 
premorbid history of neurological or neurodegenerative disorders, TBI, medicated 
psychological disorders, or evidence of a developmental delay (full scale IQ (FSIQ) < 70), as 
estimated by the National Adult Reading Test (NART).   
A total of 173 participants agreed to provide DNA samples, however three were 
unable to be genotyped, resulting in n = 170.  Genotype frequencies were determined to be in 
Hardy-Weinberg equilibrium (χ2 (5) = 6.050, p = .30).  Of these participants, 119 had 
neuropsychological data available for the time-points of interest.   Given the potentially 
confounding effect of including APOE ɛ2 carriers in APOE ɛ4 we intended to examine the 
influence of the APOE ɛ2 allele. However, due to insufficient APOE ɛ2 sample size (n = 12), 
ɛ2 carriers were excluded from this study, with the remaining 107 participants comprising 
two groups: APOE ɛ4 carrier group (ɛ4/ɛ4 and ɛ4/ɛ3) and an APOE ɛ3 homozygote group 
(ε3/ε3).  The demographic and injury related data for the APOE ɛ4 and APOE ɛ3 groups is 
provided in Table 16.  As can be seen, there were no significant differences between the 
groups for age, sex, premorbid IQ, severity of injury, or injury mechanism. 
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Table 16  
Demographic and injury related variables for APOE ɛ4 carriers (ɛ4/ɛ4 and ɛ4/ɛ3) and APOE 
ɛ3 (ɛ3/ɛ3) groups 
 APOE ε4  
(n = 30) 
APOE ε3  
(n = 77) 
t-test/χ2 p value 
Age (years) 
     Mean (SD) 
 
40.59 (16.65) 
 
40.19 (16.15) 
 
.115 
 
.909 
Sex 
     Males 
     Females 
 
17 (56.67%) 
13 (43.33%) 
 
41 (53.25%) 
36 (46.75%) 
 
.102 
 
 
.750 
 
Estimated FSIQ 
     Mean (SD) 
 
103.71 (9.18) 
 
103.50 (9.94) 
 
.101 
 
.920 
Post Traumatic Amnesia (PTA)  
Frequency (%age) 
     Mild (< 24 hours) 
     Moderate (< 1 week) 
     Severe (> 1 week) 
 
 
22 (73.33%) 
5 (16.67%) 
3 (10.00%) 
 
 
54 (70.13%) 
14 (18.18%) 
9 (11.69%) 
 
 
.114 
 
 
 
 
.945 
 
 
Glasgow Coma Scale Score (GCS) 
Frequency (%age) 
     Mild (13-15) 
     Moderate (9-12) 
     Severe (3-8) 
     Not Recorded 
 
 
27 (90.01%) 
1 (3.33%) 
1 (3.33%) 
1 (3.33%) 
 
 
72 (93.51%) 
0 (0.00%) 
2 (2.60%) 
3 (3.89%) 
 
 
2.630 
 
 
 
 
.269 
 
 
Injury Mechanism 
Frequency (%age) 
     Motor vehicle accident 
     Fall 
     Assault 
     Sports 
     Other 
 
 
14 (46.67%) 
10 (33.33%) 
4 (13.33%) 
2 (6.67%) 
0 (0.00%) 
 
 
35 (45.45%) 
21 (27.27%) 
9 (11.69%) 
9 (11.69%) 
3 (3.90%) 
 
 
2.027 
 
 
 
 
 
 
.731 
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Neuropsychological measures 
 
A battery of seven neurospychological measures was employed: Executive function 
was assessed by the Trail Making Task form B (TMTB), a measure of cognitive flexibility 
(Kortte, Horner, & Windham, 2002), and the Controlled Oral Word Association Task 
(COWAT), a measure of verbal fluency (Lezak, Howieson, & Loring, 2004).  Working 
memory was assessed by the digit span forwards and backwards (DS and DSB), digit span 
forwards-backwards ratio score (DS-FB), and letter-number sequencing (LNS) subtests of the 
Wechsler Adult Intelligence Scale IV, and information processing speed was assessed by the 
information processing (IP Speed) subtest of the Adult Memory and Information Processing 
Battery, adjusted to control for motor-speed (Coughlan & Hollows, 1985).  All tasks have 
been found to be sensitive to cognitive impairment following mild through to severe TBI 
(Dikmen, Machamer, Winn, & Temkin, 1995; Kumar, Rao, Chandramouli, & Pillai, 2013; 
Millis et al., 2001; Ponsford et al., 2000).   
 
Procedure 
 
Participants willing to be included in the current study completed additional informed 
consent, and provided a buccal swab for DNA collection.  Genotyping for APOE was 
conducted by amplification refractory mutations system (ARMS) PCR, as described by 
Donohoe, Salomaki, Lehtimaki, Pulkki, and Kairisto (1999). For the current study, 
neuropsychological data obtained at 3, 6 and 12 month assessments was analysed.  
Neuropsychological assessors were blind to genotype, and DNA assessors were blind to all 
participant details.  
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Statistical analysis 
 
SPSS version 21 was used to conduct all analyses.  T-tests and chi-square analyses 
were used to screen for sex, age, premorbid IQ and severity of injury differences between 
APOE ɛ4 carriers and non-carriers.  A mixed model approach using full information 
maximum likelihood (FIML) was conducted to compare the performance of the APOE ɛ4 and 
APOE ɛ3 groups, and to explore the interactions between APOE group and age, and APOE 
group and sex, for each task at 3, 6 and 12 months post injury.  Using the mixed model FIML 
approach permits a more robust analysis and better accounts for missing data than the 
traditional general linear model approach (Enders, 2011).  An alpha level of p = .05 was used 
to determine significance, and effect size was calculated by estimating r values following the 
formula recommended by Field (2013) for mixed model results. 
To explore the relationship between age and APOE status, participants were 
categorised as either young to middle aged adults (18 to 50 years of age; APOE ε4 n = 23, 
APOE ε3 n = 51) or older adults (51 to 75 years of age; APOE ε4 n = 7, APOE ε3 n = 26).  
These age brackets were selected in an attempt to distinguish between participants who were 
within the reproductive or post-reproductive phase of life, as this is the mean age of 
menopause for females (Gold, 2011).  The interaction between gene (APOE ɛ4 and APOE 
ɛ3) and sex (male and female) was also explored (see Table 16 for group n).   While a higher 
order exploration of the interaction between sex, age and gene would have been valuable, we 
lacked sufficient sample size to do so.  
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Results 
 
Tests of normality and skewness indicated that only scores on the TMTB deviated 
from normal, however as logarithmic and square root transformations did not significantly 
alter results the untransformed data was analysed. Figures 12 and 13 show the marginal 
means and standard errors for the age x gene and sex x gene analyses respectively, and the 
means and standard deviations stratified by genotype are also available in the supplementary 
material (Tables 17-19 in the supplementary section following chapter discussion).   
 
Age and APOE status 
 
A significant main effect for APOE status (ɛ4 carriers vs ɛ3/ɛ3 genotype) on the 
TMTB [F(1, 105.017) = 5.94, p = .017, r = .23] was present, with pairwise comparisons 
revealing that APOE ɛ4 carriers performed worse than the APOE ɛ3/ɛ3 group at 6 months 
post injury (p = .012).  A significant interaction between APOE status and time was also 
revealed for performance on the COWAT [F(2, 185.67) = 3.94, p = .021, r = .14], however 
subsequent pairwise comparisons found no significant differences at any specific time point. 
For TMTB, there was a significant main effect for age [F(1, 105.02) = 31.86, p = 
.001, r = .48] with the younger age group outperforming the older age group over all time 
points (all p’s = .001), There was also a significant interaction between age and time for the 
DSFB [F(2, 198.74) = 3.61, p = .029, r = .14], with the younger age group outperforming the 
older age group at 12 months post injury (p = .018).  A main effect for age was also revealed 
on the LNS [F(1, 105.18) = 4.89, p = .029, r = .21] and for IP Speed there was a main effect 
for age [F (1, 106.71) = 7.70, p = .007, r = .26].  No effects were found for DSB.  There was 
no significant interaction between age and APOE status for any tasks, indicating that older 
APOE ɛ4 carriers did not experience worse cognitive outcomes than the APOE ɛ3/ɛ3 group 
following TBI. 
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Figure 12.  Marginal means and standard errors (SE) for age x APOE group at 3, 6 and 12 
months post TBI. 
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Sex and APOE status 
 
A significant main effect of time on both the COWAT [F(2, 186.98) = 10.00, p = .001, r = 
.23] and IP Speed [F(2, 178.54) = 5.62, p = .004, r = .17] was present, and there was an 
interaction between time and APOE status [F(2, 186.98) = 3.07, p = .048 r = .13] however no 
significant differences were found on subsequent pairwise comparisons. There was also a 
significant main effect for sex [F(1, 107.84) = 8.01, p = .006, r = .26] with females 
outperforming males at all time-points.  An interaction between sex and APOE status was 
also revealed [F(1, 107.84) = 6.02, p = .016, r = .23] with pairwise comparisons indicating a 
trend towards female APOE ɛ4 carriers outperforming female APOE ɛ3 homozygotes (p = 
.060).  For the DS, there was an interaction between sex and time [F(2, 194.93) = 3.32, p = 
.038, r = .13] with pairwise comparisons indicating that females outperformed males at 12 
months post injury (p = .033).  A similar interaction was found between sex and time for the 
LNS task [F(2, 192.64) = 6.66, p = .002, r = .18] again with females outperforming males at 
12 months (p = .046).  There was also a trend for females to outperform males at 6 months (p 
= .062) on this task.  No effects were found for TMTB, DSB, or DSFB.  Therefore, with the 
exception of performance on the COWAT, there was no evidence of an interaction between 
sex and APOE status. 
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Figure 13.  Marginal means and standard errors (SE) for sex x APOE group at 3, 6 and 12 
months post TBI. 
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Discussion 
 
This study sought to explore the direct effect of carriage of an APOE ɛ4 allele on 
cognitive function in TBI at 3, 6 and 12 months after injury, and to also determine whether 
age or sex interact with APOE ɛ4 in affecting post-TBI cognitive function.  While there were 
no significant differences between APOE ɛ4 and APOE ɛ3 groups on measures of 
information processing speed and working memory, APOE ɛ4 carriers had poorer 
performance on the TMTB, a measure of cognitive flexibility, at 6 months post-TBI, and 
there was evidence of reduced verbal fluency performance on the COWAT.  Given that both 
the TMTB and COWAT are considered to assess aspects of executive function, this finding 
may indicate that there is a domain specific effect of possessing APOE ɛ4, whereby executive 
function is negatively impacted following TBI.  Some authors have suggested that APOE ɛ4 
does have a domain specific effect in healthy populations (Rusted et al., 2013; Wisdom, 
Callahan, & Hawkins, 2011), but no other study of TBI has reported a specific impairment in 
executive function.  In fact, only one other study has reported executive function impairment, 
and this was in conjunction with impairment to other domains (Ariza et al., 2006). Thus, 
caution must be applied in interpreting the current findings given the limited supporting 
evidence for APOE ɛ4 being associated with a domain-specific effect on executive function. 
The second aim was to investigate whether APOE ɛ4 exerts its effects via an 
antagonistic pleiotropic mechanism, whereby possession of APOE ɛ4 confers an advantage in 
young APOE ɛ4 carriers but is deleterious in older age.  Counter to the expectations from an 
antagonistic pleiotropic viewpoint, and contrary to the findings of Han and colleagues (2007), 
we did not find that young adult APOE ɛ4 performed better than their non-carrier 
counterparts, nor did we find that older APOE ɛ4 carriers performed worse than older non-
carriers.  The contrast with Han et al. is particularly noteworthy given that their sample 
consisted predominantly of young adult mild to moderate TBI suffers, as did ours.  Our 
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findings also align with the studies by Friedman and colleagues (1999), who found no 
interaction between APOE status and age on post-TBI cognitive function, and Rapoport et al. 
(2008), who did find any differences in cognitive recovery in older (> 50 years) TBI 
participants based on APOE ε4 status.   
Interestingly, Evidence from the AD literature suggests that possession of APOE ɛ4 is 
associated with increased amyloid accumulation, particularly in late adulthood, and it has 
been suggested that this increased amyloid pathology is the cause of any APOE ɛ4 associated 
cognitive impairment (Harrington et al., 2013; Jack et al., 2015).  Furthermore, as mentioned 
in the introduction, there is evidence that amyloid deposition increases following TBI, and 
that this production is accelerated in the presence of APOE ɛ4, even when TBI is considered 
mild (Hartman et al., 2002; Yang et al., 2015). Should this be the case, it is likely that older 
TBI sufferers who possess the APOE ɛ4 allele would have a pre-existing higher amyloid 
burden, which could then be further exacerbated by the injury.  Therefore it is also possible 
that given the relatively young age of our TBI sample, there was not sufficient amyloid 
burden to lead to cognitive impairment, despite the presence of APOE ɛ4. However, the 
relationship between APOE, amyloid and cognitive function remains uncertain, and it has 
also been noted that APOE is likely to exert it’s effects via a number of neuropathological 
pathways (Corona & Landreth, 2015; Fitz et al., 2015; Wolf et al., 2013). 
There was also no support for our prediction that APOE ɛ4 females would have 
poorer performance than non-ɛ4 females or males; indeed, the only significant interaction 
between sex and APOE status indicated a trend towards superior performance of APOE ɛ4 
females (as compared to non ɛ4 females) on the COWAT.  While this is counter to previous 
research in which it was suggested that APOE ɛ4 females had poorer outcomes than female 
non-carriers, it must be noted that previous research explored cognitive function in relation to 
Alzheimer’s disease and as such recruited older aged participants (Bartres-Faz et al., 2002; 
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Beydoun et al., 2012; Mortensen & Hogh, 2001), and that in the only TBI study to note an 
interaction between APOE status and sex, it was reported that only female APOE ɛ4 carriers 
over the age of 55 years experienced poorer outcomes (Ponsford et al., 2011).  Thus, it may 
be that any negative impact of APOE ɛ4 is reduced in the presence of female sex hormones, 
but becomes apparent during the post-reproductive life phase when sex hormones are in 
decline.  However, while the interaction was significant, pairwise comparisons only indicated 
a trend toward APOE ɛ4 females having better performance than APOE ɛ3 females, and 
given that there were no significant interactions between sex and APOE status on any of the 
other tasks, this effect possibly spurious and must be interpreted with caution. 
In addition to being the first study to explore the interaction between sex and APOE 
status in relation to post-TBI cognition, a further advantage of this study is that it contains 
one of the largest APOE ɛ4 samples published to date using neuropsychological tasks to 
assess recovery in the first 12 months following TBI.  Nonetheless, it is likely that larger 
cohorts may be required to detect any potential genotypic effects, given the reported small to 
modest effect sizes in this study and other prior studies (Friedman et al., 1999; Ponsford et 
al., 2011; Teasdale, Murray, & Nicoll, 2005).  It should be noted that modest effect sizes are 
still likely to have clinical significance (Ferguson, 2009), and therefore further investigation 
is justified.  Sample size also precluded us from a more nuanced exploration of the 
hypotheses.  Ideally, analysis of the relationship between age, sex, TBI and APOE would 
have been useful, as it is likely that age would moderate the effect of sex, especially for 
females who undergo distinct hormonal changes during menopause (Hoyt & Falconi, 2015).  
This issue is especially pertinent in the context of APOE, given the association reported 
between APOE expression and sex hormones, particularly estradiol (Horsburgh, Macrae, & 
Carswell, 2002; Struble et al., 2007), and therefore we recommend that future studies attempt 
to explore this relationship. 
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There is also evidence from the dementia literature that APOE ɛ4 has a dose-
dependent effect, whereby those homozygous for APOE ɛ4 have greater risk of developing 
Alzheimer’s disease than those heterozygous for APOE ɛ4 (Corder et al., 1993; Engelborghs 
et al., 2006). It is also possible that a dose-dependent effect would influence TBI severity, 
and indeed Ponsford et al. (2007) reported a trend for APOE ε4 homozygotes to have longer 
PTA and lower GCS scores following injury. Thus, combining APOE ɛ4 heterozygotes and 
homozygotes when assessing cognitive function might obscure any APOE ɛ4 related 
impairment.  Based on the current estimates of the prevalence of the three APOE genotypes, 
it can be estimated that approximately 3% of the population is likely to have the ɛ4/ɛ4 
genotype, and consistent with this estimation, three of our APOE ɛ4 carriers were 
homozygous for ɛ4 (2.5% of total sample – see supplementary material).  Unless large, multi-
site investigations are conducted, or results are reported by genotype, thereby permitting 
meta-analytic approaches to be applied, it will prove difficult to obtain sufficient sample sizes 
to separate APOE ɛ4 homozygotes and heterozygotes.  Nevertheless, exploring dose-
dependent effects in terms of post-TBI cognitive function may prove enlightening.  
Alternatively, APOEɛ4 may have region-specific effects, which could also explain the 
discrepancy between Alzheimer’s disease and TBI findings.  In TBI, frontal regions are 
frequently the most damaged (Levine et al., 2006) whereas the neurodegeneration associated 
with Alzheimer’s disease typically commences in the subcortical and temporal regions, 
before progressing to frontal and parietal areas (Delacourte et al., 1999; Double et al., 1996).  
Indeed, emerging evidence from Alzheimer’s disease research suggests there is a region 
specific effect of APOE ɛ4, and that temporal areas may be more negatively impacted by 
APOE ɛ4 possession (Hostage, Choudhury, Doraiswamy & Petrella, 2014; Westlye et al., 
2012).  Therefore, any deleterious effects of APOE ɛ4 may be diminished when cognitive 
impairment is primarily a consequence of frontal lobe damage, rather than sub-cortical and/or 
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temporal damage.  However, given the often widespread damage associated with TBI, and 
the limited empirical support to date, this possibility remains putative, and requires further 
exploration.    
There are a number of limitations to the present study.  Firstly, participants were 
mainly identified as having sustained a mild to moderate TBI, and there is tentative evidence 
that any detrimental effect of APOE ɛ4 may only be apparent when injury is severe (Ariza et 
al., 2006; Millar, Nicoll, Thornhill, Murray, & Teasdale, 2003; Noé et al., 2010).  The 
distribution of TBI severity in the present sample, however, is consistent with the prevalence 
rates in the general population in Australia and from other Western countries (Fortune & 
Wen, 1999; Tagliaferri, Compagnone, Korsic, Servadei, & Kraus, 2006). As such, the present 
results provides ecological evidence that APOE status is unlikely to be a useful biomarker in 
establishing who might experience poorer cognitive outcomes post-injury, at least for the 
majority of individuals with TBI.   Nonetheless, exploration of the impact of APOE ɛ4 on 
post-TBI cognitive function (including the potential interactions between APOE and sex or 
age) in moderate to severe TBI cohorts may prove fruitful. 
Given that the antagonistic pleiotropic mechanism is associated with reproductive 
life-phases, we chose to categorise old age as over 50 years, based on the average age of 
menopause for females (Gold, 2011). However, we acknowledge that the distinction between 
the reproductive and post-reproductive life-phase is less distinct for males, and furthermore, 
we were unable to confirm the menopausal status of our female participants.  Although one of 
the strengths of the current study was categorising participants into young and old age 
groups, it must be noted that the majority of participants fell into the younger age category 
(18-50 years n = 74, 51-70 years n = 33).  Irrespective of APOE status, it has been established 
that older age is associated with poorer outcomes following TBI (Ponsford, 2013; Senathi-
Raja, Ponsford, & Schonberger, 2010), and therefore it is possible that the lack of effects 
149 
 
 
 
reported here is due to the relatively young age of our sample.  Similarly, as would be 
expected given that males are more likely to sustain TBIs (Fortune & Wen, 1999), we had 
fewer females than males in our sample. Therefore, although we used statistical methods that 
were robust to unequal sample sizes, a larger number of participants over 50 years of age and 
more female participants would have permitted a more unbiased investigation.   
This study did not examine the effect of APOE on learning and memory. This was 
due to this study being part of a larger, already established population study, with pre-existing 
assessment protocols.  While the tasks used in the present study are sensitive to change 
following TBI, and covered a range of domains, there is some evidence that verbal memory is 
more frequently impaired in APOE ɛ4 carriers than other domains (Anderson et al., 2009; 
Crawford et al., 2002; Lawrence, Comper, Hutchison, & Sharma, 2015). Therefore, a future 
examination of APOE and learning and memory in a TBI sample is warranted. 
In conclusion, our results suggest that APOE ɛ4 is not associated with impaired 
cognitive function following TBI, and therefore APOE genotype may not have prognostic 
value in this context.  Moreover, we did not find any evidence that age interacts with APOE 
ɛ4, and as such the hypothesis that APOE may function via an antagonistic pleiotropic 
mechanism was not supported.  We also did not find a systematic interaction between sex and 
APOE ɛ4, despite the reported effect of sex hormones on the expression of APOE. In the 
absence of supporting evidence regarding age and sex interactions with APOE, our findings 
are tentative and must also be interpreted in light of the fact that many of our sample 
sustained mild TBI, and the majority were relatively young adults.  Larger studies, 
particularly in individuals with moderate to severe TBI, are needed to more thoroughly 
examine and enhance our understanding of the relationship between age, sex and APOE 
status.     
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Supplementary Material 
 
Table 17   
Means and standard deviations for neuropsychological test performance by genotype at 3 
months 
 
APOE genotype 
 ɛ4ɛ4  
(n = 3) 
ɛ4ɛ3  
(n = 27) 
ɛ4ɛ3  
(n = 4) 
ɛ3ɛ3  
(n = 77) 
ɛ3ɛ2  
(n = 10) 
ɛ2ɛ2  
(n = 2) 
TMTB 75.64 
(32.92) 
79.52 
(36.45) 
71.67 
(18.58) 
72.67 
(29.29) 
94.10 
(46.97) 
62.50 
(2.12) 
COWAT 38.12 
(11.65) 
38.38 
(11.86) 
27.33 
(7.37) 
38.58 
(11.40) 
40.30 
(10.81) 
35.00 
(15.56) 
DS 6.69  
(1.18) 
7.04  
(1.02) 
7.67 
(2.31) 
6.66  
(1.21) 
6.30  
(1.25) 
5.00  
1.14) 
DSB 4.86  
(1.21) 
4.67  
(1.21) 
5.33 
(1.53) 
5.04  
(1.24) 
4.30  
(.67) 
3.50  
(.71) 
DSFB 1.91  
(1.39) 
2.37  
(.97) 
2.33 
(1.53) 
1.63  
(1.32) 
2.80  
(2.35) 
1.50  
(.71) 
LNS 5.28  
(.95) 
5.11  
(.89) 
6.33 
(1.53) 
5.38  
(1.00) 
5.11  
(.78) 
4.50  
(.71) 
IP Speed 76.25 
(22.24) 
76.59 
(23.34) 
73.00 
(7.94) 
78.17 
(21.00) 
69.67 
(28.97) 
63.00 
(1.41) 
 
Table 18  
Means and standard deviations for neuropsychological test performance by genotype at 6 
months 
 
APOE genotype 
 ɛ4ɛ4  
(n = 3) 
ɛ4ɛ3  
(n = 27) 
ɛ4ɛ3  
(n = 4) 
ɛ3ɛ3  
(n = 77) 
ɛ3ɛ2  
(n = 10) 
ɛ2ɛ2  
(n = 2) 
TMTB 152.00 
(107.68) 
76.60 
(42.71) 
64.75 
(30.41) 
68.74 
(31.46) 
66.40 
(27.25) 
95.50 
(40.31) 
COWAT 21.33  
(7.02) 
42.41 
(11.94) 
31.00  
(8.83) 
39.05 
(11.50) 
42.20 
(10.44) 
44.00  
(.00) 
DS 7.00  
(.00) 
6.70  
(1.53) 
7.25 
(2.06) 
6.63  
(1.28) 
6.40  
(1.51) 
5.00  
(.00) 
DSB 5.67  
(2.08) 
4.89  
(1.09) 
5.50 
(2.38) 
5.08  
(1.38) 
5.10  
(.74) 
4.00  
(1.41) 
DSFB 1.33  
(2.08) 
1.81  
(1.30) 
1.75 
(.96) 
1.54  
(1.31) 
1.30  
(1.06) 
1.00  
(1.41) 
LNS 4.67  
(1.15) 
5.08  
(1.20) 
6.25 
(2.06) 
5.32  
(1.11) 
5.00  
(1.16) 
4.00  
(1.41) 
IP Speed 63.00 
(10.54) 
80.38 
(27.14) 
86.25 
(19.31) 
81.11 
(20.92) 
76.10 
(24.17) 
68.00 
(8.49) 
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Table 19   
Means and standard deviations for neuropsychological test performance by genotype at 12 
months 
 
APOE genotype 
 ɛ4ɛ4  
(n = 3) 
ɛ4ɛ3  
(n = 27) 
ɛ4ɛ3  
(n = 4) 
ɛ3ɛ3  
(n = 77) 
ɛ3ɛ2  
(n = 10) 
ɛ2ɛ2  
(n = 2) 
TMTB 159.00 
(107.48) 
68.68 
(27.72) 
54.50 
(6.36) 
68.41 
(27.45) 
77.80 
(43.16) 
85.50 
(3.54) 
COWAT 25.00  
(1.41) 
45.85 
(12.81) 
33.50 
(14.85) 
40.83 
(12.08) 
46.20 
(11.30) 
49.00 
(15.55) 
DS 6.50  
(.71) 
6.75  
(1.55) 
7.50 
(2.12) 
6.65  
(1.42) 
6.80  
(1.14) 
4.50  
(.71) 
DSB 4.50  
(.71) 
5.20  
(1.64) 
6.00 
(2.83) 
5.03  
(1.17) 
5.30  
(.95) 
3.50  
(.71) 
DSFB 2.00  
(1.41) 
1.55  
(1.82) 
1.50 
(.71) 
1.61  
(1.30) 
1.50  
(1.27) 
1.00  
(1.41) 
LNS 4.00  
(.00) 
5.40  
(.99) 
6.50 
(2.12) 
5.35  
(1.07) 
5.30  
(.68) 
5.00  
(.00) 
IP Speed 58.00  
(.00) 
84.33 
(24.15) 
102.50 
(13.44) 
79.78 
(22.99) 
74.00 
(27.22) 
76.00 
(4.24) 
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Chapter 7: General Discussion 
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Overview of Thesis Aims and Outcomes 
 
The primary aim of this thesis was to explore the role of the APOE gene in post-TBI 
cognitive function during the first 12 months following injury, with a focus on the impact of 
the APOE ɛ4 allele. A series of related research questions were also addressed, with the 
intention of providing a more nuanced and rigorous investigation of the role of the APOE 
gene in relation to cognitive function following TBI.  These included the aim of investigating 
the interaction between age and APOE ɛ4, given the tentative evidence that APOE may 
operate via an antagonistic pleiotropic mechanism; and examining the relationship between 
sex and APOE, given that the expression of APOE is known to be influenced by sex 
hormones, and there is some evidence that APOE ɛ4 females may be more vulnerable to any 
detrimental impact of this allele.  Moreover, given the proposition that APOE ɛ2 might be 
both ameliorative and dominant over APOE ɛ4 and ɛ3, it was intended that by either 
excluding APOE ɛ2 carriers from the APOE ɛ4 carrier and non-carriers groups, or treating 
them as a  separate group, a clearer understanding of the impact of APOE ɛ4 would be 
obtained.  It was also hoped that it would be possible to explore of the effect of APOE ɛ4 
when injury is moderate to severe.  Alongside these research objectives, a methodological 
study was undertaken to consider the impact of missing data in clinical assessment, by 
modelling the effect of missingness using a subset of the current thesis’ dataset.  Collectively, 
these research objectives were executed through a series of four studies.  The following 
sections summarise the aims and outcomes of each of these studies. 
 
 
 
Chapter 2 – Discussion and Key Findings 
Despite the growing number of publications describing the impact of APOE ɛ4 on 
cognitive function following TBI, at the time of writing there was yet to be a meta-analytic 
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investigation of the extant literature.  The aim of this study was to provide such an analysis, 
focusing on investigations that used psychometrically and clinically validated cognitive tasks 
in the initial 12 months following TBI.   
The meta-analyses revealed that there were no significant differences between APOE 
ɛ4 carriers and non-carriers in terms of general cognitive function, or in any of the specific 
domains that were assessed.  It was noted that there is tentative evidence that any detrimental 
effects of the APOE ɛ4 allele may only be apparent in more severe injury (Mannix et al, 
2013; Millar et al., 2003), and that age may moderate the expression of APOE in clinical 
populations (Chang et al., 2011; Han & Bondi, 2008), but that these factors were yet to be 
explored in relation to post TBI cognitive function.  Limitations of the meta-analysis and the 
related literature were also discussed, including inconsistent use of injury severity measures 
and assessment tasks, which hindered the ability to compare outcomes, and the routine 
categorising of APOE status as either APOE ɛ4 carriers or non-carriers.  Dichotomising 
APOE in this manner means that the potentially ameliorative effect of APOE ɛ2 is not 
considered separately, and inclusion of APOE ɛ2 carriers in the APOE ɛ4 and non-ɛ4 groups 
may confound findings related to the impact of APOE ɛ4.  The importance of consistent 
reporting of injury and demographic factors, stratified by APOE status, and issues regarding 
replication and publication bias in the context of candidate gene x environment studies more 
broadly, were also highlighted.  These findings were used to direct the subsequent studies in 
this thesis, with the intention of providing a more nuanced and robust investigation of the 
relationship between APOE genotype and post-TBI cognitive function. 
 
Chapter 4 – Discussion and Key Findings 
The aim of chapter 4 was to explore the relative efficacy of deletion, single, and 
multiple imputation techniques.  This was undertaken by randomly selecting a complete 
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subsample of the current thesis’ data, calculating the true parameters, then deleting a subset 
of the data to create a simulated dataset in which values were missing at random.  Estimated 
parameters were then obtained for this hypothetical data by applying deletion, mean and 
regression substitution (single imputation) and multiple imputation approaches and the 
resulting parameter estimates were compared to the known true parameters of the sample.  
This technique revealed that the multiple imputation approach provided more accurate 
estimates that the deletion or single imputation approaches, and was less likely to 
underestimate the true variance.    
The finding that multiple imputation was better able to estimate parameters, and that 
traditional approaches may reduce accuracy, highlights the need to consider missing data 
when conducting analysis.  Currently, multiple imputation cannot easily be used in some 
contexts, including longitudinal research, however it is expected that future statistical 
programmes will allow multiple imputation to be more easily applied, and therefore 
researchers should be aware of the benefits of using more sophisticated approaches to 
compensate for missing data, and aim to use them where practical.   
 
Chapter 5 – Discussion and Key Findings 
The primary aim of this study was to determine whether APOE ɛ4 significantly 
contributed to cognitive outcome during the early recovery period following TBI, once other 
injury and demographic variables were accounted for.  Regression analyses indicated that 
once injury severity, age, and premorbid IQ were accounted for, there was no evidence that 
APOE status (APOE ɛ4 homozygotes and heterozygotes versus APOE ɛ3 homozygotes) 
contributed to cognitive outcome during the early recovery phase.  The ancillary analyses 
also indicated that possessing APOE ɛ2 was not associated with better cognitive function, and 
that APOE ɛ4 carriers who sustained a moderate to severe TBI did not have poorer outcomes 
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than the APOE ɛ3 group.  It must be noted that these ancillary analyses relied on small 
samples, and the findings should be interpreted with caution.  However, considered 
collectively, the findings from this study suggest that APOE status is unlikely to influence 
cognitive function (specifically processing speed, executive function and working memory) 
during the initial recovery period following TBI, regardless of injury severity.  It could also 
be argued that this study provided evidence that incorporating APOE ɛ2 carriers into APOE 
ɛ4 and non-ɛ4 groups may not impact meaningfully on results, however given the samples 
size, this finding should be viewed with caution until replicated. 
 
Chapter 6 – Discussion and Key Findings 
The final study in this thesis explored the effect of APOE ɛ4 at 3, 6, and 12 months 
following TBI.  As well as investigating the direct effect of APOE ɛ4, the aim of this study 
was to also determine whether age or sex interacted with APOE ɛ4.  A particular interest was 
whether or not APOE ɛ4 was expressed via an antagonistic pleiotropic mechanism, whereby 
possession of the ɛ4 allele conferred beneficial effects during the reproductive life phase and 
detrimental effects in the post-reproductive life phase.  While there was some evidence that 
APOE ɛ4 carriers had poorer performance than non-carriers on the TMTB and COWAT, 
there were no significant differences detected across the majority of tasks.  Further, there was 
no evidence of an interaction between age and APOE, and on only one task was an 
interaction between sex and APOE, in which, contrary to the hypothesis, APOE ɛ4 females 
performed better than both male and female APOE ɛ3 homozygotes and APOE ɛ4 males.  In 
accordance with the results in chapter 5, this study indicated that APOE ɛ4 is not associated 
with poorer cognitive function after TBI, and that age and sex do not appear to influence the 
expression of the ɛ4 allele, although given the main effect of APOE ɛ4 on the TMTB and 
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COWAT – both measures of executive function - it is possible that there is a domain-specific 
effect of APOE ɛ4 on executive function. 
 
 
General Discussion 
 
This thesis raises questions regarding the impact and effect of APOE polymorphisms 
on post-TBI cognitive function.  The meta-analyses reported in chapter 2 found no evidence 
of a detrimental effect of APOE ε4, for either general cognitive function, or within the 
specific domains of executive function, working memory, verbal or visual memory.  The data 
obtained for these meta-analyses was from studies that had investigated the impact of APOE 
ε4 on cognitive function in the first 12 months following TBI, using psychometrically 
validated tasks.  It must be noted that publication bias and lack of replication is argued to be 
particularly prevalent in genetic investigations relating to neuropsychological and 
neuropsychiatric function (Dick et al., 2015; Duncan & Keller, 2011). Should such a 
publication bias be true across the APOE/TBI literature, this would in fact bolster the null 
effect reported here.  Although susceptible to the effects of publications bias,  meta-analyses 
have been reported to provide a more accurate estimation of effect sizes than individual 
studies even when only a small number of studies are included (Cumming, 2012), and 
therefore the findings from this analysis are compelling.  
Similarly, the finding reported in chapter 5 revealed no evidence of a detrimental 
effect of APOE ε4 during the initial recovery period when other injury and demographic 
variables were accounted for.  This lack of effect remained even when only participants with 
moderate to severe injury were assessed.  The longitudinal study reported in chapter 6 also 
indicated that APOE ε4 was not associated with reduced or delayed recovery of cognitive 
function at 3, 6 or 12 months post-injury, with the exception of poorer performance by APOE 
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ɛ4 carriers on the TMTB at 6 months, and some evidence of reduced performance by APOE 
ɛ4 carriers on the COWAT, although subsequent pairwise comparisons did not reveal 
differences at any given time-point.  As both tasks are considered to measure aspects of 
executive function (Bagiella et al., 2010; Kortte et al, 2002; Wilde et al; 2010), this finding 
may indicate a domain-specific effect of APOE ɛ4, but in the absence of supporting evidence 
from previous studies, this hypothesis remains speculative. 
Also of interest in this thesis was the proposition that age and/or sex may interact with 
APOE ɛ4.  In relation to age, it was hypothesised that the APOE gene may operate via an 
antagonistic pleiotropic mechanism, whereby possession of the APOE ɛ4 allele might confer 
some benefits prior to and during the reproductive life phase, but become deleterious in post-
reproductive life.  This prediction was instigated by the diverse range of findings outside of 
the TBI literature which indicated that APOE might function via this process (Chang et al., 
2011; Jasienska, Ellison, Galbarczyk, Jasienski, & Kalemba-Drozdz, 2015; Jochemsen, 
Muller, van der Graaf, & Geerlings, 2012; Kulminski et al., 2011; Rusted et al., 2013).  
Contrary to expectations, there was no evidence of an interaction between age and APOE 
status in relation to post-TBI cognitive function. 
The prediction that there may be an interaction between APOE status and sex was 
based on evidence from cellular and animal studies which indicated that oestrogen increases 
levels apoE (Struble, Nathan, Cady, Cheng, & McAsey, 2007), but is less effective for APOE 
ɛ4 (Lambert et al., 2004; Nathan, Barsukova, Shen, McAsey, & Struble, 2004).  Despite the 
evidence from related avenues of research, there has been little exploration of the interaction 
between age and APOE status in terms of post-TBI cognition, and no studies exploring the 
possibility that sex may interact with APOE status in relation to post-TBI cognition.  Thus it 
was proposed that there would be an interaction between sex and APOE, whereby APOE ɛ4 
females would have poorer outcomes than APOE ɛ3 females, or males of either APOE status.  
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These hypotheses were explored in the longitudinal study described in chapter 6.  One 
interaction between APOE status and sex was found on the COWAT, however pairwise 
comparisons revealed this was a non-significant trend in the opposite direction to that 
hypothesised, whereby APOE ɛ4 females had slightly better performance than the APOE ɛ3 
females.  Given the lack of theoretical support, and the lack of other significant differences, it 
is likely that this effect was spurious. 
  With the exception of tentative evidence suggesting that executive function might be 
detrimentally impacted by presence of the APOE ɛ4 allele, the findings from this thesis 
indicate that APOE ɛ4 is not associated with poorer cognitive function following TBI, even 
when demographic and injury related factors which have been reported to moderate outcomes 
are incorporated into analysis.  This supports the meta-analytic study that was initially 
undertaken.  Therefore, it appears unlikely that determining an individual’s APOE genotype 
will have any prognostic value in relation to estimating post-TBI cognitive outcomes. 
This thesis has a number of strengths.  Firstly, incorporating both meta-analytic and 
original, longitudinal research permitted a broad, multifaceted investigation, with the findings 
from each study converging to indicate little or no effect of APOE ɛ4.   The inclusion of age 
and sex as interacting factors was also beneficial given that, despite evidence from animal 
TBI models, the possible interaction between APOE status and sex or age had not been 
systematically explored in adult TBI populations. The treatment of APOE ε2 carriers as a 
separate group also allowed a more focused comparison of the three APOE alleles, which has 
not typically occurred in previous literature.  Finally, at the time of writing, the studies in 
chapters 5 and 6 contained some of the largest published samples of TBI participants in 
which both APOE genotyping and cognitive assessment was undertaken within 12 months of 
injury.  Moreover, a range of neuropsychological tasks that are known to be sensitive to 
change following TBI were employed.  Overall, these factors have allowed a more focused 
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and integrative exploration of the relationship between APOE and cognitive function 
following TBI than has occurred to date.   
  
 
Issues Relating to Assessment of Injury and Cognitive Function in TBI Populations 
 
TBI severity: Sample characteristics and comparability of GCS and PTA 
estimates.  
It has been suggested that any detrimental effect of APOE ɛ4 may only be apparent 
when injury is severe (Ariza et al., 2006; Millar, et al., 2003; Noe, et al., 2010), and although 
a preliminary analysis was conducted in this thesis on only moderate to severe participants at 
the acute recovery phase, the majority of participants recruited for this thesis were classified 
as having sustained mild TBIs.   Arguably, this thesis reflects typical prevalence rates of mild 
TBI in western populations (Fortune & Wen, 1999; Tagliaferri, Compagnone, Korsic, 
Servadei, & Kraus, 2006), and therefore provides an ecologically valid investigation. As such 
the lack of differences between APOE ɛ4 and non-carriers reported here suggests that this 
biomarker is unlikely to be useful for predicting post-injury cognitive function for the general 
TBI population.  However, the possibility remains that APOE status is important when injury 
is moderate or severe, and therefore further investigation is needed in this population.    
There are also discrepancies in estimation of injury severity depending on the scale 
used, and this issue has also been identified in previous research (Sherer et al., 2008).  In the 
studies reported in chapters 5 and 6, PTA estimates classified more participants as having 
moderate-severe injury severity than GCS.  GCS is often used as an estimator of injury 
severity, however there is compelling evidence that PTA is more closely associated with 
outcome, and as such may be a better estimate of injury severity (Balestreri et al., 2004; 
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Perrin et al., 2015).  Although PTA and GCS are both provided here to improve ability to 
compare this study to other studies, this research highlighted the disparity that can arise from 
assessing injury severity using GCS and PTA.  There are two key concerns regarding injury 
estimations in relation to this thesis: Firstly, the studies included in the meta-analysis (chapter 
2) utilised a range of approaches to estimate severity, making comparisons challenging.  
Secondly, as mentioned above, in the current sample the use of GCS resulted in fewer 
participants being identified as having moderate or severe TBI than when PTA estimates 
were used.  This issue is unsurprising given the reported disparity between these measures 
(Sherer et al., 2015; Sherer et al., 2008), and is unavoidable until more accurate biomarkers of 
severity are determined.  Although it is recognised that PTA estimates tend to better predict 
outcome, GCS remains the more common measure, partly due to its use in the emergency 
medical setting, which makes it an easily obtainable estimate, but the differences reported 
here emphasise the need for researchers to be aware of the discrepancies and reduced 
comparability between studies using GCS or PTA.  It is therefore suggested that reporting 
both GCS and PTA in future studies will allow more accurate comparisons between studies, 
and will also be especially useful should meta-analytic or other integrative approaches be 
employed in future.    
 
Scope of cognitive assessment. 
The participants recruited for the studies in chapters 5 and 6 were part of a larger 
population study, with the neuropsychological testing protocols having already been 
established.   As a result only processing speed, executive function and working memory 
tasks were used to assess neuropsychological function.   In the broader TBI literature, 
attention, executive function and memory are the domains most commonly impaired, even in 
mild TBI (Mathias & Wheaton, 2007; McDonald, Flashman & Saykin, 2002; Rabinowitz & 
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Levin, 2014; Rohling et al., 2011).  Although the meta-analysis in chapter 2 did not find that 
either verbal or visual memory were impacted by APOE status, there is some evidence from 
previous findings that APOE ɛ4 may influence memory, and particularly verbal memory, 
more than other cognitive domains (Anderson et al., 2009; Ariza et al., 2006; Crawford et al., 
2002; Eramudugolla et al., 2014; Noe, Ferri, Colomer, Moliner, & Chirivella, 2010; 
Sundström et al., 2004).  Therefore including measures of visual and verbal memory would 
have broadened the scope of this thesis.  
A further issue identified in this thesis is the inconsistent use of cognitive tasks to 
assess outcome.  A broad range of tasks have been utilised in TBI research (Tate et al., 2013), 
which can make comparisons between studies challenging, and thus had implications for the 
meta-analysis reported in chapter 2.  Clearly a range of tasks are needed to adequately cover 
the range of cognitive functions, however it may be useful for future assessment to use some 
core tasks (with the inclusion of additional measures where needed) to allow more accurate 
comparison between studies, and to permit later integrative analyses such as meta-analysis to 
be undertaken.  Wilde and colleagues (2010) and Bagiella et al. (2010) have both 
recommended a range of tasks that they suggest should be routinely incorporated into 
cognitive assessment after TBI.  As outlined in chapter 2 of this thesis, Wilde et al. also 
provide a stratified protocol which encourages the inclusion not only of validated tasks that 
are known to be sensitive to change following TBI but also of emerging measures, which will 
hopefully lead to the development and validation of new methods of assessment.  As well as 
providing data from measures that are known to be reliable and valid, this may also 
encourage the evolution of neuropsychological assessment in relation to TBI.  It is therefore 
recommended that researchers consider utilising the tasks recommended by Wilde et al to 
ensure a comprehensive coverage of all cognitive domains, and to foster the development of 
new assessment tasks. 
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It should also be noted that premorbid intellectual capacity was estimated by using the 
NART, rather than education level.  It has been reported that the NART may underestimate 
premorbid functioning when TBI is more severe, however this effect appears to diminish 
when TBI is mild or moderate (Morris et al., 2005).  There is also some evidence from non-
impaired populations indicating that the NART may have reduced reliability as a predictor 
for cognitive measures other than verbal intelligence and FSIQ (Schretlen, Buffington, 
Meyer, & Pearlson, 2005).  While the majority of the participants in the current thesis had 
sustained mild to moderate injuries, it is possible that inclusion of education level may have 
improved accuracy in estimating premorbid function, and future studies may benefit from 
using both reading and education tasks concurrently. 
 
Issues Relating to APOE; ɛ4 dose-dependency, and gene-gene interactions 
 
It is possible that APOE ε4 is expressed in a dose-dependent manner, whereby any 
detrimental effects would be more pronounced when the ε4 allele is present in the 
homozygous condition.  There is evidence from non-TBI literature that there is a dose-
dependent effect for APOE ɛ4 in relation to increased risk for APOE ɛ4 homozygotes 
developing AD (Corder et al., 1993), and evidence that APOE ɛ4 homozygotes experience 
greater age-related cognitive decline than APOE ɛ4 heterozygotes (Kang, Logroscino, De 
Vivo, Hunter, & Grodstein, 2005; Nilsson et al., 2006).  In TBI literature, researchers have 
consistently grouped ε4 heterozygotes and homozygotes together, which is pragmatic given 
the small number of individuals who are likely to be homozygous for ε4, but unfortunately 
this means that there is scant evidence to determine whether there is a dose-dependent effect 
for post-TBI cognitive function.  The exception to this is a study by Ponsford and colleagues 
(2007) in which a trend was observed for those with the ε4/ε4 genotype to have poorer 
general outcome following TBI, however the researchers were unable to explore this due to 
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insufficient sample size.  Approximately 3% of the population is likely to have the ε4/ε4 
genotype, and so exploring the dose-dependency effect of APOE ε4 will prove challenging 
unless a multi-centre or meta-analytic approach is taken, and given the prevalence of this 
genotype the clinical relevance may be limited. Nonetheless, it may be worth exploring this 
possibility in order to better understand the role of APOE in relation to cognitive function.    
Although this thesis also groups APOE ɛ4 homozygotes and heterozygotes together, the 
descriptive data for each genotype has been provided as part of chapter 6, in the hopes that 
this may be utilised by future meta-analytic research, and it is suggested that future research 
provide similar data. 
There have also been calls for a more integrative approach when exploring the role of 
candidate genes in relation to psychological function and illness, and in particular the need to 
investigate gene x gene interactions has been stressed (Dick et al., 2015).  It may therefore 
prove fruitful to explore whether the APOE gene interacts with other genes in the context of 
post-TBI cognition.  Indeed, there is evidence from other clinical groups that the brain-
derived neurotrophic factor (BDNF) gene may interact with APOE in relation to memory 
function (Richter-Schmidinger et al., 2011; Ward et al., 2014), and it has been reported that  
allelic variation BDNF and also in other genes such as catechol-O-methyltransferase 
(COMT), Ankyrin repeat and kinase domain-containing 1 (ANKK 1), and kidney and brain 
expressed protein (KIBRA) could influence cognitive outcome following TBI (Lipsky et al., 
2005; McAllister et al., 2012; Wagner et al., 2012; Yue et al., 2015).  Thus, exploring 
polygenetic effects in relation to post-TBI cognitive function is warranted, and with the 
growing availability of sophisticated and time- and cost-efficient genotyping, this avenue of 
research is becoming increasingly feasible. 
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Limitations of treating age and sex independently 
 
Although sex and age differences have been discussed separately here, it is important 
to note that both factors should be considered conjointly.  Given that the antagonistic 
pleiotropy hypothesis suggests that declines would not be seen until the post-reproductive life 
phase, categorising participant age by considering reproductive status, rather than treating age 
as a linear variable, may improve the ability to detect any age-related changes.  This is 
particularly apposite for females, who typically experience a distinct reduction in sex 
hormones during menopause, whereas males have a more gradual and linear decline in sex 
hormone levels (Hoyt & Falconi, 2015).  Nevertheless, both males and females may 
experience cognitive declines that are a function of changes in sex hormones across the 
lifespan which may in turn interact with APOE genotype (Holland, Bandelow, & Hogervorst, 
2011; Yaffe, Haan, Byers, Tangen, & Kuller, 2000).  Unfortunately sample size precluded an 
exploration of this interaction, but future research into the effect of APOE ɛ4 may benefit 
from considering age and sex differences in an integrated manner, ideally either through 
using mixed modelling or moderation analysis rather than employing traditional linear 
approaches, which are unlikely to detect non-linear relationships and outcomes. 
Furthermore, it was not possible to categorise females by menopausal status in the 
current thesis.  If this had occurred, it may have been possible to conduct additional analyses 
involving only pre-menopausal females.  
 
 
Directions for Future Research 
 
A region and/or domain-specific effect for APOE ɛ4? 
Imaging studies indicate that APOE ε4 is associated with greater atrophy of 
hippocampal and entorhinal regions in both healthy and clinical samples (Heise, Filippini, 
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Ebmeier, & Mackay, 2011; Hostage, Choudhury, Doraiswamy, & Petrella, 2014; O'Dwyer et 
al., 2012; Westlye et al., 2012), and that presence of the APOE ɛ4 allele accelerates atrophy 
in hippocampal and temporal regions in the context of AD (Manning et al., 2014), although it 
must be noted that this was not observed a TBI study (Isoniemi, Kurki, Tenovuo, Kairisto, & 
Portin, 2006).  Given that the neurodegeneration associated with AD typically commences in 
the subcortical and temporal regions, before progressing to frontal and parietal areas 
(Delacourte et al., 1999; Double et al., 1996), whereas TBI is associated with more diffuse 
and variable damage, and is most commonly associated with frontal-lobe dysfunction 
(Bendlin et al., 2008; Levine et al., 2006; MacKenzie et al., 2002), it is possible that the 
effects of the APOEɛ4 allele may be diminished when structural atrophy is diffuse or not 
focussed in temporal regions.   
Such an effect would also explain the evidence that possession of the APOE ɛ4 allele 
might be specifically associated with poorer verbal and episodic memory, as has been 
reported in TBI and non-clinical populations (Anderson et al., 2006; Ariza et al., 2006; 
Crawford et al., 2002; Lawrence et al, 2015; Wilson et al., 2002).   This thesis did not use 
measures of verbal or episodic memory, however these findings suggest that cognitive 
functions such as memory, which rely heavily on hippocampal activation, may be more 
vulnerable to the effects of APOE ɛ4 than other domains following TBI, and highlights the 
need to use sensitive and specific cognitive assessments, rather than rely on general outcome 
measures to estimate cognitive impairment.  It was not possible to test verbal memory in the 
current thesis, but the use of specific tasks in this thesis also indicated the possibility that 
APOE ɛ4 may have domain specific effects insofar as there was tentative evidence that 
executive function was negatively impacted by the presence of the APOE ɛ4 allele, although 
this finding does not align with the evidence of preferential atrophy of temporal/hippocampal 
regions. 
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Premorbid effect versus TBI-induced impairment 
There is also evidence that healthy APOE ɛ4 carriers demonstrate poorer cognitive 
performance and reduced white-matter integrity.  In line with the proposition that APOE ɛ4 
may be associated with region-specific effects, hippocampal and temporal regions appear to 
have reduced myelination in healthy APOE ɛ4 carriers, with evidence that this is associated 
with specific reductions in memory (Heise et al., 2011; Honea, Vidoni, Harsha, & Burns, 
2009; Wilson et al., 2002).  As discussed in chapter 2, a recent meta-analysis by Wisdom and 
colleagues (2011) also indicated that APOE ɛ4 was associated with modest decreases in 
episodic memory in healthy populations.  As well as providing further support for a region-
specific effect, these findings may indicate that any reduction in the cognitive function of 
APOE ɛ4 TBI sufferers is reflective of premorbid differences, and that APOE ɛ4 carriers do 
not experience greater impairment as a direct result of injury.  However, in the only published 
study to date that has compared pre- and post-injury cognition, Sundström and colleagues 
(2004) reported that when compared to pre-injury test performance, APOE ɛ4 carriers 
demonstrated post-injury cognitive declines in attention and memory, whereas non-carriers 
did not.  Therefore, it is feasible that possession of APOE ɛ4 does increase severity of 
cognitive impairment after TBI, but until further research occurs which uses either a within 
groups approach or includes a healthy age-matched control group, this supposition remains 
speculative. 
Does APOE ɛ4 influence cognition by increasing amyloid burden?  
It has been established that that accumulation of amyloid increases with both age 
(Jack et al., 2015), and following TBI (Chen et al., 2004; Smith et al., 2003; Yang et al., 
2015), and it appears there is a relationship between APOE and amyloid pathology, with 
Shinohara, Petersen, Dickson, and Bu (2013) reporting an inverse correlation between 
accumulation of amyloid pathology and level of apoE, with others finding that amyloid 
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accumulation increases in the presence APOE ɛ4 (Hartman et al., 2002; Nicoll et al., 1995; 
Yin et al, 2014).  As discussed in the introduction and in chapter 6, this could explain the 
connection between APOE ɛ4 and increased risk of AD (Bales et al., 2009), and cognitive 
impairment (Harrington et al., 2013; Jansen et al, 2015; Nilsson et al., 2002), and therefore  
the relationship between APOE, amyloid deposition and post-TBI cognitive function 
warrants exploration.  Specifically, it is possible that when APOE ɛ4 carriers sustain a 
moderate to severe TBI in later life, the existing amyloid burden results in poorer outcomes. 
This hypothesis would also align with a region-specific explanation of the effect of APOE ɛ4, 
given that amyloid aggregation is known to commence in medial-temporal regions (Thal, 
Rub, Orantes, & Braak, 2002). However, there is some evidence that presence of amyloid 
pathology is not associated with poorer cognitive function in TBI (Kawai et al., 2013), and it 
must also be noted that the relationship between APOE and amyloid accumulation is likely to 
be complex, and that APOE ɛ4 is also likely to impact on cognition via a number of 
neuropathological pathways beyond amyloid accumulation (Corona & Landreth, 2015; Fitz et 
al., 2015; Wolf et al., 2013).  Nonetheless, the relationship between APOE genotype and 
amyloid deposition and clearance could potentially account for the antagonistic pleiotropic 
mechanism that has been proposed by some researchers. 
 
Conclusions 
 
The aim of this thesis was to explore the role of APOE ɛ4 in cognitive function after 
TBI.  Collectively, the meta-analytic and original research undertaken for this thesis indicted 
that possession of APOE ɛ4 is unlikely to be associated with poorer neuropsychological 
function in the first 12 months following TBI, suggesting that determining APOE genotype 
will be of little prognostic value when predicting cognitive outcome following TBI.  
However, there was tentative evidence that possession of APOE ɛ4 was associated with 
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reduced executive function in our sample.  While this might indicate that APOE ɛ4 is 
associated with a domain-specific effect, in the absence of supporting evidence from other 
studies to date, this finding must be interested cautiously and may be spurious. 
It is acknowledged that although including mild TBI participants in the current 
research provided an ecologically valid investigation, it is possible that APOE ɛ4 exerts a 
detrimental effect in moderate to severe TBI, and furthermore, may have a region-specific 
effect that translates specifically to memory impairment.  As such, focussing on moderate to 
severe TBI, and/or inclusion of measures of memory could prove fruitful for future 
researchers.  This thesis also revealed the need for a more rigorous and focussed exploration 
of the relationship between APOE genotype and post-injury outcomes.  In particular, gene x 
environment and gene x gene interactions, alongside the investigation of the impact (if any) 
of APOE ɛ2 and dose-dependency, may prove enlightening.  In addition, the impact of 
missing data was explored and it was demonstrated that when missing data is ignored or 
compensated for using single imputation approaches, the true variability may be attenuated, 
whereas emerging approaches such as multiple imputation appear to better compensate for 
missingness.  It is therefore important that researchers are aware not only of the potential 
impact of missing data, but also keep up-to-date with new generation analyses, and 
incorporate them into research as software becomes available.  If this occurs, along with 
consistent use of core neuropsychological measures to assess cognition and reporting of data 
by genotype, then it is likely that research will be more robust and clarify the impact of 
APOE in TBI populations. 
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